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Gene Discovery in Nonsyndromic Cleft Lip with or without Cleft Palate 
Brett Chiquet 
Advisor: Jacqueline T. Hecht, PhD 
Nonsyndromic cleft lip with or without cleft palate (NSCLP), a common, complex 
orofacial birth defect that affects approximately 4,000 newborns each year in the United 
States, is caused by both genetic and environmental factors.  Orofacial clefts affect the 
mouth and nose, causing severe deformity of the face, which require medical, dental and 
speech therapies.  Despite having substantial genetic liability, less than 25% of the genetic 
contribute to NSCLP has been identified.  The studies described in this thesis were 
performed to identify genes that contribute to NSCLP and to demonstrate the role of these 
genes in normal craniofacial development.  Using genome scan and candidate gene 
approaches, novel associations with NSCLP were identified.  These include MYH9 (7 SNPs, 
0.009≤p<0.05), Wnt3A (4 SNPs, 0.001≤p≤0.005), Wnt11 (2 SNPs, 0.001≤p≤0.01) and 
CRISPLD2 (4 SNPs, 0.001≤p<0.05). The most interesting findings were for CRISPLD2.  
This gene is expressed in the fused mouse palate at E17.5.  In zebrafish, crispld2 localized to 
the craniofacial region by one day post fertilization.  Morpholino knockdown of crispld2 
resulted in a lower survival rates and altered neural crest cell (NCC) clustering.  Because 
NCCs form the tissues that populate the craniofacies, this NCC abnormality resulted in 
cartilage abnormalities of the jaw including fewer ceratobranchial cartilages forming the 
lower jaw ( three pairs compared to five) and broader craniofacies compared to wild-type 
zebrafish.  These findings suggest that the CRISPLD2 gene plays an important role in 
normal craniofacial development and perturbation of this gene in humans contributes to 
orofacial clefting.  Overall, these results are important because they contribute to our 
vi 
 
understanding of normal craniofacial development and orofacial clefting etiology, 
information that can be used to develop better methods to diagnose, counsel and 
potentially treat NSCLP patients. 
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Chapter 1: Craniofacial development and nonsyndromic cleft lip with or 
without cleft palate 
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1.0. Introduction 
 
Craniofacial development is a tightly regulated process that involves the complex 
orchestration of genetic and environmental factors, including interaction of cell growth, 
growth factors and receptors, the convergence and fusion of the facial and palatal processes, 
apoptosis, and adequate nutrient supply.  An intricate system of checks and balances exists 
to ensure that normal development occurs 
1,2
.  In the following chapters, an in depth 
examination of orofacial clefting will be presented, including the etiology mechanism, with 
emphasis on understanding how genetic variations can alter normal craniofacial 
development and contribute to abnormal lip and palate development. 
 
1.1. Normal craniofacial development 
Craniofacial morphogenesis is a complex process involving the interaction of cell 
growth, growth factors and receptors, and apoptosis to guide the convergence and fusion of 
the facial and palatal processes 
3-5
. Many genes are involved and regulate the development 
of the craniofacial region, including growth factors (e.g., FGFs, TGFs, PDGFs, EGFs, BMPs 
and respective receptors), signaling molecules (e.g., WNT family, SHH and respective 
receptors) and transcription factors (e.g., MSX, DLX, LHX, PRRX and BARX family genes 
and respective receptors) 
3,6-21
.  
The upper lip, primary palate and secondary palate form sequentially from connective 
tissue derived from neuroectoderm between gestational days 20 and 56, as illustrated in 
Figure 1.1 
14
. Neural crest cells (NCCs) migrate and differentiate at embryonic day 17, 
expressing homeobox, MSX and DLX family genes, which direct craniofacial patterning 
14
. 
Mesenchyme from the first branchial arch forms the maxillary, lateral nasal, and 
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Figure 1.1: Human craniofacial 
development.  (A) 27 day, (B) 
34 day, and (C) 38 day 
embryos demonstrate the 
convergence of the processes 
that form the external 
craniofacies.  FP = frontonasal 
process, MNP = medial nasal 
process, LNP = lateral nasal 
process, Max = maxillary 
process, Mand = mandibular 
process.  Palatal shelves shown 
at (D) seven and (E) eight 
weeks.  PM = premaxilla/ 
primary palate, PS = palatal 
shelf.  Modified from [14]. 
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medial nasal processes by day 32 
14
. The maxillary processes grow medially, pushing the 
lateral nasal process superiorly and allowing the maxillary process to fuse with both the 
lateral and medial nasal process. The two medial nasal processes fuse to form a continuous 
upper lip by gestational day 36 and external lip development is complete by gestational day 
38 
14,18,24
. 
The primary and secondary palates are formed between gestational days 38-56, after 
upper lip morphogenesis is complete. The primary palate is also derived from both the 
maxillary and medial nasal processes. After fusion of the upper lip, proliferation of 
mesenchyme causes the intermaxillary segment to project into the oral cavity by day 44, 
forming the primary palate and dividing the oral and nasal cavities 
18,24,25
.  The secondary 
palate is formed from the downward projections of the maxillary processes that descend into 
the oral cavity and lie lateral to the tongue (lateral palatine processes). By day 56, the tongue 
descends, allowing the two lateral palatine shelves to elevate, grow medially, and meet 
together 
14,18
. The epithelial edges can then undergo necrosis to allow fusion between the 
lateral palatine shelves, nasal septum and primary palate 
14,18,24
. Palatal development is 
complete by gestational day 60 
19
. 
 
1.2. Development of cleft lip and palate 
Cleft lip and palate is the result of improper fusion of the processes that form the face, 
caused by abnormal morphogenesis of the upper lip and primary palate either by misguided 
epithelial movement, disrupted epithelial-mesenchymal (EMT) transformation, or disrupted 
apoptosis 
24
.  Failure of these mechanisms result in insufficient growth, decreased nutrients 
and/or a diminished degradation of the epithelial seam covering the growth processes, each 
5 
 
 
Figure 1.2: NSCLP patients (a,c) pre- and 
(b,d) post-surgery. 
predisposing cleft lip and palate 
14
.  A cleft of the lip and/or palate results from a failure of 
fusion of the (1) frontonasal prominence with the medial nasal process, (2) the primary 
palate with the secondary palate or (3) the lateral palatine shelves with each other 
14
. 
1.3. Nonsyndromic cleft lip with or without cleft palate 
Orofacial clefting is a common, 
complex birth defect that can occur as 
part of more than 400 syndromes or as 
an isolated malformation 
(nonsyndromic) 
3
.  Nonsyndromic cleft 
lip with or without cleft palate (NSCLP; 
Figure 1.2) has a birth prevalence of 1.4/1000 live births in Caucasian and Hispanic 
populations with males affected twice as frequently as females 
3,29
. Orofacial clefting is 
more common in Native American and Japanese populations (3.6/1000 and 2.1/1000 live 
births, respectively) and less frequent in African populations (0.3/1000 live births) 
3,6,30,31
.  
There is a higher prevalence of clefts in individuals who live in rural areas and have a lower 
than average socioeconomic status 
19,33
.  Between 20–30% of cases occur in families where 
clefting has previously occurred; the remaining 70–80% of cases occur in families without a 
history of orofacial clefts 
3
. 
A cleft can occur on either one (unilateral, 90%) or both (bilateral, 10%) side(s) of the 
face, and the majority of unilateral clefts occur on the left side (66%) 
19
.  Clefts are classified 
as either complete or incomplete, depending on the extent of the cleft to the naris (a 
complete cleft involves the naris) and can involve either the primary or primary and 
secondary palate 
19
.  Eighty percent of bilateral clefting cases involve the palate 
3
.  
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Nonsyndromic cleft palate only (NSCPO) is considered to be a separate birth defect from 
NSCLP.  NSCPO has a lower birth prevalence that is independent of racial background and 
occurs more often in females than in males 
34,35
.  Moreover, cleft palate occurs more often as 
part of a syndrome than CLP 
36
.  Table 1.1 summarizes these differences.   
 
 
Table 1.1:  Comparison of NSCLP and NSCPO 
  NSCLP NSCPO  
Birth Prevalence* 1.4 0.5  
Differences in birth prevalence 
between ethnicities 
Yes No 
 
Male:Female Ratio 2:1 2:3  
Syndromes Associated**  292 554  
Nonsyndromic cases 75% 50%  
*Per 1000 live births          **OMIM search on July 21, 2010   
 
 
 
Other types of clefts and malformations [cleft lip only, microform cleft, notched gums 
where a cleft normally occurs, discontinuous obicularis oris muscle, and dental anomalies 
(tooth agenesis, microdontia, supernumerary teeth, or malposition)] comprise the cleft lip 
and palate spectrum 
37-39
.  Recent studies have advocated for the complete phenotyping of 
affected individuals so that the dataset can be stratified by subphenotype (i.e., overt or 
occult) in order to reduce heterogeneity (see Section 1.4) 
38,40
.  This may increase the 
likelihood of identifying the gene(s) that contribute to the NSCLP spectrum 
38
. 
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1.4. Etiology of NSCLP 
NSCLP is a complex disorder that does not follow normal Mendelian patterns of 
inheritance; rather NSCLP exhibits etiological heterogeneity wherein both genetic and 
environmental factors can predispose an orofacial cleft 
41-43
.  Additionally, gene-gene and/or 
gene-environment interactions may contribute to clefting 
10,36,44
.  The following sections 
discuss the evidence for etiologic heterogeneity of NSCLP. 
1.4.1.  Genetic causes of NSCLP 
Evidence for a genetic etiology for NSCLP comes from studies that show (1) a 
heritability for NSCLP of 76%, (2) monozygotic twins are ten-fold more likely to be 
concordant for a cleft compared to dizygotic twins (40% vs. 4.2%), (3) siblings of affected 
individuals have an increased risk of having a cleft (s = 30-40) compared to the general 
population, and (4) clefting aggregates in families 
3,45
.  However, NSCLP does not follow a 
Mendelian pattern of inheritance 
19
.  The multifactorial model, in which genes and 
environmental factors contribute to the orofacial clefting phenotype, is generally accepted as 
the inheritance paradigm for NSCLP 
10,36
.  It has been estimated that between three and 
fourteen genes play an etiologic role in a single population 
42
; therefore, the number of total 
genes may be greater.  Despite the high heritability associated with NSCLP, only one gene, 
interferon regulatory factor 6 (IRF6), has consistently been found to be associated with 
NSCLP in different populations 
46-49
. Other gene associations have been identified, including 
RARA, TGFα, TGFβ, p63, MYH9, BCL3, and MSX1, but have been inconsistent and 
account for only a small percentage of the underlying genetic heritability 
10,50-55
. 
1.4.2. Environmental causes of NSCLP 
8 
 
Evidence for an environmental cause(s) of NSCLP come from epidemiological studies 
that show an increased birth prevalence of clefting after in utero exposure to putative 
teratogens, such as antiepileptic medications, smoking and folic acid deficiency 
10,56,57
.  The 
only one of these environmental triggers that has consistently proven to increase the risk of 
NSCLP is in utero exposure to antiepileptic medications phenytoin and phenobarbital, both 
of which are folic acid antagonists that decrease folate metabolism and absorption, lowering 
the availability of nutrients for the developing embryo 
56-58
.  Maternal folic acid 
supplementation, which has been shown to decrease the birth prevalence of neural tube 
defects by up to 70%, has not had a similar effect in orofacial clefting birth prevalence 
29,59-
61
.  However, studies have shown that higher than physiologic doses of folic acid 
supplementation (>6mg/day) can decrease the recurrence in women at high risk of having a 
child with NSCLP and NSCPO 
62,63
.  Studies evaluating whether exposure to either tobacco 
smoke or folic acid deficiency play an etiologic role in NSCLP have yielded inconsistent 
results 
64-69
.   
1.4.3. Gene-environment interaction etiology of NSCLP 
An increasing number of studies have focused on identifying gene-environment 
interactions as a cause of NSCLP.  One area has been smoking metabolism genes.  
Cytochrome P450 proteins, epoxide hydrolase, glutathione transferases and arylamine N-
acetyltransferase (NAT) genes all function in the metabolism/detoxification of smoking 
byproducts 
13,44
.  Fetal genotypes that cause a deficiency in the enzyme product are 
potentially at a greater risk of having an orofacial cleft if they were exposed to smoking 
byproducts 
13,44,70,71
.  Similarly, byproducts from smoking can interfere with normal 
development by causing growth retardation, and studies have found gene-environment 
9 
 
interactions between smoking and variants in transforming growth factors, muscle segment 
homeobox and retinoic acid receptor genes 
13,41,69,72-76
.  However, these results have not been 
consistently observed in all studies 
70,71,73,74,76-80
. 
Maternal folate supplementation and variation in genes that regulate folate metabolism 
has also been studied extensively for gene-environment interactions, especially two 
polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene: C677T and 
A1298C.  Both MTHFR polymorphisms have been shown to decrease MTHFR activity and 
the C677T polymorphism also decreases circulating folate and increases homocysteine 
levels 
81-84
.  However, like the smoking studies, MTHFR studies have produced inconsistent 
results 
64,65,67,68,84-96
. 
 
1.5. Approaches to gene identification in NSCLP 
Section 1.4.1 presented evidence that there is a substantial genetic component to NSCLP 
etiology.  Thus, research has been targeted to identify the genes that cause NSCLP.  Two 
methods, genome scans and candidate gene approaches, have been utilized to identify the 
genetic component to NSCLP.  Briefly, genome-wide scans utilize polymorphic markers 
that cover the genome to identify regions that are linked to and/or associated with a 
phenotype of interest.  In contrast, candidate gene approaches are a more targeted approach 
that identifies specific genes that either (1) play a biologically plausible role in craniofacial 
development, (2) are knocked out of murine models with a clefting phenotype, (3) are 
deleted, translocated, or implicated in syndromes associated with an orofacial cleft 
phenotype, or (4) are shown to be linked and/or associated in previous NSCLP studies.  The 
10 
 
following sections will discuss how these approaches have been used to identify genetic 
variants that contribute to the clefting phenotype. 
1.5.1. Genome scans 
NSCLP is a genetically heterogeneous disease, with different genes responsible for 
disease etiology in different populations 
41-43
.  A number of genome scans have been 
performed NSCLP families of different ethnicities, including Chinese, Syrian, European and 
European American (Caucasian), Indian, Filipino and African American 
97-107
.  Table 1.2 
lists the regions identified by NSCLP genome scans, including those presented in Chapter 
four.  Notably, there are six regions that were positive in five or more NSCLP genome 
scans; five of these contain known NSCLP genes, as shown in parentheses: 1p36.13-31 
(MTHFR), 2p16.3-11.2 (TGFα), 2q32-37.2 (SATB2), 3p26-21.2, 6q21-27 (T) and 16q21-24 
(CRISPLD2).  Interestingly, the IRF6 gene (see Section 1.4.1) is found in the 1q32 region 
which has been identified in three of the genome scans, including the two meta-analysis 
studies (Table 1.2). 
1.5.2. Candidate gene approach 
1.5.2.a.  Development genes 
Normal craniofacial development, as mentioned in Section 1.1, involves the complex 
interaction of numerous genes, including growth factors, transcription factors, signaling 
molecules, and their respective receptors.  Genes that direct the craniofacial processes to 
form, migrate and fuse together to form the face are prime candidates because perturbation 
of any of these genes has the potential to alter normal craniofacial morphogenesis.  Such 
candidate genes include FGFs, TGFs, BMPs, MSXs, DLXs, WNTs and SHH 
15,108-132
. 
11 
 
 
 
 
 
 
Table 1.2:  Chromosomal regions identified in NSCLP genome scans† 
 
 
 
†Table modified from [99] 
X denotes publication reported significant association to at least part of the region indicated 
*Denotes dataset also used in 2004 meta-analysis 
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1.5.2.b.  Syndromic genes 
An orofacial cleft can occur as part of the phenotype of syndromes that follow a normal 
Mendelian single-gene pattern of inheritance.  There are 292 syndromes that are associated 
with the CLP phenotype (see Table 1.1, page 6) 
133
.  Van der Woude syndrome (VWS; 
OMIM: #119300) and popliteal pterygium syndrome (PPS; OMIM 119500) are two 
autosomal dominant syndromes that both have a clefting phenotype and are both caused by 
mutations in the IRF6 gene 
134-142
.  Lower lip pits occur in conjunction with orofacial 
clefting in 85% of VWS cases, with the remaining 15% of VWS cases having only an 
orofacial cleft phenotype (CLP and/or CP) 
143
.  This latter observation suggested that IRF6 
may play a role in the etiology of NSCLP 
144
.  IRF6 coding mutations have not been found 
in NSCLP patients, but polymorphic markers have been shown to be in linkage 
disequilibrium and associated with NSCLP in multiple studies 
46,47,49,145,146
.  IRF6 animal 
and promoter studies have supported these results and are discussed in Sections 1.5.2.d and 
1.6, respectively 
147-149
. 
1.5.2.c.  Chromosomal abnormalities 
Chromosomal deletions, duplications, translocations or copy number variants are useful 
in identifying regions of the genome that may contain disease-associated genes 
22,23,26-28,32
.  
While patients with identifiable abnormalities typically have multiple birth defects, the 
gene(s) in these chromosomal regions become candidate genes.  A number of chromosomal 
abnormalities have been identified in patients with cleft lip and palate, including eight 
regions that have also been identified in NSCLP genome scans (Tables 1.2 and 1.3).  These 
regions provide new areas to identify candidate genes and test for association to NSCLP. 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.3:  Chromosomal abnormalities in CLP syndromes. 
 
Chromosomal Region Type of Abnormality Reference 
1q21-25 Deletion 
22
 
2p22.2* Deletion 
23
 
2q37.1* Deletion 
23
 
3p26-21* Duplication 
26
 
4p/tetrasomy 9p Deletion/Tetrasomy 
27
 
4p16.3 Deletion 
28
 
4p16-15* Deletion 
22
 
4q31-35* Deletion 
22
 
der(4) t(4;20)(q35;q13.1) Trisomy 
32
 
6p24* Deletion 
23
 
7p15.3 Microdeletion 
23
 
7q34-35* Deletion 
22
 
10p15-11 Duplication 
26
 
11p14-11 Duplication 
26
 
13q22-34* Duplication 
26
 
 
*Indicates region has also been identified in a NSCLP genome 
scan (see Table 1.2, page 11). 
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1.5.2.d.  Animal studies that suggest NSCLP genes 
Animal models have proven to be a useful tool in elucidating the genetic etiology of 
NSCLP 
150,151
.  There are three types of approaches to study NSCLP using animal models: 
(1) mutagenic and teratogenic screens, (2) spontaneous clefting strains and (3) targeted 
genetic studies of candidate genes.  The mutagenic and teratogenic screens utilize chemical 
reagents such as N-ethyl-N-nitrosourea (ENU) to create a phenotype-driven screening model 
152
.  The resultant abnormal phenotypes can then be used to determine the causative genetic 
factor.  Studies have demonstrated that ENU-injected animals have a higher frequency of 
orofacial clefting than control animals, providing models that can be used to identify 
NSCLP genes 
153,154
.  However, this approach has not been actively pursued. 
Spontaneous clefting is a common occurrence (5-30%) in the A/WySn, A/HeJ and A/J 
inbred mouse strains 
155-157
.  Two gene loci, clf1 and clf2, have been identified as 
contributing to the clefting phenotype and have provided researchers with new regions of the 
mouse genome to interrogate for clefting genes 
158,159
.  The clf2 region is on mouse 
chromosome 11qE1, and contains two adjacent WNT genes: Wnt3 and Wnt9B 
160
.  Both 
function in the canonical WNT signaling pathway and regulate midfacial development and 
upper lip fusion (see Chapter 4, Section 4.2.1) 
9,159
.  Additionally, chapter four presents data 
from our study interrogating variants in seven WNT genes for association with NSCLP, 
which was undertaken because of the results from mouse studies and because the WNT gene 
family plays an important role in craniofacial development (see Section 1.5.2.a). 
 To determine if putative NSCLP genes contribute to the clefting phenotype, targeted 
gene studies in mouse models have proven useful in identifying gene function(s) 
161,162
. For 
example, mutations in IRF6 cause VWS and PPS, both of which are associated with 
15 
 
orofacial clefts (see Section 1.5.2.b) 
46,47,49,134-142,145,146
.  Two IRF6 mouse models, one with 
IRF6 knocked out and the other with a missense mutation that eliminates IRF6 DNA 
binding activity, have furthered the understanding of IRF6 protein function 
147,149,163
.  These 
studies have shown that without a functional IRF6 protein, abnormal keratinocyte 
differentiation and proliferation cause the keratinocytes to poorly adhere and improperly 
fuse together 
147,149
.  This results in craniofacial (cleft palate, missing external ears and a 
short snout), limb and skin anomalies 
147,149
. The presence of non-craniofacial anomalies 
demonstrates that IRF6 plays a critical role in mouse development beyond the face 
137,138,140,142,164
.  This type of targeted gene approach has been used for other NSCLP 
candidate genes, including BMP4 and its receptor BMPR1α, Pax9, Sox11, and Tbx10, 
where knockdown of each of these genes in the mouse model has produced a clefting 
phenotype 
151,165,166
.  
Other animal models have been utilized to study clefting genes, including zebrafish and 
chicken 
167
.  Zebrafish have been used to study several genes involved in craniofacial 
development, including the Runx, Dlx and Sox families of transcription factors 
168-170
.   The 
Dlx gene family has been shown to play a role in cartilage differentiation 
169
 while the Runx 
gene family functions in cell fate determination and chondrogenesis 
168
.  Two Sox9 
orthologs are part of a complex signaling network that controls craniofacial skeleton 
development 
170
.  Chicken embryos have been used to study fusion of the primary palate and 
lip 
167
.  Research in chick models has shown that TGF-β3 and the bone morphogenetic 
proteins regulate palate migration and fusion 
171,172
. 
 
1.6. Genetic variation as the cause of disease phenotype 
16 
 
While linkage analyses have proven to be a useful analytical tool in determining the 
causative gene in single-gene disorders, association studies are useful to study common, 
complex disorders, such as NSCLP, that do not follow Mendelian patterns of inheritance 
173
.  
Association studies test whether sequence variants have an altered frequency in a population 
of interest compared to the control population 
174
.  Three types of sequence variants, or 
polymorphisms, are assessed in association studies: (1) coding, (2) promoter/regulatory, and 
(3) intronic.  
Coding variants, or those exonic changes that are translated into protein, can be either 
nonsynonymous (protein-changing) or synonymous (non-protein-changing).  
Nonsynonymous variants alter amino acid sequence in the protein structure and therefore 
affect normal protein function 
175
.  Synonymous variants do not alter the protein structure; 
however, it has recently been shown that they can alter amino acid translation time, which 
may be detrimental to gene function by altering protein folding 
176
.  Therefore, both 
synonymous and nonsynonymous coding changes have the potential to alter gene function 
and disrupt normal development. 
Sequence variants in the promoter or regulatory region may alter protein levels and thus 
protein function 
177,178
.  Recent research has shown that a common IRF6 risk variant, 
rs642961, disrupts an AP-2α binding site upstream of the IRF6 gene 148.  Transcription 
factor AP-2α is expressed in the craniofacial processes and limbs and mutations in AP-2α 
cause Branchiooculofacial syndrome (OMIM:#113620), a syndromic form of CLP that also 
includes a lip pits 
148,179
.  Together, this data gives suggests that AP-2α and IRF6 are 
involved in a NSCLP etiological pathway. 
17 
 
Intronic variants do not alter amino acid sequence, but may alter gene function if they 
(1) are in normally conserved splice sites or intron/exon junctions or (2) are in linkage 
disequilibrium with disease loci 
180-182
.  While intronic variants have been associated with 
several complex disorders, such as IRF6 variants in NSCLP, RET variants in Hirschsprung 
Syndrome and complement factor H in age-related macular degeneration, actually defining 
how these polymorphisms affect on gene function remains to be defined 
46,47,49,183-185
. 
 
1.7. The role of the dentist in NSCLP treatment 
 The health care costs of caring for a child with an orofacial cleft is more than $100,000 
and creates a significant financial and healthcare burden for these families 
186
. Years of 
therapy by a team of specialists are required to attain satisfactory functional correction 
187
.  
Besides the surgical interventions that are required to repair the defect, a number of other 
therapies play an integral role in treating NSCLP patients.  Speech therapists are needed to 
assess and treat articulation and resonance problems that exist secondary to the altered oral 
anatomy 
187
.  Genetic healthcare professionals have the diagnostic capabilities to distinguish 
between syndromic and nonsyndromic forms of clefting, as well as counseling the family on 
recurrence risks for future pregnancies and natural histories.  Dentists are needed to address 
a number of dental-related problems, including tooth agenesis at the cleft site, 
supernumerary teeth, tooth crowding, hypoplastic enamel, that often affect NSCLP patients 
188
.  Children with CL/P are also predisposed to dental caries; damage to the primary 
dentition compromises the permanent dentition and success of future surgical and 
orthodontic therapies 
189
.  Together, these groups of specialists ensure that NSCLP patients 
can have complete rehabilitation.  
18 
 
 
1.8. Significance of this study 
 NSCLP is a common birth defect caused by both genetic and environmental factors, 
neither of which have been fully elucidated because of the complex etiologic heterogeneity 
of this disorder.  Therefore, the need to identify these NSCLP genes is high.  Identification 
of genetic loci has multiple benefits, including assisting in better counseling and diagnosis, 
and also leading to therapeutic interventions for those at high risk for having a child with an 
orofacial cleft.  Additionally, this research has aided in understanding craniofacial 
development which will in turn lead to a better understanding of the causes of orofacial 
clefts.  The goal of this project was to further delineate the genetic etiology of NSCLP using 
both genomic screening and candidate gene testing approaches in our well-characterized 
nonHispanic white and Hispanic NSCLP families. 
This thesis will detail the efforts toward the goal of gene identification in NSCLP.  
Chapters 3 and 4 demonstrate the usefulness of using genome scan and candidate gene 
approaches to identify NSCLP genes, respectively.  Chapter three describes the 11 regions 
identified in a genome scan of ten NSCLP families.  Examination of the most significant 
region, 22q12.2-12.3, showed that the MYH9 gene, which had previously been implicated to 
clefting etiology in an Italian population, was associated with NSCLP.  Chapter 4 describes 
the interrogation of seven WNT genes and showed that variations in genes that direct normal 
facial development, specifically those WNT genes that regulate neural crest cell 
proliferation and migration, were associated with NSCLP.  Chapter 5 describes studies 
identifying the CRISPLD2 gene which resides in the chromosome 16q24.1 region, identified 
in genome scan studies.  CRISPLD2 is a novel gene which we showed was both associated 
19 
 
with NSCLP and expressed in the developing murine craniofacies.  Chapter 6 discusses the 
results of candidate gene testing of the CRISPLD1 gene and testing of interactions between 
variants in folate pathway genes and both CRISPLD1 and CRISPLD2.  Chapter 7 describes 
studies delineating the role of CRISPLD2 in craniofacial development in zebrafish.  
Altogether, these studies demonstrate the usefulness of different approaches to identify the 
genetic etiology of complex disorders and have contributed to enhancing our knowledge of 
NSCLP. 
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Chapter 2: Materials and methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  Portions of this chapter are taken from previous publications where I was the first 
author.  Guidelines from each of these journals do not require permission to reproduce 
manuscript content as part of a thesis (http://www.nature.com/reprints/ permission-
requests.html, http://www.oxfordjournals.org/access_purchase/publication_rights.html). 
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Figure 2.1:  Example pedigrees of a 
(A) multiplex and (B) simplex trio 
families.  Solid shapes represent an 
affected individual. 
 
2.1. Dataset 
Institutional review board (IRB) approval for the use of these samples had previously 
been obtained (HSC-MS-03-090 from the University of Texas Health Science Center at 
Houston’s Committee for the Protection of Human Subjects and 20010904 from the Ohio 
State University’s Internal Review Board and the University of Antioquia-Colombia Dental 
School’s Scientific Committee).  Our primary (discovery) dataset was comprised of 568 
NSCLP families (1725 individuals).  These families were collected from three centers: 
Texas Children’s Hospital in Houston, Texas, the University of Texas Craniofacial Clinic in 
Houston, and Children’s Hospital in Boston, Massachusetts.  Two hundred and forty-six 
families, which included 971 individuals, were collected from the Clinica Noel in Medellín, 
Columbia, and used as a validation population for some of our studies.  The clinical 
information about the populations is listed in Table 2.1.  All cases were examined for the 
presence of other malformations and for a syndrome by a clinical geneticist.  Only 
individuals with NSCLP were included in this study.  Those patients diagnosed with a 
syndromic form of clefting were excluded from 
this study.  Gender, ethnicity, severity of clefting, 
completeness of clefting and family history (FH) 
of clefting (multiplex vs. simplex) (Figure 2.1) 
were recorded in patients charts. 
After obtaining informed consent, blood 
and/or saliva were collected from patients and 
parents, as well as other family members when 
there was a positive FH of NSCLP.  DNA was 
22 
 
Table 2.1: NSCLP Dataset  
23 
 
extracted from the blood using the Roche DNA Isolation Kit for Mammalian Blood (Roche, 
Switzerland) and from the saliva using the Oragene Purifier for Saliva (DNA Genotex, Inc., 
Ontario, Canada) following manufacturer’s protocol 190. 
 
2.2. Polymorphism selection and genotyping 
Single nucleotide polymorphisms (SNPs) were chosen based on the following criteria: 
(1) heterozygosity was greater than or equal to 0.3, (2) SNP must be polymorphic in the 
nonHispanic white (NHW) population with a minor allele frequency greater than 0.2, (3) 
one SNP per 10 kb, (4) exonic and coding SNPs were given priority over intronic SNPs, and 
(5) SNPs that “tagged” for multiple SNPs were given preference over SNPs that were not in 
linkage equilibrium with other SNPs.  Haploview was used to identify tagSNPs 
191
.  For the 
MYH9 study, SNPs were genotyped based on a previously published study 
55
.  For the folate 
gene pathway studies, SNPs (93/96) were selected from two SNPlex™ pools designed by 
Dr. Richard Finnell’s laboratory 192.  The three SNPs that could not be incorporated into the 
new SNPlex chemistries were replaced following our standard criteria.  Data from three 
short tandem repeat (STR) markers previously genotyped in Dr. Hecht’s laboratory were 
also included in the analysis, two for the WNT studies and one for the CRISPLD2 studies 
106,193
.  Information on the genes interrogated, marker type and genotyping platform used is 
listed in Table 2.2. 
Polymorphic markers were purchased from Applied Biosystems (AB, Foster City, 
California) and genotyped on our samples following the manufacturer’s protocol.  For 
Taqman® assays, the AB 7900HT Sequence Detection System was used to make 
genotyping calls, whereas the AB 3730 and AB GeneMapper® Software v4.0 were used to 
24 
 
Table 2.2: SNPs genotyped in these studies 
25 
 
26 
 
 
 
27 
 
SNPlex™ assays.  Genotype calls were imported into Progeny Lab database management 
software (South Bend, Indiana).  Mendelian inconsistencies and discrepancies between 
sample duplicates were identified and corrected using PedCheck software 
194
. 
 
2.3. Genome scan 
Ten multiplex families were subjected to a genome scan using 
the 6K Illumina Linkage IVb mapping panel. These families were 
selected from our data set on the basis of the number of affected 
individuals and availability of DNA.  Nine families were non-
Hispanic white and one (F1100) was African American [Figure 
2.2]. Under our dominant model, four of the non-Hispanic white 
families, 100, 1000, 1200 and 3000, can yield maximum LOD 
scores greater than 1 (1.6, 1.5, 1.1 and 1.2, respectively). A 
maximum LOD score of 2.98 is possible for the African-
American family. Among the non-Hispanic white families, there 
were 30 affected individuals of 67 individuals. In family 100 
(F100), there were two siblings (III-4 and III-9) who were 
reported to have a notched gum in childhood, a finding that could 
indicate a microform cleft lip. However, these diagnoses could 
not be clinically confirmed. Therefore, the linkage analysis was 
performed twice: first, assuming these individuals to be affected 
and then coding them as unknown with regard to the cleft 
phenotype. There were 27 genotyped individuals in the African-
American family, 7 of whom were affected. 
The Illumina Linkage IVb mapping panel consisting of six 
008 SNPs was used on a BeadStation system (Illumina Inc.). 
Allele detection and genotype calling were performed using the 
BeadStudio software (Illumina Inc.).  
105
 
 
 
2.4. Analyses 
The analyses were performed on the population in aggregate and then on the dataset 
stratified by presence/absence of FH of NSCLP.  SAS (Statistical Analysis Software) v9.1 
was used to calculate allele frequencies and Hardy-Weinberg equilibrium (HWE).  When the 
allele frequencies differed between the ethnicities, the analysis was performed on each 
28 
 
Figure 2.2: NSCLP families in genome scan* 
 
 
 
*Solid shapes indicate individuals with NSCLP.  Half-filled samples F100-III-4 and F100-
III-9 had notched gums and were analyzed as affected and unknown. 
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population separately.  GOLD (Graphical Overview of Linkage Disequilibrium) was used to 
calculate pairwise linkage disequilibrium (LD) and displayed using Haploview 
191,195
. 
A panel of linkage and association testing approaches was used to analyze genotyping 
data.  MERLIN (Multipoint Engine for Rapid Likelihood INferences) 
196
 and Simwalk2 
197
 
were utilized to perform parametric and nonparametric linkage analysis under previously 
defined linkage parameters 
106
. 
Four types of analyses to detect single SNP association with NSCLP were utilized: 
FBAT (family based association test), PDT (pedigree diequilibrium test), geno-PDT 
(genotype PDT), and APL (association in the presence of linkage).  Each of these analytic 
tools makes different assumptions; each was used to optimize the amount of information 
obtained from the data.  FBAT has the ability to detect both linkage and association between 
genetic markers and disease genes 
198
.  PDT is an application of the traditional transmission 
disequilibrium test (TDT) that incorporated extended multiplex families into analysis instead 
of only nuclear families, and therefore allowed more information to be analyzed 
199
.  The 
geno-PDT is an extension of the PDT that tested for association using the transmission of 
specific genotypes to detect association 
200
.  PDT has more power to detect an association 
when a disease displays additive inheritance while geno-PDT is better suited when 
inheritance pattern is either dominant and recessive 
200
.  The APL test provided a powerful 
test statistic in situations when parental genotypes are missing 
201
.  In addition to single SNP 
analysis, multiple SNP haplotypes were analyzed using APL and HBAT (haplotype based 
association test) 
198,201
.  To detect if there were any gene-gene interactions between SNPs in 
different genes, the generalized estimating equations (GEE) as implemented in SAS was 
used 
202
. 
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Two approaches were utilized to correct for multiple testing.  First, for FBAT, a raw P-
value was obtained under normal FBAT assumptions and a “corrected” P-value was 
obtained using the empirical variance extension of FBAT (FBAT-e), which corrected for 
inflated P-values from pedigrees with multiple affected individuals 
198
.  Additionally, the 
Bonferroni correction (0.05/number of independent tests) was also used.  However, the 
Bonferroni approach may be too conservative, as the SNPs genotyped in each gene may not 
be independent of each other because of linkage disequilibrium.  Therefore, for our studies, 
when genotyping multiple genes, we used a Bonferroni correction where the number of 
genes tested were divided by 0.05. 
 
2.5. Sequencing  
DNA from probands from 24 multiplex NSCLP families that had one of the over-
transmitted/susceptible haplotypes 
203
 were used to sequence the fifteen exons of the 
CRISPLD2 gene.  Primer sets, shown in Table 2.3, were designed to capture all exonic 
sequences and at least 50 basepairs upstream (5’) and downstream (3’) of the intron/exon 
junctions.  PCR was performed using thermal cyclers with the following conditions: 30 
cycles of 95°C for 45 s, TM°C for 90 s, and 68°C for 90 s (TM°C listed in Table 2.3).  PCR 
products were purified (Qiagen, Valencia, CA and Millipore, Billerica, MA) according to 
manufacturer’s protocol.  Sequencing was performed by LoneStar Labs (Houston, TX) and 
analyzed using Sequencher v4.8 (Gene Codes, Ann Arbor, MI).  All variants were validated 
by either sequencing from the reverse primer or TaqMan® SNP assay. 
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Table 2.3:  CRISPLD2 sequencing primer information 
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2.6. Silver Staining 
A 16-23 bp polythymine stretch in exon 15 of CRISPLD2 was analyzed to confirm 
Mendelian inheritance.  The 187-bp region containing this variant was amplified using 
CRISPLD2-specific primers (5’:CAGTGTGAGTTGACCCCATC; 
3’:CACTGCACGCTACCTTGGG) with the following conditions: 30 cycles of 95°C for 30 
s, 57.2°C for 90 s, 68°C for 90 s  The product was denatured and run on a polyacrylamide 
gel, fixed, and stained, as previously described 
204
.  Alleles were read and frequencies 
evaluated using the chi-square test. 
 
2.7. Evaluation of sequence variations 
Patient/proband sequences were compared to consensus sequences found at 
www.ncbi.nlm.nih.gov and www.ensembl.org websites using Sequencher v4.8 (Gene 
Codes, Ann Arbor, MI).  Computer algorithms were utilized to determine the predicted 
effect of each sequence variant identified (see review 
205
).  Coding variants were analyzed 
using PolyPhen (http://www.bork.embl-heidelberg.de/ PolyPhen) to predict the effect of 
amino acid substitution on protein structure/function and SIFT 
(http://blocks.fhcrc.org.sift/SIFT.html) to analyze conserved protein domains for favorable 
or unfavorable substitution effects. Sequence variants at the intron/exon junctions were 
analyzed using the ESEfinder (http://www.rulai.cshl.edu/tools/ESE/) program to predict 
whether mRNA splicing was affected 
206,207
. Transcriptional binding site prediction 
programs PATCH and AliBaba2 programs were used to assess untranslated and putative 
promoter regions sequence variants that could alter gene expression (http://www.gene-
 33 
 
regulation.com/pub/ programs.html) 
208,209
. These bioinformatic approaches typically over-
predict protein changes 20-30% of the time 
210
; however, this was preferred over not 
detecting a putative biologic function of the variant. 
 
2.8. CRISPLD2 expression studies 
2.8.1. Mouse 
RIKEN mouse CRISPLD2 cDNA clone, 3321402M02, 
extracted from the head of an E17.5 C57BL/6 mouse, was 
obtained from GeneService (Cambridge, UK). DNA was 
extracted using a Qiagen midiprep kit (Valencia, CA, USA). A 
CRISPLD2-specific 514-bp probe was generated by PCR 
amplification using the following murine specific primers: 
5’CRISPLD2 (ATGAACGTCTGGGGAGACAC) and 
3’CRISPLD2 (GTACCATCCCATTCCTGGTG). PCR was 
performed in a thermal cycler, with 30 cycles of 95°C for 30 s, 
548C for 90 s, 68°C for 90 s. The probe was gel purified (Qiagen) 
and sequenced for verification (Lone Star Labs, Houston, TX, 
USA). PCR products were subcloned into pZErO-2 vector 
(Invitrogen, Carlsbad, CA, USA) using manufacturer’s protocol. 
The product was linearized using NotI and SpeI restriction 
enzymes and sequenced (Lone Star Labs) to determine sense 
versus antisense orientation. 
Whole mouse C57/Bl6 embryos (E12.5–E17.5) were fixed in 
paraffin and sectioned (sagittal and frontal) 6 mm thick. Sections 
showing craniofacial structures were used in this study.  Antisense 
CRISPLD2 clones were labeled with 35S and in situ 
hybridizations were carried out using standard protocols to detect 
CRISPLD2 expression 
211
. Sense CRISPLD2 clones were used as 
a negative control. 
203
 
 
2.8.2. Zebrafish 
Two zebrafish CRISPLD2 probes were generated from wild-type whole adult zebrafish 
using SuperScript™ III Reverse Transcriptase (Invitrogen, Carlsbad, CA).   CRISPLD2-
specific primers (5’set1: CGAGGAAAGTGGAAAAGTACAGTA; 3’set1: 
GATTGTCTAAAGAACAAACCATCATTA; 5’confirm: 
 34 
 
CCCAAAATATCAAGTGTGAGAC; 3’confirm: CCATTCTTCAAGGTGCCGG) were 
PCR amplified using the following thermocycler conditions: 30 cycles of 95°C for 30 s, 
(53°C or 57°C, for set 1 and confirm, respectively) for 90 s, 68°C for 90 s.  PCR products 
were purified (Qiagen, Valencia, CA) and sequenced (LoneStar Labs, Houston, TX).  PCR 
products were then subcloned into Zero Blunt® TOPO® PCR Cloning Kit for Sequencing 
(Invitrogen, Carlsbad, CA) following the manufacturer’s protocol.  NotI and PstI restriction 
enzymes were used to linearize the probe and sequencing (LoneStar Labs) was performed to 
determine orientation.  Antisense DIG-labeled probes (Roche Cat. No. 11277073910, 
Switzerland) were generated to detect CRISPLD2 expression and sense DIG-labeled probes 
were used as the negative control.  Wild-type zebrafish were collected at the following 
stages for in situ hybridization analysis: 5-7 and 13-15 somites, 1-, 2-, 3-, 4- and 5 days post 
fertilization (dpf).  In situ hybridizations were performed using standard techniques 
(www.zfin.org) 
212
.  LAS Montage Module (Leica, Wetzlar, Germany) was utilized to 
capture images. 
 
2.9.  Morpholino (MO) studies 
Two MO antisense oligonucleotides were designed by GeneTools (Philomath, OR) to 
inject into zebrafish embryos: one to knockdown CRISPLD2 (crispld2MO: 
TCGATGTCAGGCGGTCTTACTTGGG) and a control MO (ControlMO: 
TGTAAACAGACTCACTTGTGTGTAG).  Both MOs were diluted in nuclease free water 
to a stock concentration of 65mg/mL.  The stock concentration was further diluted with 
nuclease free water to a working concentration of 12mg/mL.  Injections (0.5-6 mg/mL) were 
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diluted in Danieu buffer and 0.5 uL of 2% phenol red was added to facilitate injections.  
One- to two-cell embryos were injected with 4pL of MO. 
Embryos were stored at 28°C and observed and photographed at 1, 2, 3, 4 and 5 dpf.  
Gross abnormalities and survival  rates were tallied.  Tallies were normalized to wild-type 
observations.  The chi-square test was utilized to assess differences between uninjected, 
control injected and knockdown injected embryos 
213
.  Embryos were harvested at 1 and 5 
dpf for neural crest cell (NCC) marker and alcian blue staining, respectively. 
Morpholino knockdown efficiency was assessed by extracting RNA from whole 
zebrafish embryos at 1- and 5 dpf using SuperScript™ III Reverse Transcriptase (Invitrogen, 
Carlsbad, CA) and standard protocols (www.zfin.org) 
212
.  Quality of RNA was assessed by 
gel analysis (Ambion Dentauring Agarose Gel Electrophoresis, 
http://www.ambion.com/techlib/append/supp/rna_gel.html) and quantity by 
spectrophotometer.  CRISPLD2 set1 primers were used to detect CRISPLD2 expression.  β-
actin-specific primers (5’: CAGGATCTTCATCAGGTAGTCTGTCA; 3’: 
GTTTTCCCCTCCATTGTTGGAC) were used as a control and were PCR amplified under 
the following thermocycler contidions: 30 cycles of 95°C for 30 s, 57°C for 90 s, 68°C for 
90 s. 
 
2.10. Zebrafish expression studies 
Zebrafish embryos were collected at either 1dpf for whole mount in situ hybridization 
studies or 5dpf for cartilage staining.  Embryos collected at 1 dpf were dechorionated using 
1:1000 pronase solution.  Embryos were fixed in 4% paraformaldehyde and stored at -20°C 
in 100% methanol.  Dlx2 probe were obtained from Dr. Eric Swindell.  In situ hybridizations 
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were performed as described in Section 2.8.1.  Alcian blue staining was performed on 5 dpf 
embryos following standard protocol 
212
.  Images were collected using the LAS Montage 
Module (Leica, Wetzlar, Germany). 
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Chapter 3: MYH9 identified by the Genome Scan Approach 
 
 
 
 
Note:  The information presented in this chapter was published in 2009, in which I was the 
primary author:  “Genomic screening identifies novel linkages and provides further evidence 
for a role of MYH9 in nonsyndromic cleft lip and palate.”  European Journal of Human 
Genetics.  17 (2): p.195-204.  The European Journal of Human Genetics Journal does not 
require permission to reproduce manuscript content “in whole or in part in any printed 
volume (book or thesis) of which they are the author(s)” (http://www.nature.com/reprints/ 
permission-requests.html).   
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3.0. Introduction 
Genome scans, as discussed in section 1.5.1, use polymorphic markers to identify 
chromosome regions of the genome that are linked and/or associated with disease etiology.  
This is an important approach has been used to identify genes causing complex disorders in 
different populations 
41-43
.  Therefore, we used a genome scan to identify novel NSCLP 
chromosome regions in our dataset. 
 
3.1. Materials and Methods 
The details of the NSCLP family population, sample collection and DNA extraction, 
Linkage IVb Panel, SNP selection criteria, genotyping, and analyses (parametric and 
nonparametric linkage parameters and analysis, PDT, G-PDT, APL and GEE) are described 
in Chapter 2. 
For this study, ten multiplex families (nine NHW and one African American) were 
subjected to Illumina Linkage IVb mapping panel (see Figure 2.2, page 28).  Note that in 
Family 100, there are two individuals with reported notched gums, which may be part of the 
clefting spectrum (see Section 1.3).  Therefore the data was analyzed in two ways: first with 
these individuals coded as “affected” and then with status codes as “unknown”.  The results 
of the analyses of the large African American family (F1100) were part of the work of 
another student and are not included here. 
Based on the genome scan results, 439 NSCLP families (122 multiplex and 308 simplex 
parent-child trios) were genotyped using ten MYH9 SNPs (Table 3.1).  Six of these SNPs 
were used in a previous study of Italian NSCLP families 
55
.  Four SNPs were selected using 
our SNP selection criteria (described in Section 2.2).  Two SNPs (rs5995288 and 
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Table 3.1:  MYH9 SNPs genotyped in this study and allele frequencies 
Gene  dbSNP Chr:bp Location Alleles* 
NHW 
MAF
a
 
Hispanic 
MAF
b
 
MYH9 rs7078 22:35007860 downstream T/C 0.30 0.25 
MYH9 rs4821478 22:35020059 intron 28 A/G 0.35 0.35 
MYH9 rs2009930 22:35029252 intron 19 C/T 0.35 0.37 
MYH9 rs2239783 22:35035074 intron 15 C/T 0.26 0.27 
MYH9 rs3752462 22:35040129 intron 13 C/T 0.36 0.37 
MYH9 rs1002246 22:35044605 intron 10 T/C 0.66 0.67 
MYH9 rs2071731 22:35048804 intron 5 G/A 0.63 0.66 
MYH9 rs713659 22:35058638 intron 3 G/A 0.58 0.63 
MYH9 rs713839 22:35063884 intron 3 A/G 0.62 0.65 
MYH9 rs739097 22:35076025 intron 1 A/G 0.44 0.36 
 
*Major allele as identified in NHW listed first 
a
Minor allele frequency of nonHispanic white dataset 
b
Corresponding frequency in Hispanic of nonHispanic white minor allele 
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rs2269529) were genotyped in the Italian assay 
55
 but were not included in this study 
because they were not available for TaqMan (Applied Biosystems, California) chemistries. 
 
3.2. Results 
3.2.1. Genome scan 
Ten families were subjected to the Illumina Linkage IVb SNP 
genome-wide panel. Nine nonHispanic white families generated 
11 chromosomal regions with a LOD > 1.5 with parametric and/or 
nonparametric analysis [Table 3.2; Figure 3.1A-F].  The highest 
LOD score for either methodology was to two SNPs in the 
chromosome 22q12.2-q12.3 region (rs762883 and rs9862).  Three 
of the families, 100, 1000, and 3000, had maximum LOD score 
greater than 1.0 in the region (1.05, 1.11 and 1.12 respectively), 
although not for the same set of SNPs (data not shown).  
105
 
 
3.2.2. Candidate gene testing 
Ten MYH9 SNPs were genotyped in our NHW and Hispanic samples.  All SNPs had a 
>95% call rate and were in HWE.  The allele frequencies between SNPs in the NHW and 
Hispanic populations did not differ (Table 3.1); therefore, the data was analyzed in 
aggregate as well as stratified by FH 
214
. 
Two point parametric and nonparametric analyses in the 
combined dataset found evidence for linkage to a single SNP, 
rs1002246, in MYH9 (HLOD = 1.58 and p = 0.0006, 
respectively) [Table 3.3].  There was no evidence for linkage by 
multipoint analysis (data not shown).  However, all three methods 
of association analysis identified evidence for altered transmission 
of this same SNP, rs1002246 [Table 3.4].  In addition, PDT 
detected evidence for an altered transmission of three additional 
SNPs.  When the data was stratified by family history, a 
marginally significant association was still present for SNP 
rs1002246 in the simplex dataset (p = 0.03).  Inspection of all 
two-SNP haplotypes found that most haplotypes constructed with 
rs1002246 and containing the “A” allele were overtransmitted, 
but generally did not reach significance, even when stratified by 
ethnicity and/or family history (data not shown).  The minor allele 
frequency (i.e., frequency of the “A” allele) was 0.34 in the 
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Table 3.2:  Genome Scan Results in nonHispanic white dataset* 
 
        Maximum LOD Score 
        Parametric Nonparametric 
(hLOD) (LOD) 
Chr Region dbSNP cM Aff
a
 Unk
b
 Aff
a
 Unk
b
 
3 3p23 rs342758 58.08 0.35 0.85 0.92 1.64 
3 3p21.1 rs11235 71.53 0.87 1.58 0.49 1.03 
3 3p13-14.1** rs736333 94.05 0.24 0.67 0.65 1.53 
5 5p13.3** rs1966983 51.74 0.94 1.64 0.72 1.19 
5 5q35.2 rs1875189 192.51 0.57 0.53 1.59 1.04 
6 6q27 rs727811 177.17 0.85 1.66 0.28 0.45 
7 7q36.2-36.3** rs7795368 182.8 1.7 2.59 0.57 1.16 
9 9q22.2-22.32** rs1048510 97.53 1.78 1.27 0.96 0.82 
9 9q33.2-33.3 rs1984001 132.41 1.46 0.95 1.87 1.73 
22 22q11.23-12.1 rs763281 21.41 1.75 1.22 1.46 0.99 
22 22q12.2-12.3** rs762883 36.94 2.66 2.12 2.49 2.17 
*Modified from 
105
. 
**Indicates novel region identified 
aAff = Analysis of F100 individuals with notched gums classified as affected 
bUnk = Analysis of F100 individuals with notched gums classified as unknown  
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Figure 3.1: LOD score plots shown by cMs for the nonHispanic white families for chromosomes 
(A) 2, (B) 3, (C) 6, (D) 7, (E) 9 and (F) 22.  Blue line indicates parametric analysis and red line 
indicates nonparametric analysis.  Solid lines indicates analysis with Family 100 III-4 and III-9 
coded as affected while dotted lines indicates analysis with those individuals as unknown. 
 
 
 
 
(A)                                                                          (B) 
(C) (D) 
(E) (F) 
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Table 3.3:  MYH9 SNP linkage results* 
 
      Parametric Nonparametric 
dbSNP cM bp HLOD Alpha LOD P value 
rs7078 35.008 35007860 0.018 0.083 0.01 0.4 
rs4821478 35.02 35020059 0.033 0.109 0.02 0.4 
rs2009930 35.029 35029252 0 0 -0.07 0.7 
rs2239783 35.035 35035074 0.174 0.213 0 0.5 
rs3752462 35.04 35040129 0.108 0.205 0.12 0.2 
rs1002246 35.045 35044605 1.578 0.694 2.26 0.0006 
rs2071731 35.049 35048804 0 0 0 0.5 
rs713659 35.059 35058638 0 0 0 0.5 
rs713839 35.064 35063884 0 0.005 0 0.5 
rs739097 35.076 35076025 0 0 -0.01 0.6 
 
*Modified from 
105
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nonHispanic whites.  Haplotypes with the “G” rs1002246 allele 
were either undertransmitted or demonstrated the expected 
transmission.  
105
 
 
3.3. Discussion 
In this study, we performed a linkage scan to identify regions of the genome that 
potentially harbor NSCLP candidate genes that contribute to the etiologic heterogeneity of 
our NHW dataset.  Eleven regions with a LOD score > 1.5 were identified, including five 
novel regions that have not been identified in previous NSCLP genome scans (Table 3.2).  
The 22q12.2-12.3 region, which was one of the novel genome scan regions, was the largest 
linkage peak in this study (LOD = 2.66).  The MYH9 gene is in this region 
160
.  MYH9 is a 
class II nonmuscle myosin heavy chain gene involved in cell movement, cytokenesis and 
intracellular organization 
215
.  Mutations in MYH9 cause MYH9-related diseases: May-
Hegglin anomally (OMIM:155100), Sebastian syndrome (OMIM:605249), Fechtner 
syndrome (OMIM:153640) and Epstein syndrome (OMIM:153650).  These disorders are 
characterized by macrothrombocytopenia with inclusions of either granulocytes or 
leukocytes, kidney impairment, sensorineural deafness and cataracts can also be found in 
some of the MYH9-related diseases; however, none of these syndromes include a clefting 
phenotype 
216
.  MYH9 knockout mice are embryonic lethals and mice heterozygous for the 
knockout MYH9 allele are grossly normal 
217,218
.  MYH9 was identified as a candidate gene 
for NSCLP because immunohistochemistry studies show high levels of MYH9 expression in 
the palatal shelves prior to fusion, indicating that MYH9 plays an important role in palate 
development and is a potential NSCLP candidate gene 
215
.  Moreover, Martinelli et al. 
recently detected an association between MYH9 SNP rs3752462 and NSCLP in Italian 
NSCLP families (p=0.02) 
55
. 
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To further evaluate the role of MYH9 in NSCLP, ten intragenic and 
flanking SNPs, which included six of the SNPs genotyped in the Italian 
families, were interrogated in our NSCLP sample. 
Linkage was found between a single SNP, rs1002246, in the MYH9 
gene and our entire dataset [Table 3.3], consistent with the prior 
identification of this region in our genome scan.  PDT, G-PDT and APL 
analyses all identified this SNP in our entire NSCLP sample.  
rs1002246 differs from the SNP found in the Italian NSCLP sample 
[Table 3.4].  rs1002246 is in intron 10 of the MYH9 gene but this is not 
in a region associated with intron- exon splicing.  While intronic SNPs 
do not typically alter protein structure, an association with intronic 
variants has been reported for a number of complex diseases 
46,47,49,183-
185,203
.  rs1002246 is in a region of reduced LD that can complicate 
identifying at-risk haplotypes.  In fact, we were unable to identify a 
high-risk haplotype. Interestingly, rs3752462, the SNP identified by the 
Italian group, was only marginally significant in both datasets [Table 
3.4].  Our finding of linkage by parametric and nonparametric analyses 
and association strongly suggests that MYH9 may play a causal role in 
NSCLP.  Nevertheless, we cannot conclusively exclude the possibility 
that another gene in the 22q12.2-12.3 chromosomal region is 
contributing to the positive linkage and association.  We are continuing 
to evaluate this region.  
105
 
 
Ten other regions were identified in this genome scan with a LOD > 1.5, including four 
regions that have not been previously identified in genome scans (3p14.1-13, 5p13.3, 
7q36.2-36.3 and 9q22.22-22.32) (see Table 1.2, page 11).  Three of the regions identified do 
not contain known NSCLP candidate genes (3p23, 3p14.1-13 and 5p13.3).  The remaining 
seven regions (3p21.1, 5q35, 6q27, 7q36.2-36.3, 9q22.2-22.32, 9q33.2-33.3, and 22q11.23-
12.1) have either previously been identified in other genome scans or contain known 
NSCLP candidate genes. 
The 3p21.1 region was reported in Syrian and NHW samples 
103,193
.  We have previously 
reported an association between three short tandem repeats in this region and NSCLP and 
suggested that Wnt5A may play an etiologic role in NSCLP because of its proximity to these 
polymorphic variants 
193
.  Additionally, SNP interrogation of Wnt5a has shown that intronic 
SNP rs566926 is associated to NSCLP 
118
.  Wnt5A is expressed in the central nervous 
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system and facial processes during murine development and thus is considered a 
biologically plausibe candidate gene 
193,219
.  In Chapter 4, we describe a panel of WNT 
genes that were interrogated for association with NSCLP; association was detected between 
an intronic Wnt5A SNP and NSCLP (see Section 4.1) 
118
. 
The 5q35 region was identified in a genome scan of Chinese multiplex families and 
contains 2 candidate genes: msh homolog 2 (Msx2) and fibroblast growth factor receptor 4 
(FGFR4) 
98,160
.  Msx2 is expressed in the developing craniofacial processes.  Mutations in 
the Msx2 gene cause midline facial clefts and a constellation of anomalies including 
amelogenesis imperfecta, cleft lip and palate and polycystic kidney disease 
220,221
.  
Sequencing of Msx2 in NSCLP patients has identified four putatively benign mutations 
126
.  
The FGF signaling pathway plays a critical role in craniofacial development and 
perturbations in many of the FGF pathway genes cause craniofacial abnormalities, including 
syndromic cleft lip and palate 
24
.  FGFR4 plays a significant role in myogenesis in the 
developing head but no association with NSCLP has been reported 
111
.   
A genome scan study of Indian families reported linkage to chromosome region 6q27 
97
.  
The transcription factor T (T) gene is in this region and plays a critical role in mesoderm 
formation and differentiation 
222
.  Mutations in the T-box 22 (Tbx22) gene, which is in the 
same family as T, causes X-linked cleft palate and ankyloglossia syndrome (OMIM: 
#303400).  Additionally, the T gene was considered a strong candidate for spina bifida but 
those results have been inconsistent 
223,224
.  Association studies between T and NSCLP have 
not been reported. 
The 7q36.2-36.3 region is novel and contains sonic hedgehog 
homolog (SHH) and engrailed homeobox 2 (EN2), two known NSCLP 
candidate genes.  SHH plays a critical role in the development and 
patterning of the craniofacial processes that give rise to the developing 
lip and palate 
131
.  Mutations in the human SHH gene cause 
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holoprosencephaly-3, which can be associated with cleft lip and palate 
(OMIM: #142945) 
225
; SHH null mice can have cleft palate 
110
.  
However, single strand conformational polymorphism analysis of the 
SHH gene in NSCLP patients has not identified any disease-causing 
mutations 
132
.  EN2 plays a role in central nervous system development 
and has also been implicated in autism spectrum disorders (OMIM: 
#608636) 
226
.  Previous RFLP testing found no association between the 
EN2 gene and NSCLP 
227
.  Although no positive findings have been 
found, these remain candidate genes of interest. 
Two regions on chromosome 9, 9q22.2-22.32 and 9q33.2-33.3, 
were identified in this genomic scan.  The 9q22.2-22.32 region is novel 
and contains both the BarH-like homeobox 1 (Barx1) and patched 
homolog 1 (PTCH1).  Mouse Barx1 is expressed in the first and second 
branchial arches which form the craniofacial processes 
130
.  The role of 
Barx1 in NSCLP has not been evaluated.  PTCH1, an SHH receptor, in 
combination with Barx1, plays a role in midface structure formation 
129
.  
Mutations in PTCH1 cause Basal Cell Nevus syndrome (BCNS; 
OMIM: #109400) and five percent of BCNS patients have cleft lip and 
palate 
228
.  Interestingly, forkhead box E1 (FOXE1), which plays a role 
in thyroid morphogenesis, is located just outside this region in 9q22.33 
229
.  The FOXE1 region has been identified in NSCLP genome scans 
230
. 
Mutations in FOXE1 cause Bamforth-Lazarus syndrome of which cleft 
palate is a associated finding (OMIM: #241850).  However, sequencing 
of the FOXE1 gene in NSCLP probands identified two missense 
mutations, both of which were predicted to be benign 
126
.  
105
 
 
22q11.23-12.1 was previously reported in a genome study of Indian families 
97
.  This 
region is of particular interest because it contains glutathione s-transferase theta 1 and 2 
(GSTT1 and GSTT2) genes that are involved in the metabolism of tobacco byproducts 
71,77,79,160
.   Exposure to tobacco smoke during pregnancy and fetal GSTT1-null alleles, 
which have been shown to interact with maternal smoking, have inconsistently been 
identified as a risk factor for NSCLP 
71,77,79
. 
 
3.4. Summary 
Here, we report six novel regions (2p22, 3p13-14.1, 5p13.3, 7q36.2-
36.3, 9q22.2-22.32 and 22q12.2-12.3) that can be interrogated for 
NSCLP genes.   We identified eight regions that were previously 
implicated in other genomic scans in a variety of populations.  The 
strongest linkages were found for the 8q21.3-24.12 and 22q12.2-12.3 
regions, with the MYH9 (chromosome 22) gene exhibiting the strongest 
 49 
 
evidence for a causal role.  This gene should be further evaluated in 
other populations for its possible role in NSCLP.  The results of this 
study are important as they provide additional regions to search for new 
NSCLP genes and confirm the findings of earlier genomic scans.  Our 
findings also demonstrate that large multiplex families with complex 
disorders can be successfully used in genome mapping strategies.  
105 
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Chapter 4: Evaluation of WNT genes identified by the Candidate Gene 
Approach 
 
 
 
 
 
 
Note:  The information presented in this chapter was published in 2008, in which I was the 
primary author:  “Variation in WNT genes is associated with non-synromic cleft lip with or 
without cleft palate.”  Human Molecular Genetics.  17 (14): p.2212-2218.  The Human 
Molecular Genetics Journal does not require permission to reproduce manuscript content “in 
full or in part in a thesis or dissertation” (http://www.oxfordjournals.org/access_purchase/ 
publication_rights.html).
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4.0. Introduction 
As discussed in section 1.5.2, the candidate gene approach has provided important 
insights about genetic variation contributing to nonsyndromic orofacial clefts.  The 
wingless-type (WNT) family of genes and signaling pathway play a critical role in growth 
and development, including embryonic induction, epithelial and mesenchymal cellular 
polarity, cell fate determination, cytoskeletal organization and cell proliferation 
112,231,232
.  
WNT genes are expressed in vertebrate craniofacies throughout development, including 
those processes that form the lip and palate 
20,21,112,114,115,117,233,234
.  Moreover, craniofacial 
abnormalities, including orofacial clefts, are found in WNT knockout mice and zebrafish 
116,235
.  Based on all of these observations, we hypothesized that the WNT genes were 
biologically plausible candidate genes for NSCLP and undertook interrogation of this family 
of genes. 
 
4.1. WNT gene family  
 There are 19 WNT genes which share a conserved  motif of 23-24 cysteine residues and 
produce 350-400 amino acid palmitoylated protein products 
15,112
.  These genes function in 
either the canonical or noncanonical WNT pathway 
15,113,231
.  The canonical WNT pathway 
involves the binding of the WNT signaling molecule to a Frizzled gene receptor, activating 
dishevelled (Dvl) and stabilizing β-catenin, which can then enter the nucleus, form a 
complex with transcription factor/lymphoid enhancer-binding factor (TCF/LEF), and 
activate downstream target genes (i.e., CyclinD1, c-myc) (Figure 4.1) 
15,113
.  Wnts -1, -2, -2B, 
-3, -3A, -6, -7B, -8A, 8B and -9B all function via the canonical WNT pathway.  Wnts -4, -5A, 
and -11 have been shown to function without β-catenin or TCF-mediated transcription 
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Figure 4.1: Schematic of the canonical WNT pathway. 
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Legend: LRP = low density lipoprotein; Dvl = disheveled; TCF/LEF = transcription 
factor/lymphoid enhancer-binding factor (TCF/LEF) 
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in noncanonical WNT pathways, including axon guidance, stem cell differentiation and 
planar cell polarity 
119,231,236-238
.  Six WNT genes (Wnts -5b, -7a, -9a, -10a, -10b, and -16) 
have not been assigned to either the canonical or noncanonical pathway. 
 
4.2. Selection of WNT candidate genes 
Seven WNT genes were chosen for this study: Wnt3, Wnt9B, Wnt3A, Wnt11, Wnt8A, 
Wnt5A, and Wnt7A.  Table 4.1 lists specific details about each gene and their unique 
properties. 
4.2.1.  Wnt3 and Wnt9B 
As discussed in section 1.5.2.d, the clf2 region in the A/WySn mouse strain that is 
associated with orofacial clefting in mice contains both the Wnt3 and Wnt9B genes 
158
.  
Recent studies have identified an inserted transposable element downstream of Wnt9B that 
inhibits normal Wnt9B expression 
159
.  Additionally, when A/WySn mice were bred with 
Wnt9B-/- mice, there was a higher prevalence of clefting in the progeny (67%) versus in the 
founders 
116
.  This data suggest that Wnt9B is responsible for the clefting phenotype in 
murine models and therefore an excellent candidate gene for NSCLP. 
Wnt3 is a NSCLP candidate gene because a nonsynonymous Wnt3 mutation causes 
Tetra-Amelia (OMIM:#273395), a rare autosomal recessive disorder in which individuals 
are missing all four limbs and may have an orofacial clefting phenotype 
239
.  Additionally, 
Wnt3 has been shown to antagonize Sonic Hedgehog (SHH) signaling in chick neural plate 
patterning, from which neural crest cells (NCCs) migrate 
16
.  Notably, SHH was in one of 
the regions identified in the genome scan discussed in chapter three (see 
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Table 4.1:  WNT genes interrogated in this study 
 
NI = No syndrome identified 
Gene 
Chromosomal 
Region 
Previously 
Identified 
NSCLP 
Region 
Predicted 
Function 
Animal Models 
Syndrome/ 
OMIM# 
Wnt3 17q21.32 Yes 
100
 
Primary axis 
formation 
240
 
Knockout mouse 
lacks anterior-
posterior 
patterning
240
 
Tetra-Amelia 
(#273395) 
239
 
Wnt3A 1q42.13 No 
Neural 
patterning 
241
 
Vestibular 
morphogenesis 
242
 
NI 
Wnt5A 3p14.3 Yes 
193
 
Stem cell 
differentiation 
243,244
 
Chicken- 
mesenchymal 
expression in the 
craniofacies 
120
 
NI 
Wnt7A 3p25.1 
Yes 
98,100,103
 
Formation 
and CNS 
vascular 
differentiation 
245
 
Knockout mouse 
infertile due to 
abnormal 
mullerian duct 
formation/regressi
on 
246
 
Al-
Awadi/Raas-
Rothschild 
syndrome 
(#276820) 
247
; 
Fuhrmann 
syndrome 
(#228930) 
248,249
 
Wnt8A 5q31.2 Yes 
98
 
NCC 
migration 
114
 
Zebrafish and 
Xenopus- initial 
induction of neural 
crest 
115,250
 
NI 
Wnt9B 17q21.32 Yes 
100
 Midfacial 
morphogenesi
s 
9
 
Mouse- Cleft lip 
116
 
NI 
Wnt11 11q13.5 Yes 
98,101
 Neural 
patterning
241
 
Zebrafish 
knockout- midline 
defects 
235
 
NI 
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Section 3.3) 
105
.  Therefore, variation in Wnt3 may disrupt normal craniofacial development 
and contribute to clefting etiology.     
4.2.2. Wnt3A 
Wnt3A, in mice, has been shown to control the fate of both 
mesenchymal and NCCs in the craniofacial processes and to 
regulate palatal fusion 
21
.  Embryonic expression of Wnt3A is 
upregulated by fibroblast growth factor 8 (FGF8), which is highly 
expressed in the facial primordia and is also an important 
regulator of craniofacial development 
24,251
.  Additionally, Wnt3A 
signaling is also decreased when fibroblast growth factor receptor 
1 (FGFR1), which regulates the epithelial-mesenchymal 
transformation necessary for normal palatal development, is 
inactivated 
251
.  
118
 
 
4.2.3. Wnt11 
Embryogenic studies have shown that Wnt11 is necessary for 
directing migrating NCCs, which will later form ectomesenchyme 
of the developing face 
14,114
.  Also, bone morphogenic protein 4 
(BMP4), which functions in the same pathway as Msx homeobox 
genes, is necessary for upper labial fusion in mice 
24,252
, and 
downregulates Wnt11 during normal urogenital development 
11
.  
Inactivation of BMP4 causes cleft lip in mice; therefore, the 
relationship between BMP4 and Wnt11 suggests that variation in 
Wnt11 could play an etiological role in NSCLP 
252
.  
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4.2.4. Wnt8A 
Wnt8A, like Wnt3A and Wnt11, has been shown to play an important role in NCC 
differentiation, NCC migration and craniofacial development in the mouse 
14,21,114
.  
NCCs are derived in the neural tube and migrate into the 
pharyngeal/branchial arches and differentiate into connective tissue and 
bone of the head and neck 
14,253
.  Several mouse studies have 
demonstrated that genes inactivated in NCCs (i.e., Tgfbr2, Tcof1 and AP-
2alpha) cause orofacial clefting, as well as other malformations 
254-256
.  
118
.  
 
Together, this supports that Wnt8A is a putative NSCLP candidate gene. 
4.2.5. Wnt5A 
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We previously identified a region on chromosome 3p21-14 
between two STR markers that may harbor a clefting gene 
193
.  
Wnt5A is a candidate gene in this region because in situ 
hybridization studies have shown that Wnt5A is expressed in the 
frontonasal prominence and maxillary process, which fuse to form 
the primary palate 
20
.  
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4.2.6. Wnt7A 
Mutations in Wnt7A cause Fuhrmann syndrome (OMIM:228930), which consists of 
bowed femurs, aplasia or hypoplasia of the fibula, and poly-, syn-, and oligodactyly 
248,249
; 
cleft lip and palate is an occasional finding in this syndrome 
257
.  Mutations in Wnt7A also 
cause Al-Awadi/Raas-Rothschild syndrome (OMIM:276820), which present with 
hypoplastic limbs and “unusual facies”, including a “high and narrow palate” 258.  The palate 
phenotypes in these syndromes suggest that Wnt7A is a potential candidate gene for NSCLP. 
 
4.3. Materials and Methods 
The details of the NSCLP family population, sample collection and DNA extraction, 
SNP selection criteria, genotyping, and analysis (PDT, G-PDT, APL and GEE) are 
completely described in chapter 2. 
For this study, 566 NSCLP families (132 multiplex, 235 simplex parent-child trios and 
199 simplex parent-child duos) were genotyped using 38 SNPs.  This included ten in Wnt3, 
six in Wnt3A, one in Wnt5A, nine in Wnt7A, three in Wnt8A, three in Wnt9B and six in 
Wnt11 (Table 4.2).  Two previously genotyped Wnt5A STRs were also included in the 
analysis 
193
.   
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Table 4.2:  WNT SNPs genotyped in this study and allele frequencies 
Gene  dbSNP Chr:bp Location Alleles† 
NHW 
MAF
a
 
Hispanic 
MAF
b,*,**,***
 p-value 
Wnt3A rs708111 1:226257988 upstream C/T 0.483 0.524 0.290 
Wnt3A rs708114 1:226264119 intron 1 C/T 0.469 0.557* 0.034 
Wnt3A rs3094912 1:226276438 intron 1 A/T 0.454 0.500 0.228 
Wnt3A rs3121310 1:226291447 intron 2 A/G 0.308 0.382 0.055 
Wnt3A rs752107 1:226313974 downstream C/T 0.308 0.356 0.175 
Wnt3A rs1745420 1:226318355 downstream C/G 0.144 0.178 0.193 
Wnt5A rs566926 3:55487719 downstream A/C 0.261 0.333 0.550 
Wnt7A rs1124480 3:13832970 upstream C/T 0.459 0.418 0.274 
Wnt7A rs9840696 3:13840076 intron 1 A/G 0.375 0.392 0.651 
Wnt7A rs6778046 3:13846680 intron 1 C/T 0.369 0.415 0.212 
Wnt7A rs9863149 3:13858361 intron 1 C/T 0.315 0.216** 0.004 
Wnt7A rs934450 3:13862730 intron 1 A/G 0.329 0.257* 0.037 
Wnt7A rs1433354 3:13872246 intron 2 A/G 0.305 0.453*** <0.0001 
Wnt7A rs6442414 3:13881839 intron 2 A/G 0.312 0.221** 0.008 
Wnt7A rs11128663 3:13887851 downstream C/G 0.400 0.297** 0.005 
Wnt7A rs4685048 3:13897736 downstream A/C 0.487 0.412* 0.046 
Wnt8A rs4835761 5:137445768 upstream A/G 0.469 0.489 0.619 
Wnt8A rs2040862 5:137447888 intron 2 C/T 0.172 0.108* 0.030 
Wnt8A rs2306110 5:137455986 downstream A/C 0.477 0.489 0.765 
Wnt11 rs663746 11:75571777 upstream C/T 0.498 0.474 0.524 
Wnt11 rs1533763 11:75578175 intron 1 A/T 0.209 0.172 0.272 
Wnt11 rs1533767 11:75583448 exon 3 A/G 0.267 0.279 0.718 
Wnt11 rs689095 11:75591735 intron 4 A/G 0.307 0.324 0.667 
Wnt11 rs596339 11:75594155 intron 4 A/G 0.338 0.412 0.060 
Wnt11 rs1568507 11:75596967 downstream A/T 0.315 0.324 0.820 
Wnt3 rs142167 17:42150418 downstream A/G 0.258 0.523*** <0.0001 
Wnt3 rs7216231 17:42170907 downstream A/G 0.055 0.409*** <0.0001 
Wnt3 rs199525 17:42203002 intron 4 G/T 0.220 0.159 0.070 
Wnt3 rs70602 17:42214876 intron 1 C/T 0.219 0.149* 0.041 
Wnt3 rs199501 17:42217772 intron 1 A/G 0.256 0.538*** <0.0001 
Wnt3 rs199498 17:42220763 intron 1 C/T 0.241 0.489*** <0.0001 
Wnt3 rs111769 17:42227151 intron 1 C/T 0.416 0.258*** <0.0001 
Wnt3 rs3851781 17:42246300 intron 1 C/T 0.474 0.657*** <0.0001 
Wnt3 hCV1139279 17:42248220 upstream C/G 0.198 0.11** 0.005 
Wnt3 rs9890413 17:42256448 upstream A/G 0.363 0.215*** 0.0002 
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Gene  dbSNP Chr:bp Location Alleles† 
NHW 
MAF
a
 
Hispanic 
MAF
b,***
 p-value 
Wnt9B rs2165846 17:42296365 intron 1 A/G 0.421 0.720*** <0.0001 
Wnt9B rs1530364 17:42306776 intron 2 A/G 0.261 0.317 0.128 
Wnt9B rs197915 17:42345521 downstream A/G 0.434 0.432 0.972 
   
†Major allele as identified in NHW listed first 
a
Minor allele frequency of nonHispanic white dataset 
b
Corresponding frequency in Hispanic of nonHispanic white minor allele 
*p<0.05; **p<0.01; **p<0.001 
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4.4. Results 
All SNPs were in Hardy-Weinberg equilibrium.  Comparisons of 
SNP allele frequencies, after Bonferroni correction, showed 
significant differences between European Americans and 
Hispanics (p<0.001) in 3 of the 7 genes [Table 4.2].   Therefore, 
in addition to an overall analysis of the complete dataset, the data 
were stratified by ethnicity and examined separately.  There was 
no evidence for linkage under any of the tested parametric models 
or with nonparametric methods for any of the regions 
[(Supplemental Table 4.1)]. 
PDT and Geno-PDT results for the entire dataset are presented 
in [Table 4.3].  Out of the seven genes interrogated, 5 have SNPs 
that meet a nominal threshold of 0.05.  If we correct the 
significance level for the number of genes tested, then SNPs in 
three genes (Wnt3A, Wnt5A and Wnt11) still yield significant 
results (p<0.007).   [Table 4.4 (and Supplemental Tables 4.2 and 
4.3)] contain the results of PDT, Geno-PDT and APL analyses 
when the families were grouped by ethnicity and also subdivided 
according to the presence or absence of family history (FH).  
SNPs meeting a nominal threshold (p-value <0.05) were found in 
each gene, generally by multiple methods.  In the overall 
European American sample, and when by stratified by FH, 
associations were identified with multiple SNPs in Wnt3, Wnt5A 
and Wnt11 [Table 4.4].   In addition, SNPs in Wnt7A were 
significant in the total European American sample and in the 
positive FH subgroup, while a SNP in Wnt9B was significant 
only in the positive FH subgroup.  Multiple SNPs in Wnt3A were 
significant in the total European American sample and in the 
negative FH subgroup and a SNP in Wnt8A was significant in the 
negative FH subgroup.  
When examining the entire Hispanic sample or when stratifying 
by FH, associations were identified for SNPs in Wnt3A and 
Wnt9B.  Two SNPs were significant in the total sample; one of 
these was significant in the negative FH subgroup.  One SNP in 
Wnt11 was significant in the positive FH subgroup and when the 
sample was considered as a whole.  Lastly, a SNP in Wnt3 was 
significant in the positive FH subgroup.  Overall, across ethnicity, 
the same SNPs were significant in four genes: Wnt3A (2 SNPs), 
Wnt7A (4 SNPs), Wnt11 (1 SNP) and Wnt9B (1 SNP) and both 
ethnicities had significant SNPs in Wnt3, although there was no 
overlap. 
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Table 4.3:  Results of WNT association analysis in complete dataset.* 
 
Gene dbSNP PDT G-PDT 
Wnt3 rs142167 0.147 0.278 
Wnt3 rs7216231 0.359 0.584 
Wnt3 rs199525 0.353 0.636 
Wnt3 rs70602 0.132 0.302 
Wnt3 rs199501 0.190 0.249 
Wnt3 rs199498 0.269 0.220 
Wnt3 rs111769 0.498 0.331 
Wnt3 rs3851781 0.914 0.219 
Wnt3 hCV1139279 0.299 0.519 
Wnt3 rs9890413 0.853 0.741 
Wnt3A rs708111 0.127 0.310 
Wnt3A rs708114 0.378 0.570 
Wnt3A rs3094912 0.334 0.352 
Wnt3A rs3121310 0.034 0.088 
Wnt3A rs752107 0.021 0.022 
Wnt3A rs1745420 0.006 0.009 
Wnt7A rs1124480 0.290 0.314 
Wnt5A D3S3719 0.320 0.340 
Wnt5A rs566926 0.002 0.008 
Wnt5A D3S2408 0.757 0.358 
Wnt7A rs9840696 0.272 0.483 
Wnt7A rs6778046 0.172 0.049 
Wnt7A rs9863149 0.183 0.415 
Wnt7A rs934450 0.209 0.454 
Wnt7A rs1433354 0.228 0.437 
Wnt7A rs6442414 0.665 0.091 
Wnt7A rs11128663 0.229 0.332 
Wnt7A rs4685048 0.010 0.049 
Wnt8A rs4835761 0.490 0.067 
Wnt8A rs2040862 0.306 0.045 
Wnt8A rs2306110 0.535 0.164 
Wnt9B rs2165846 0.962 0.971 
Wnt9B rs1530364 0.869 0.939 
 61 
 
Wnt9B rs197915 0.469 0.149 
Wnt11 rs663746 0.083 <0.001 
Wnt11 rs1533763 0.199 0.378 
Wnt11 rs1533767 0.099 0.009 
Wnt11 rs689095 0.386 0.151 
Wnt11 rs596339 0.747 0.747 
Wnt11 rs1568507 0.124 0.178 
 
*All SNPs with p<0.01 are bolded. 
 
 
 
 
 
 
Table 4.4:  Results of WNT association analysis by ethnicity and family history* 
A. NHW All Positive FH Negative FH 
Gene dbSNP
†
 PDT G-
PDT 
APL PDT G-
PDT 
APL PDT G-
PDT 
APL 
Wnt3 rs70602 0.154 0.308 0.041 0.309 0.585 0.009 0.299 0.426 0.365 
Wnt3 rs199498 0.162 0.239 0.161 0.087 0.139 0.006 1.000 0.941 0.947 
Wnt3 rs9890413 0.948 0.698 0.593 0.932 0.216 0.504 0.840 0.005 0.835 
Wnt3A rs752107 0.023 0.027 0.003 0.31 0.441 0.125 0.0178 0.027 0.009 
Wnt5A rs566926 0.005 0.016 0.004 0.043 0.107 0.049 0.0462 0.144 0.02 
Wnt8A rs2040862 0.352 0.055 0.061 0.581 0.372 0.085 0.009 0.016 0.001 
Wnt9B rs197915 0.160 0.051 0.573 0.072 0.180 0.003 0.926 0.060 0.310 
Wnt11 rs663746 0.067 0.001 0.449 0.104 0.047 0.278 0.361 0.014 0.849 
Wnt11 rs1533767 0.114 0.012 0.001 0.744 0.010 0.100 0.006 0.016 0.003 
    
B. Hispanics All Positive FH Negative FH 
Gene dbSNP
†
 PDT G-
PDT 
APL PDT G-PDT APL PDT G-
PDT 
APL 
Wnt3A rs708111 NS NS NS 0.034 0.135 0.007 0.297 0.426 0.005 
Wnt3A rs3094912 0.343 0.572 0.031 NS NS NS 0.162 0.240 <0.001 
Wnt3A rs1745420 0.083 0.157  <0.001 0.096 0.264 0.009 0.346 0.376 0.008 
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*All SNPs with p<0.01 are shown and p≤0.007 are bolded. 
The results of haplotype analysis are shown in [Table 4.5].  
Because of the small sample size, data were not stratified by FH.  
In both European American and Hispanic samples, four 
haplotypes in Wnt3A and one in Wnt8A were significantly 
associated [Table 4.5].  Wnt11 haplotypes were only significant in 
the European American sample [Table 4.5].  While some of the 
SNPs within genes were in significant LD, most of the SNPs in 
the significantly overtransmitted haplotypes had r
2
 < 0.3 
[Supplemental Table 4.3].   
GEE analysis identified significant gene-gene interactions for 
SNPs in Wnt3A and Wnt3 (p=0.0037) in the European American 
sample and SNPs in Wnt3A and Wnt5A in the Hispanic sample 
(p=0.0388) [Table 4.6].  Models for interaction considering 
dominant and recessive main effects were tested in the European 
American sample.  The best model for increased susceptibility 
was when at least one copy of the rarer allele was present at each 
locus (p=0.03, data not shown).   Interestingly, when there was 
homozygosity for the common allele in Wnt3, the rare allele in 
Wnt3A was protective (p = 0.007, data not shown).  The Hispanic 
sample was too small to evaluate the main effects.  
118
 
 
 
4.5. Discussion 
In this study we interrogated seven WNT genes (Wnt3, Wnt9B, Wnt3A, Wnt11, Wnt8A, 
Wnt5A, and Wnt7A) for association with NSCLP.  We found that (1) all seven genes reached 
nominal significance (p<0.05) in this study, (2) Wnt3A, Wnt5A and Wnt11 remained 
significant after implementing a modest Bonferroni correction, and (3) only Wnt3A was 
associated with NSCLP in both populations and all analyses. 
Though the seven WNT genes in this study were selected because of the roles each has 
in craniofacial development (see Section 4.2), it was surprising that we found association 
with each gene and NSCLP (p<0.05).  These results raised issues concerning multiple 
testing. 
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Table 4.5:  Overtransmitted WNT haplotypes by ethnicity 
A. NHW      
Gene SNP1 SNP 
order* 
SNP2 SNP 
order 
Overtransmitted  
Haplotype 
p-value 
Wnt3 rs142167 1 rs199525 3 2,1 0.049 
Wnt3 rs7216231 2 rs199525 3 2,1 0.033 
Wnt3 rs199525 3 rs70602 4 1,2 0.05 
Wnt3A rs708111 1 rs752107 5 2,1 0.010 
Wnt3A rs708114 2 rs752107 5 1,1 0.014 
Wnt3A rs3094912 3 rs752107 5 1,1 0.037 
Wnt3A rs3121310 4 rs752107 5 2,1 0.017 
Wnt3A rs752107 5 rs1745420 6 1,2 0.001 
Wnt8A rs4835761 1 rs2306110 3 1,1 0.05 
Wnt11 rs663746 1 rs1533767 3 2,2 0.047 
Wnt11 rs1533763 2 rs596339 5 2,2 0.012 
Wnt11 rs1533767 3 rs1568507 6 2,2 0.013 
B. Hispanics      
Gene SNP1 SNP 
order* 
SNP2 SNP 
order 
Overtransmitted  
Haplotype 
p-value 
Wnt3 rs199498 6 rs9890413 10 2,2 0.047 
Wnt3A rs708111 1 rs3121310 4 1,1 0.022 
Wnt3A rs708111 1 rs752107 5 1,1 0.008 
Wnt3A rs708111 1 rs1745420 6 1,2 0.007 
Wnt3A rs708114 2 rs3094912 3 2,1 0.004 
Wnt3A rs708114 2 rs1745420 6 2,2 <0.001 
Wnt3A rs3094912 3 rs3121310 4 1,1 <0.001 
Wnt3A rs3094912 3 rs752107 5 1,1 <0.001 
Wnt3A rs3094912 3 rs1745420 6 1,2 0.003 
Wnt3A rs3121310 4 rs752107 5 1,1 0.027 
Wnt3A rs3121310 4 rs1745420 6 1,2 <0.001 
Wnt3A rs752107 5 rs1745420 6 1,2 <0.001 
Wnt8A rs4835761 1 rs2306110 3 2,2 0.049 
*Order of SNP within candidate gene 
+All SNPs with p <0.05 are shown and p ≤0.007 are bolded 
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Table 4.6:  WNT gene-gene interactions* 
Population Gene1/SNP Gene2/SNP GEE p-value 
nonHispanic whites Wnt3A/rs752107 Wnt3/rs70602 0.004 
Hispanic Wnt3A/rs1745420 Wnt5A/rs566926 0.039 
*All SNPs with P <0.05 are shown and P <0.007 are bolded. 
 
 
 
The issue of correcting for multiple tests is complicated when 
multiple methodologies are performed, and neither the tests nor 
all the SNPs are independent.  Moreover, which correction factor 
to use is further complicated when the SNPs are in genes 
considered viable candidates from other scientific evidence.  
Therefore, we elected to report results meeting a nominal p-value 
of 0.05.  In addition, for the association studies of the individual 
SNPs, we have employed a correction factor of 7 (0.05/7 = 0.007) 
to take into consideration the number of genes evaluated.  This 
represents a generally acceptable correction strategy; one not as 
stringent as a strict Bonferroni, yet still taking the number of 
totally independent analyses into account.  This correction is not 
employed in the haplotype or gene-gene interaction analyses, as 
these are truly exploratory in nature and are restricted by sample 
size.  Clearly, replication of these studies is critical, as well as 
examining gene sequences to identify etiologic susceptibility 
mutations.  
118
. 
 
While multiple testing remains an issue, the most striking results came from two genes 
that play a role in NCC differentiation and migration, Wnt3A and Wnt11 (Tables 4.3 and 4.4)  
Wnt3A was significant in the complete dataset for both ethnicities, regardless of FH of 
NSCLP (Tables 4.3 and 4.4).  Wnt3A was also significant in haplotypes and GEE 
interactions in both ethnicities (Tables 4.5 and 4.6).  Of interest, each of the six Wnt3A SNPs 
genotyped was significant in at least one of the above analyses.  None of the SNPs were 
coding variants or change transcription binding sites.  rs752107 is in the 3’ untranslated 
(UTR) region.  Polymorphisms and mutations in 3’-UTRs have been associated with other 
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diseases, including ITGB2 and Hirschsprung disease-associated enterocolitis, SOX10 and 
complex severe neurocristopathy and GATA4 and congenital heart disease 
259-261
.  The other 
five Wnt3A SNPs are intronic.  Intronic SNPs are associated in several complex diseases, 
including NSCLP, Hirschsprung disease and age-related macular degeneration 
46,47,49,183-185
; 
however, finding functional explanations for these intronic SNP associations is difficult. 
Interestingly, the Wnt3A haplotype of rs752107 and rs1745420 was significant in both the 
NHW (p=0.001) and Hispanic (p<0.001) groups (Table 4.5).  GEE analysis also identified 
interaction between Wnt3A SNPs and SNPs in Wnt3 and Wnt5A in our NHW and Hispanic 
groups, respectively (Table 4.6).  The GEE test does not detect biochemical interactions; 
however, Wnt3A and Wnt3 are both involved in NCC development 
16,21
 while Wnt5A and 
Wnt3A are both expressed in the craniofacial processes that form the upper lip and palate 
20,24,251
.  Therefore, detection of interactions is consistent with the biologic functions of these 
genes. 
Overall, the results from this study suggest that variations in WNT genes that contribute 
to normal craniofacial development also play an etiological role in NSCLP.  Specifically, 
those WNT genes that function in NCC differentiation and migration (Wnt3A and Wnt11) 
were highly associated with NSCLP.  During development, NCCs form the connective 
tissue and skeleton that become the craniofacies 
254
.  The results suggest that altered 
regulation in any or multiple of these genes can predispose an individual to NSCLP. 
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Supplemental Table 4.1:  WNT linkage disequilibrium results 
 
A. Wnt3 
dbSNP rs142167 rs7216231 rs199525 rs70602 rs199501 rs199498 rs111769 rs3851781 hCV1139279 rs9890413 
rs142167   0.471 0.101 0.160 0.797 0.738 0.015 0.018 0.037 0.000 
rs7216231 0.065   0.102 0.129 0.428 0.293 0.113 0.039 0.031 0.040 
rs199525 0.581 0.004   0.718 0.096 0.130 0.255 0.153 0.010 0.082 
rs70602 0.638 0.003 0.767   0.149 0.144 0.243 0.124 0.002 0.126 
rs199501 0.798 0.063 0.621 0.765   0.769 0.021 0.000 0.023 0.001 
rs199498 0.673 0.003 0.640 0.716 0.731   0.009 0.032 0.031 0.015 
rs111769 0.029 0.002 0.025 0.026 0.024 0.025   0.095 0.045 0.209 
rs3851781 0.064 0.001 0.074 0.082 0.074 0.098 0.018   0.152 0.343 
hCV1139279 0.001 0.001 0.006 0.005 0.003 0.004 0.128 0.163   0.037 
rs9890413 0.030 0.002 0.040 0.039 0.031 0.045 0.165 0.361 0.120   
 
B. Wnt3A 
dbSNP rs708111 rs708114 rs3094912 rs3121310 rs752107 rs1745420 
rs708111   0.027 0.688 0.021 0.176 0.157 
rs708114 0.289   0.001 0.463 0.012 0.001 
rs3094912 0.561 0.040   0.004 0.217 0.190 
rs3121310 0.137 0.484 0.013   0.014 0.014 
rs752107 0.195 0.030 0.282 0.054   0.005 
rs1745420 0.082 0.010 0.135 0.000 0.046   
 
C. Wnt5A 
STR/dbSNP D3S3719 rs566926 D3S2408 
D3S3719   0.000 0.000 
rs566926 0.000   0.000 
D3S2408 0.000 0.000   
 
D. Wnt7A 
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dbSNP rs1124480 rs9840696 rs6778046 rs9863149 rs934450 rs1433354 rs6442414 rs11128663 rs4685048 
rs1124480   0.024 0.030 0.003 0.004 0.014 0.006 0.003 0.001 
rs9840696 0.087   0.731 0.111 0.155 0.239 0.023 0.008 0.014 
rs6778046 0.065 0.799   0.193 0.239 0.252 0.044 0.003 0.026 
rs9863149 0.037 0.214 0.244   0.679 0.001 0.001 0.013 0.002 
rs934450 0.032 0.219 0.263 0.900   0.011 0.003 0.004 0.001 
rs1433354 0.004 0.142 0.158 0.002 0.000   0.085 0.033 0.029 
rs6442414 0.000 0.014 0.015 0.075 0.084 0.008   0.598 0.369 
rs11128663 0.001 0.000 0.000 0.015 0.019 0.021 0.533   0.487 
rs4685048 0.010 0.015 0.012 0.018 0.022 0.115 0.322 0.526   
 
E. Wnt8A 
dbSNP rs4835761 rs2040862 rs2306110 
rs4835761   0.081 0.935 
rs2040862 0.128   0.079 
rs2306110 0.932 0.118   
 
F. Wnt9B 
dbSNP rs2165846 rs1530364 rs197915 
rs2165846   0.018 0.062 
rs1530364 0.030   0.124 
rs197915 0.082 0.069   
 
G. Wnt11 
dbSNP rs663746 rs1533763 rs1533767 rs689095 rs596339 rs1568507 
rs663746   0.000 0.044 0.009 0.000 0.007 
rs1533763 0.026   0.004 0.094 0.296 0.092 
rs1533767 0.108 0.018   0.021 0.004 0.017 
rs689095 0.023 0.120 0.058   0.327 0.948 
rs596339 0.027 0.445 0.017 0.232   0.318 
rs1568507 0.012 0.114 0.047 0.885 0.237   
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Supplemental Table 4.2:  All WNT association results in NHW families 
  All Positive Family 
History 
Negative Family 
History 
Gene Marker PDT Geno-
PDT 
APL PDT Geno-
PDT 
APL PDT Geno-
PDT 
APL 
Wnt3A rs708111 0.103 0.257 0.778 0.11 0.114 0.366 0.558 0.203 0.867 
Wnt3A rs708114 0.340 0.555 0.55 0.217 0.315 0.556 0.931 0.919 0.778 
Wnt3A rs3094912 0.485 0.335 0.698 0.778 0.657 0.723 0.455 0.449 0.75 
Wnt3A rs3121310 0.014 0.033 0.065 0.051 0.073 0.499 0.137 0.319 0.08 
Wnt3A rs752107 0.023 0.027 0.003 0.31 0.441 0.125 0.0178 0.027 0.009 
Wnt3A rs1745420 0.024 0.034 0.092 0.301 0.377 0.283 0.033 0.067 0.204 
Wnt7A rs1124480 0.528 0.667 0.681 0.842 0.853 0.957 0.439 0.603 0.539 
Wnt7A rs9840696 0.229 0.473 0.958 0.040 0.097 0.047 0.288 0.584 0.149 
Wnt7A rs6778046 0.127 0.162 0.407 0.03 0.031 0.067 0.612 0.888 0.670 
Wnt7A rs9863149 0.176 0.366 0.784 0.038 0.058 0.205 0.846 0.687 0.608 
Wnt7A rs934450 0.2 0.341 0.889 0.053 0.029 0.168 0.673 0.34 0.384 
Wnt7A rs1433354 0.319 0.535 0.622 0.167 0.254 0.322 0.831 0.827 0.728 
Wnt7A rs6442414 0.733 0.168 0.933 0.371 0.34 0.833 0.598 0.278 0.720 
Wnt7A rs11128663 0.399 0.526 0.886 0.633 0.416 0.897 0.455 0.745 0.793 
Wnt7A rs4685048 0.027 0.085 0.097 0.129 0.351 0.152 0.105 0.192 0.291 
Wnt5A D3S3719 0.343 0.365 n/a 0.343 0.365 n/a n/a n/a n/a 
Wnt5A rs566926 0.005 0.016 0.004 0.043 0.107 0.049 0.0462 0.144 0.02 
Wnt5A D3S2408 0.599 0.286 n/a 0.599 0.286 n/a n/a n/a n/a 
Wnt8a rs4835761 0.399 0.069 0.46 0.561 0.265 0.194 0.067 0.086 0.129 
Wnt8a rs2040862 0.352 0.055 0.061 0.581 0.372 0.085 0.009 0.016 0.001 
Wnt8a rs2306110 0.409 0.188 0.818 0.749 0.679 0.052 0.117 0.113 0.197 
Wnt11 rs663746 0.067 0.001 0.449 0.104 0.047 0.278 0.36139 0.01449 0.849 
Wnt11 rs1533763 0.267 0.464 0.338 0.858 0.245 0.193 0.05 0.097 0.053 
Wnt11 rs1533767 0.114 0.012 0.001 0.744 0.010 0.100 0.006 0.016 0.003 
Wnt11 rs689095 0.374 0.127 0.540 0.943 0.217 0.652 0.135 0.219 0.289 
Wnt11 rs596339 0.463 0.762 0.152 0.244 0.499 0.236 0.927 0.891 0.311 
Wnt11 rs1568507 0.144 0.143 0.213 1.000 0.181 0.462 0.02 0.062 0.047 
Wnt3 rs142167 0.108 0.23 0.051 0.294 0.553 0.107 0.190 0.359 0.222 
Wnt3 rs7216231 0.662 0.289 0.714 0.162 0.162 0.092 0.394 0.477 0.315 
Wnt3 rs199525 0.437 0.731 0.182 0.309 0.557 0.017 0.908 0.985 0.777 
Wnt3 rs70602 0.154 0.308 0.041 0.309 0.585 0.009 0.299 0.426 0.365 
Wnt3 rs199501 0.102 0.188 0.049 0.149 0.281 0.026 0.431 0.642 0.366 
Wnt3 rs199498 0.162 0.239 0.161 0.087 0.139 0.006 1.000 0.941 0.947 
Wnt3 rs111769 0.435 0.334 0.993 0.150 0.296 0.251 0.502 0.043 0.422 
Wnt3 rs3851781 0.736 0.187 0.604 0.534 0.206 0.722 0.772 0.746 0.791 
Wnt3 hCV1139279 0.217 0.366 0.597 0.278 0.335 0.808 0.535 0.801 0.689 
Wnt3 rs9890413 0.948 0.698 0.593 0.932 0.216 0.504 0.840 0.005 0.835 
Wnt9B rs2165846 0.697 0.887 0.715 0.381 0.556 0.668 0.538 0.771 0.403 
Wnt9B rs1530364 0.574 0.828 0.644 0.083 0.146 0.298 1.000 0.821 0.856 
Wnt9B rs197915 0.160 0.051 0.573 0.072 0.180 0.003 0.926 0.060 0.310 
 69 
 
Supplemental Table 4.3:  All WNT association results in Hispanic families 
  All Positive Family 
History 
Negative Family 
History 
Gene Marker PDT Geno-
PDT 
APL PDT Geno-
PDT 
APL PDT Geno-
PDT 
APL 
Wnt3A rs708111 0.858 0.698 0.314 0.034 0.135 0.007 0.297 0.426 0.005 
Wnt3A rs708114 0.819 0.925 0.422 0.655 0.513 0.813 0.593 0.701 0.425 
Wnt3A rs3094912 0.343 0.572 0.031 0.796 0.892 0.301 0.162 0.240 0.001 
Wnt3A rs3121310 0.450 0.570 0.473 0.739 0.264 0.867 0.251 0.556 0.349 
Wnt3A rs752107 0.695 0.744 0.082 0.706 0.853 0.100 0.491 0.280 0.261 
Wnt3A rs1745420 0.083 0.157 0.001 0.096 0.264 0.009 0.346 0.376 0.008 
Wnt7A rs1124480 0.106 0.040 0.252 0.706 0.080 0.851 0.103 0.189 0.118 
Wnt7A rs9840696 0.876 0.747 0.336 1.000 0.755 0.810 0.847 0.925 0.330 
Wnt7A rs6778046 0.886 0.026 0.110 0.763 0.467 0.979 0.746 0.044 0.084 
Wnt7A rs9863149 0.858 0.576 0.911 0.796 0.801 0.100 1.000 0.625 0.133 
Wnt7A rs934450 0.866 0.429 0.531 0.439 0.714 0.090 0.655 0.456 0.017 
Wnt7A rs1433354 0.456 0.689 0.214 0.257 0.411 0.651 0.746 0.946 0.227 
Wnt7A rs6442414 0.724 0.386 0.440 0.414 0.641 0.508 1.000 0.450 0.867 
Wnt7A rs11128663 0.194 0.345 0.892 0.706 0.641 0.943 0.209 0.258 0.914 
Wnt7A rs4685048 0.131 0.182 0.337 1.000 1.000 0.800 0.096 0.122 0.330 
Wnt5A D3S3719 0.734 0.526 n/a 0.734 0.526 n/a n/a n/a n/a 
Wnt5A rs566926 0.182 0.432 0.154 0.781 0.185 0.401 0.144 0.129 0.242 
Wnt5A D3S2408 0.459 0.526 n/a 0.459 0.526 n/a n/a n/a n/a 
Wnt8a rs4835761 0.695 0.814 0.251 0.763 0.837 0.507 0.796 0.925 0.360 
Wnt8a rs2040862 0.637 0.783 0.636 0.157 0.157 0.260 1.000 1.000 0.850 
Wnt8a rs2306110 0.564 0.650 0.181 0.763 0.837 0.524 0.617 0.758 0.223 
Wnt11 rs663746 1.000 0.031 0.245 0.025 0.104 0.282 0.336 0.080 0.081 
Wnt11 rs1533763 0.366 0.608 0.622 0.564 0.564 0.323 0.480 0.683 0.924 
Wnt11 rs1533767 0.637 0.701 0.900 0.414 0.414 0.997 1.000 0.585 0.867 
Wnt11 rs689095 1.000 1.000 0.851 0.157 0.264 0.469 0.593 0.467 0.915 
Wnt11 rs596339 0.134 0.131 0.370 1.000 1.000 0.456 0.083 0.116 0.204 
Wnt11 rs1568507 0.617 0.659 0.971 0.317 0.513 0.894 0.439 0.301 0.911 
Wnt3 rs142167 0.866 0.953 0.730 0.480 0.367 0.463 0.847 0.642 0.943 
Wnt3 rs7216231 0.353 0.492 0.989 0.257 0.135 0.983 0.670 0.210 0.993 
Wnt3 rs199525 0.531 0.678 0.997 0.317 0.317 0.194 0.670 0.627 0.943 
Wnt3 rs70602 0.617 0.607 0.658 0.317 0.317 0.190 0.796 0.445 0.750 
Wnt3 rs199501 0.465 0.696 0.495 0.706 0.641 0.683 0.532 0.546 0.369 
Wnt3 rs199498 0.414 0.376 0.531 0.706 0.641 0.688 0.467 0.155 0.410 
Wnt3 rs111769 0.847 0.946 0.358 0.317 0.513 0.073 1.000 0.798 0.442 
Wnt3 rs3851781 0.414 0.758 0.676 1.000 1.000 0.037 0.394 0.741 0.440 
Wnt3 hCV1139279 0.593 0.695 0.810 0.564 0.564 0.309 0.366 0.578 0.492 
Wnt3 rs9890413 0.683 0.908 0.980 0.157 0.157 0.145 1.000 0.722 0.851 
Wnt9B rs2165846 0.127 0.204 0.755 0.564 0.564 0.040 0.059 0.155 0.369 
Wnt9B rs1530364 0.480 0.685 0.740 0.414 0.641 0.982 0.695 0.766 0.677 
Wnt9B rs197915 0.034 0.050 0.082 0.317 0.317 0.204 0.020 0.040 0.044 
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Chapter 5: Identification of association between NSCLP and a novel gene in 
region 16q24.1: CRISPLD2 
 
 
 
 
 
 
 
Note:  The information presented in this chapter was published in 2007, in which I was the 
primary author:  “CRISPLD2: a novel NSCLP candidate gene.”  Human Molecular 
Genetics.  16 (18): p.2241-2248.  The Human Molecular Genetics Journal does not require 
permission to reproduce manuscript content “in full or in part in a thesis or dissertation” 
(http://www.oxfordjournals.org/access_purchase/ publication_rights.html). 
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5.0. Introduction 
Genome scans, like the one performed for chapter three, identify regions that potentially 
harbor a disease gene for a given population.  Given the etiologic heterogeneity for NSCLP, 
genome scans on different populations often do not return identical results (refer to Table 
1.2, page 11).  Additionally, regions identified in these genome scans do not always reveal 
previously identified and/or biologically plausible disease genes.  In this chapter, data is 
presented for one such region, 16q24.1, and the identification of a novel gene family, 
CRISPLD, that contributes to the genetic etiology of NSCLP. 
 
5.1. Chromosome 16q24.1 
In 2000, Prescott et al. performed a genome scan on a dataset comprised of caucasian 
sib-pairs from the UK and identified eleven regions across the genome that potentially 
harbor a clefting locus 
101
.  In a follow-up to that study, our laboratory genotyped the same 
genetic markers that showed linkage with association in their study in our large multiplex 
NSCLP nonHispanic white families 
106
.  Six regions, 2p13, 2q37, 11p12-14, 12q13, 16p13 
and 16q24, were identified 
106
.  Significant linkage was found to STR marker d16S3037 on 
chromosome 16q24.1 (p=0.00063).  Three other NSCLP genome scans and two meta-
analyses also suggested that a clefting gene is located near 16q21-24  
97,99,100,103,104,262
.  Two 
potential candidate genes lie within 1 Mb of this marker: interferon regulatory factor 8 
(IRF8) and cysteine-rich secretory protein LCCL domain containing 2 (CRISPLD2) 
160
.  
These genes were chosen as potential NSCLP candidate genes because (1) IRF8 is in the 
same gene family as IRF6, which has been associated with NSCLP, and (2) CRISPLD2 is 
795 bp 5’ of d16s3037 46,49,160. 
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5.2. Materials and Methods 
The details of the NSCLP family population, sample collection and DNA extraction, 
SNP selection criteria, genotyping, analysis (FBAT and HBAT), transcription binding site 
prediction algorithms, sequencing, silver staining and in situ hybridizations are described in 
Chapter 2. 
For this study, 63 multiplex families (56 nonHispanic white and seven Hispanic) and 
287 simplex parent-child trios or duos (213 nonHispanic white and 74 Hispanic) were 
genotyped with 18 SNPs (Table 5.1).  Additionally, a total of 246 Columbian NSCLP 
families (114 multiplex and 132 simplex parent-child trios) were genotyped with 12 
CRISPLD2 SNPs (Table 5.1).  The discrepancy in number of SNPs genotyped in the 
different datasets is due to the elimination of SNPs in linkage disequilibrium with other 
SNPs. 
 
5.3. Results 
5.3.1.  Microsatellite analysis 
In a follow-up study to Prescott et al.’s genome wide scan, we 
genotyped 37 STRs in 47 multiplex NSCLP families 
106
.  Reanalysis of 
the original data stratified by ethnicity with FBAT showed an 
additional microsatellite marker, D16S3037, with significant linkage 
with association to NSCLP (p=0.00063).  D16S3037 maps to 
chromosome 16q24.1.  There are 35 known genes in this region based 
on UniProt, RefSeq and GenBank mRNA. 
203
 
 
5.3.2. Candidate Gene Testing 
Interferon regulatory factor 8 (IRF8) was chosen as the first 
candidate gene because IRF8 belongs to the same family as IRF6, 
mutations in which are causal for Van der Woude syndrome and 
IRF6 variants have been shown to play an etiologic role in 
NSCLP 
46,47,49,135,137
.  Also, IRF8 is 1 Mb downstream of 
D16S3037.  Seven IRF8 SNPs (2 flanking and 5 intragenic) 
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Table 5.1:  16q24.1 SNPs genotyped in this study and allele frequencies 
 
Gene  dbSNP Chr:bp Location Alleles† 
NHW 
MAF
a
 
Hispanic 
MAF
b,*,**,***
 
Columbian 
MAF
c
 
IRF8 rs7193803 16:84482924 upstream G/T 0.306 0.4 NT 
IRF8 rs305082 16:84494729 intron 2 T/C 0.173 0.167 NT 
IRF8 rs305080 16:84499525 intron 2 C/T 0.283 0.308 NT 
IRF8 rs2292980 16:84502827 intron 3 A/G 0.286 0.308 NT 
IRF8 rs2280378 16:84510496 intron 7 C/T 0.418 0.423 NT 
IRF8 rs1568391 16:84513055 exon 9 T/G 0.447 0.8*** NT 
IRF8 rs880365 16:84517113 downstream C/T 0.21 0.467* NT 
CRISPLD2 rs4572384 16:83400728 upstream T/C 0.396 0.717*** 0.503*** 
CRISPLD2 rs1874014 16:83413267 intron 1 A/C 0.443 0.261*** NT 
CRISPLD2 rs8051428 16:83424753 intron 1 C/T 0.355 0.495** NT 
CRISPLD2 rs1546124 16:83429802 exon 2 C/G 0.298 0.322 0.294 
CRISPLD2 rs1874015 16:83435283 intron 2 T/C 0.307 0.193* 0.751*** 
CRISPLD2 rs12051468 16:83437215 exon 3 A/G 0.454 0.313** 0.338 
CRISPLD2 rs8061351 16:83440853 exon 4 T/C 0.284 0.32 0.393 
CRISPLD2 rs2646129 16:83444995 intron 5 A/G 0.368 0.185*** NT 
CRISPLD2 rs2326398 16:83460468 intron 8 A/G 0.344 0.312 0.315 
CRISPLD2 rs721005 16:83463849 exon 9 C/G 0.396 0.348 0.358 
CRISPLD2 rs774206 16:83477709 intron 13 A/G 0.364 0.283 0.334 
CRISPLD2 rs767050 16:83480610 exon 14 G/A 0.445 0.383 0.42 
CRISPLD2 rs2646112 16:83495601 intron 14 G/A 0.082 0.129 NT 
CRISPLD2 rs2641670 16:83498731 exon 15 G/A 0.21 0.371*** 0.266 
CRISPLD2 rs4783099 16:83499080 exon 15 C/T 0.364 0.423 0.412 
CRISPLD2 rs16974880 16:83500389 exon 15 T/G 0.301 0.371 0.316 
CRISPLD2 rs903194 16:83502930 downstream T/G 0.397 0.291 NT 
CRISPLD2 rs2641674 16:83510855 downstream T/C 0.373 0.303 NT 
 
†Major allele as identified in NHW listed first 
a
Minor allele frequency of nonHispanic white dataset 
b
Corresponding frequency in Hispanic dataset of nonHispanic white minor allele 
c
Corresponding frequency in Columbian dataset of nonHispanic white minor allele; p-values 
represent allele frequency differences between Columbian and Hisp datasets. 
*p<0.0125; **p<0.001; **p<0.0001 
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were genotyped in our Caucasian and Hispanic cohorts [Figure 
5.1A].  All SNPs were in Hardy-Weinberg equilibrium (HWE).  
Two SNPs had significantly different allele frequencies between 
the Hispanic and Caucasian populations [Table 5.1].  Hence, 
families were stratified by ethnicity  
for all statistical analyses.  There was significant linkage 
disequilibrium (LD) between SNPs within IRF8 (data not shown).  
No evidence for linkage or association with NSCLP was found by 
either parametric or nonparametric linkage analysis.  Previous 
interrogation of IRF6 in these populations showed an increased 
transmission of haplotypes constructed with the major allele 
rs2013162 (p=0.009) 
46
.  Using this haplotype and all IRF8 SNPs, 
IRF8-IRF6 gene-gene interaction was not detected.  The 
Colombian population was not genotyped for IRF8.   
Further evaluation of the 16q24.1 region for candidate genes 
revealed the cysteine-rich secretory protein LCCL domain 
containing 2 (CRISPLD2) gene, which is 795 bp upstream of 
D16S3037.  Eighteen CRISPLD2 SNPs (4 flanking and 14 
intragenic) were genotyped in the Caucasian and Hispanic 
multiplex families and simplex parent-child trios [Figure 5.1].  All 
SNPs were in HWE.  Seven of the 18 SNPs had significantly 
different allele frequencies between the Caucasian and Hispanic 
groups with a Bonferroni correction applied and p-value of 0.0125 
used as the criterion for significance [Table 5.1].  Parametric and 
nonparametric linkage analysis in the multiplex families did not 
demonstrate linkage in any of the ethnic groups.  FBAT analysis 
of the simplex Caucasian trios did not detect any altered 
transmission.  However, in the Caucasian multiplex families, 
altered transmission of several SNPs at the CRISPLD2 locus was 
noted [Table 5.2].  SNP rs1546124 (p=0.0006) yielded the largest 
p-value; SNPs rs4783099 and rs16974880 also yielded suggestive 
p-values (p=0.08 and p=0.03, respectively).  When correcting for 
multiplex pedigrees, FBAT p-values are still significant for 
rs1546124 and suggestive for rs4783099 and rs16974880 (p=0.01, 
p=0.16, p=0.07, respectively).  SNPs rs4783099 and rs16974880 
are in strong LD (D’=0.869), so haplotypes comprised of 
rs1546124 with either rs4783099 or rs16974880 were then tested 
[Table 5.3].  For the rs1546124-rs4783099 haplotype, an excess 
transmission of the 1-1 haplotype was detected when correcting 
for multiplex pedigrees (86 transmitted, 69 expected; p=0.002) 
with an overall departure from expected observed (p=0.01).  
There was an overtransmission of the 1-2 haplotype for 
rs1546124 and rs16974880 (83 observed vs. 66 expected, 
p=0.001), and an overall departure from expected for all the 
haplotypes (p=0.01).    
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Figure 5.1:  (A) IRF8 and (B) CRISPLD2 SNPs genotyped in this study* 
 
 
 
 
*Arrow denotes ATG start site 
†Taken from 203. 
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Table 5.2:  NHW and Hispanic CRISPLD2 FBAT results†* 
 NHW Hispanic 
dbSNP Praw Pcorrected Praw Pcorrected 
rs4572384 0.832 0.825 0.532 0.549 
rs1874014 0.356 0.368 0.853 0.853 
rs8051428 0.673 0.686 0.093 0.093 
rs1546124 0.001 0.012 0.532 0.532 
rs1874015 0.455 0.519 0.467 0.532 
rs12051468 0.960 0.967 0.505 0.450 
rs8061351 0.695 0.761 0.028 0.024 
rs2646129 0.646 0.700 0.225 0.166 
rs2326398 0.109 0.189 0.048 0.056 
rs721005 0.159 0.249 0.086 0.086 
rs774206 0.488 0.558 0.144 0.117 
rs767050 0.774 0.777 0.411 0.423 
rs2646112 0.178 0.262 0.808 0.808 
rs2641670 0.215 0.120 0.465 0.450 
rs4783099 0.081 0.169 0.206 0.217 
rs16974880 0.030 0.068 0.160 0.189 
rs903194 0.291 0.355 0.819 0.808 
rs2641674 0.937 0.937 0.371 0.317 
     
*Modified from 
203
 
†p<0.05 in bold 
 
Table 5.3:  CRISPLD2 Caucasian multiplex haplotypes†* 
rs1546124 rs4783099 rs16974880 Observed Expected p-value 
Allele 1 Allele 1  86 69 0.002 
Allele 1 Allele 2  36 40 0.38 
Allele 2 Allele 1  24 34 0.02 
Allele 2 Allele 2  8 2 0.27 
Allele 1  Allele 1 31 37 0.131 
Allele 1  Allele 2 83 66 0.001 
Allele 2  Allele 1 n/a n/a n/a 
Allele 2  Allele 2 22 31 0.05 
 
†Taken from 203. 
*p≤0.001 in bold 
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As the Hispanic sample is small, FBAT analysis was 
performed on the combined simplex and multiplex families.  A 
slightly altered transmission of SNPs rs8061351 (p=0.03) and 
rs2326398 (p=0.05) vwas noted [Table 5.2].  When correcting for 
multiplex pedigrees, FBAT p-values remain significant for 
rs8061351 (p=0.02) and become suggestive for rs2326398 
(p=0.06).  There was no evidence for altered transmission of a 
haplotype consisting of either these two SNPs or the SNPs 
identified in the Caucasian multiplex sample. 
A third NSCLP population consisting of Colombian multiplex 
families and simplex parent-child trios was tested.  Twelve 
CRISPLD2 SNPs that were informative in the Caucasian and 
Hispanic populations were run on the Colombian NSCLP 
population [Table 5.1].  In a comparison between the Hispanic 
and Colombian families, two SNPs (rs4572384 and rs1874015) 
had significantly different allele frequencies [Table 5.1].  
Interestingly, the Colombian sample generally had frequencies 
between the Caucasian and Hispanic samples.  Parametric and 
nonparametric linkage analysis did not show any evidence for 
linkage with NSCLP nor was there evidence for altered 
transmission in the Colombian multiplex and simplex families. 
There was significant linkage disequilibrium between SNPs 
genotyped in each population [Supplementary Table 5.1].  Both 
Caucasian [Supplementary Figure 5.1] and Hispanic 
[Supplementary Figure 5.2] populations contain an LD block 
encompassing the region spanning rs2641670 to rs16974880.  
While they both also exhibit strong LD in the region defined by 
rs2326398 to rs767050, this region is divided into two LD blocks 
in the Hispanics.  In addition, the Hispanics have an additional 
LD block consisting of rs1546124 and rs1874015.  A formal 
comparison of the LD between the Hispanics and the Caucasians 
detected significant differences based on D’ and r (p<0.0001 for 
both).  Because the Colombian sample was not genotyped for all 
of the SNPs, a statistical comparison between the LD patterns of 
the Colombians with either the Hispanic or the Caucasian 
populations was not  performed.  However, a visual inspection of 
the Colombian LD blocks found by Haploview [Supplementary 
Figure 5.3] reveals a pattern similar to that of the Hispanics. 
203
 
 
5.3.3. Expression Study 
CRISPLD2 in situ hybridizations were performed on E12.5-
E17.5 mouse sagittal and coronal sections to determine the 
CRISPLD2 expression in the developing embryo.  CRISPLD2 
was expressed in the developing oro- and nasopharynx at E13.5 
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[Figure 5.2A], the mandible at E14.5 [Figure 5.2B] and the 
cartilage primordia of the nasal bones, palate and tooth germs at 
E17.5 [Figure 5.2C].  CRISPLD2 is expressed in the liver at 
E14.5 and all time points examined [Figure 5.2D].  No other 
organ systems showed significant levels of expression. 
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5.3.4. Sequencing 
Fifteen exons and approximately 100bp of the intron/exon borders were sequenced in the 
CRISPLD2 gene in 25 individuals with CRISPLD2 susceptible haplotype.  Table 5.4 and 
Figure 5.3 summarizes the 20 sequence variants identified.  Nine variants were identified in 
the 5’ regions of the exons, including a previously unidentified polymorphism nine basepairs 
5’ of exon 12 (8:83468536; T>T/C).  One variant was identified in a 3’ region of an exon 
(exon 13); this variant has not been previously described (8:83471733; A>A/C).  Ten exonic 
single basepair variants were found, all previously identified, including three coding 
changes.  A stretch of 16-23 polythymines was identified in the untranslated portion of exon 
15.  The sequencing results from this region suggested that the length of this polythymine 
stretch was polymorphic.  Silver stained PCR products from this region for the 25 probands 
identified three different sizes of polythymine stretches (Figure 5.4).  To determine the 
normal frequency of these three alleles, silver staining was performed on the PCR products 
of this region on a total of 300 controls, including 100 unaffected parents of isolated NSCLP 
patients (CLP Parent Control), 100 unaffected parents of sporadic clubfoot cases (CF Parent 
Control) and 100 CEPH samples (CEPH Control).  The allele frequencies of each of the 
groups are listed in Table 5.5.  The allele frequencies significantly differed between the 
proband group versus each of the control groups (χ2 p=0.005); however, when comparing the 
frequencies of alleles in the cases versus the controls as a collective group, no significance 
was detected (χ2 p=0.32). 
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Figure 5.2:  CRISPLD2 expression in the mouse at (A) E13.5, (B) E14.5, (C) E17.5 and (D) 
E13.5 *† 
 
 
*Arrows denote expression.  T= tongue; Max= maxilla; Mand= mandible; P= palate; TG= 
tooth germ; L= liver. 
†Taken from 203. 
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Table 5.4:  SNP variants identified during sequencing. 
     Previous Sequencing 
dbSNP** bp Location Alleles† Source* MAF MAF 
rs7403974 83411052 5' exon 1 G/A Seq n/a 0.2 
rs2172623 83411102 exon 1 C/T Seq n/a 0.042 
rs4783086 83440412 5' exon 4 C/T Seq n/a 0.438 
rs4783087 83440475 5' exon 4 T/C Seq n/a 0.458 
rs8061351 83440603 exon 4 T/C TaqMan 0.284 0.289 
rs4783090 83441617 5' exon 5 G/A NCBI 0.223 1 
rs4782674 83445796 5' exon 6 C/T NCBI 0.242 0.125 
rs4782675 83445811 5' exon 6 C/T NCBI 0.242 0.125 
rs721004 83463481 5' exon 9 G/C NCBI 0.082 0.083 
rs721005 83463599 exon 9 C/G TaqMan 0.396 0.396 
SNP T>T/C 83468536 5' exon 12 T/C Seq n/a 0.042 
SNP A>G/A 83471733 3' exon 13 A/G Seq n/a 0.04 
rs767050 83480360 exon 14 A/G TaqMan 0.445 0.479 
rs3803632 83497673 5' exon 15 G/C; C/A NCBI 0.033 0.091 
rs1874008 83497980 exon 15 C/T NCBI 0.227 0.292 
rs12445556 83498390 exon 15 G/A NCBI 0.008 0.063 
rs2641670 83498481 exon 15 G/A TaqMan 0.210 0.260 
rs2646108 83498565 exon 15 G/A NCBI 0.188 0.140 
rs4783099 83498830 exon 15 C/A TaqMan 0.364 0.200 
rs17773634 83498876 exon 15 A/C NCBI 0.127 0.180 
 
†Major allele listed first 
*The source for the Previous MAF is listed here.  Seq = sequence data, TaqMan = SNP 
previously genotyped in our laboratory, NCBI = National Center for Biotechnology 
Information PubMed resource 
**SNP = novel SNP 
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Figure 5.3:  Schematic of variants identified during sequencing* 
 
 
 
*Green variants are 5’ of respective exon, blue variants are within the respective exon, purple variants are 3’ of the exon.  Numbers 
after the variant indicate the number of basepairs within the exon and the number of sequenced individuals that have the variant. 
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Figure 5.4:  Alleles identified during silver staining. 
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Table 5.5:  Polythymine tract allele frequencies. 
 
Allele 
CLP 
Proband 
Families 
CLP 
Parent 
Control 
CF Parent 
Control CEPH Control 
1 55% 61% 67% 59.8% 
2 1.7% 7% 1.5% 1.8% 
3 43% 32% 31% 38% 
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5.4. Discussion 
In this study, we evaluated the chromosome 16q24.1 region for 
a NSCLP genetic locus.  This region was first identified by 
Prescott et al. in a genome scan of Caucasian NSCLP sib pairs, and 
subsequently in four other genome scans of different NSCLP 
populations 
97,99,101,103,104
.  Analysis of STR D16S3037 in our 
dataset provided evidence for an association with NSCLP 
(p=0.00063).  Two candidate genes, IRF8 and CRISPLD2, were 
found in close proximity to this STR.  IRF8 was initially evaluated 
because it is 1 Mb downstream of D16S3037 and because it 
belongs to the same gene family as IRF6.  Mutations in IRF6 cause 
Van der Woude syndrome (VWS [OMIM:119300]), which is 
characterized by lower lip pits, CLP, CP or hypodontia 
135
.  In 
addition,  genetic variation in IRF6 has recently been shown to 
play an etiological role in the development of NSCLP 
46-49
.  No 
association was found for IRF8 and no interaction with IRF6 was 
detected in our dataset.   
CRISPLD2 is the closest gene to D16S3037, mapping 795 bp 
upstream.  While the function of CRISPLD2 is unknown, it 
contains a LCCL domain, which is common to other known genes 
[i.e., COCH (Coagulation factor C homolog; cochlin), Akhirin and 
CLCP1 (CUB, LCCL-homology coagulation factor V/VIII 
homology domains protein)] 
263-266
.  The function of the LCCL 
domain is speculated to be either structural, immunologic, or 
involved in cell motility 
264-266
.  Mutations in the LCCL domain of 
COCH have been identified in autosomal dominant nonsyndromic 
sensorineural deafness disorder (DFNA9 [OMIM:601369]) 
267
.  
Akhirin, which also contains a LCCL domain in the N-terminus, is 
postulated to play a role in chicken retinal development 
263
.  Recent 
research suggests that CLCP1 has a role in cellular motility and is 
regulated by ubiquitination 
265
.  Interestingly, a member of the 
ubiquitin family of genes, SUMO1 (small ubiquitin-like modifier 
1), has been shown to post-translationally modify genes involved 
in palatal morphogenesis and haploinsufficiency of SUMO1 has 
recently been linked to orofacial clefting 
268
. 
FBAT statistical analyses, which were performed without 
correcting for multiplex pedigrees, suggested an association with 
NSCLP in both our Caucasian and Hispanic populations.  After 
correcting for multiplex pedigrees, CRISPLD2 was only 
significantly associated with our Caucasian cohort [Table 5.2].  In 
the Caucasian population, SNP rs1546124, which is in exon 2, 51 
bp upstream of the ATG start codon, showed significantly altered 
transmission (p=0.01).  This sequence change in the putative 
promoter region could disrupt different regulatory elements, such 
as, a RNA polymerase binding or transcription factor 
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activator/inhibitor binding; either could affect CRISPLD2 protein 
expression which would affect the developmental process 
269,270
.  
To determine if this is theoretically the case, two transcription 
binding site prediction programs, PATCH and AliBaba2, were 
used 
208,209
.  Both identified a Sp1 site at rs1546124, which has 
either a C or G at this location in the DNA sequence.  However, 
PATCH predicts a Sp1 site when G is present but not with C, 
whereas AliBaba2 predicts two Sp1 sites for the G allele and 1 for 
the C allele.  Thus it is plausible that rs1546124 has an effect on 
CRISPLD2 expression.  Future functional studies are planned.  
SNPs rs4783099 and rs16974880 showed suggestive p-values 
(p=0.08 and p=0.03, respectively) and are in the 3’ UTR region of 
CRISPLD2 and thus were not submitted for this type of analysis. 
In the Hispanic simplex population, rs8061351 and rs2326398, 
in exon 4 and intron 8, gave evidence of association to NSCLP 
(p=0.02 and p=0.06, respectively; [Table 5.2]).   The exon 4 SNP 
is a synonymous change and should not affect the CRISPLD2 
protein.  However, synonymous SNPs in the medium-chain acyl-
CoA dehydrogenase (MCAD) and survival of motor neuron 
(SMN) genes that do not code for an amino acid change in the 
protein have been shown to interact with regulatory elements and 
alter gene function 
271
.  Also, synonymous changes have been 
shown to change amino acid translation time, resulting in altered 
protein structure and function 
176
.  These studies suggest that 
rs8061351 may play a functional role and needs to be further 
investigated.  It is unknown whether rs2326398, which is not a 
splice site or in a coding region, might cause a functional change in 
the protein 
180,181
.    Intronic SNPs have been shown to be 
associated with other complex diseases, such as IRF6 with 
NSCLP, RET (RET proto-oncogene) with Hirschsprung disease 
and CFH (complement factor H) with age-related macular 
degeneration 
46,47,49,183-185
.  Together, this suggests that common 
genetic variation in noncoding regions may be important and 
should not be overlooked in complex human diseases. 
FBAT analysis of our Caucasian multiplex cohort 
demonstrated an overtransmission of haplotypes consisting of 
rs1546124 and either rs4783099 or rs16974880, the latter of which 
are in strong LD (D’=0.859, p<0.00000) [Table 5.3].  This 
suggests that these SNPs may be disease causing variants or 
mutations exist that are in linkage disequilibrium with these 
overtransmitted haplotypes.  Sequencing of the CRISPLD2 gene in 
affected probands who have received one of the associated 
haplotypes is being performed.  
The CRISPLD2 SNPs were tested in a secondary population 
consisting of multiplex families and simplex parent-child trios 
from Colombia. The SNP allele frequencies were significantly 
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different from the original Hispanic population [Table 5.1].  This is 
not unexpected, as there is likely less admixture in the Colombian-
Hispanic population compared to the Texas-Hispanic population 
272
.  No association was found in the Colombian population with 
CRISPLD2 and NSCLP, in contrast to the Texas-Hispanic 
population.  This finding supports the theory that NSCLP is an 
etiologically heterogeneous disease and that genetic variation in 
different genes underlies NSCLP in different populations 
42
. 
 To evaluate whether CRISPLD2 plays a role in craniofacial 
development, in situ hybridization was performed at various stages 
of development.  Mouse embryos from E12.5 to E17.5, which are 
the critical stages of palatal development, showed that CRISPLD2 
is expressed in the mandible, cartilaginous primordia of the 
developing nose, palate, oro- and nasopharynx and liver [Figure 
5.2].  Thus, CRISPLD2 is expressed during facial development. 
203
 
 
To identify variants in CRISPLD2 that may segregate with NSCLP, 25 probands with 
overtransmitted susceptibility halplotypes were sequenced.  20 single basepair variants were 
identified, including ten exonic changes and ten intronic changes.  Of the exonic changes, 
only three were in the coding region.  Two of these three (rs8061351 and rs767050) are 
nonsynonymous changes and are not expected to alter the protein.  SNP rs721005 is a 
synonymous change, substituting serine for a threonine.  PolyPhen (http://www.bork.embl-
heidelberg.de/ PolyPhen) and SIFT (http://blocks.fhcrc.org.sift/SIFT.html) predict this amino 
acid substitution to be benign and tolerant, respectively.  Additionally, these three coding 
SNPs were previously genotyped in this sample set and were not associated to NSCLP 
203
. 
One variant, rs7403974, was identified in the intron sequence 40 bp 5’ of exon 1 (Figure 
5.3).  AliBaba2 and PATCH transcription binding site programs 
208,209
 both predict that a 
G>A nucleotide change results in a loss of a Sp1 binding site, potentially altering binding of 
regulatory elements to the CRISPLD2 gene.  This is similar to the transcription binding site 
change associated with SNP rs1546124, as previously discussed 
203
, further suggesting that 
transcriptional control of CRISPLD2 by Sp1 might play an etiologic role in NSCLP. 
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A 358 bp gap of noncoding sequence in exon 15 was difficult to sequence.  The 
chromatogram of this region suggested a stretch of 16-23 thymines.  Three alleles were 
identified in this region in our 25 probands and 300 controls (Figure 5.4).  The allele 
frequency of Allele 2, the rarest allele, was greater in the CLP parent control group versus the 
remaining groups, and is likely responsible for the overall χ2 significance level p=0.005.  
However, when combining the three control groups into one, significance was not detected, 
suggesting that this variant does not contribute to NSCLP etiology. 
These results demonstrate that variation in the CRISPLD2 may 
contribute to the NSCLP phenotype and that CRISPLD2 is 
expressed in the craniofacial region during critical time points of 
palatal fusion.  Variation in CRISPLD2 could affect CRISPLD2 
protein levels or could affect binding sites of other transcription 
factors that regulate CRISPLD2 expression.  This could lead to a 
perturbation of normal development and predisposition to orofacial 
clefting.  These results suggest that CRISPLD2 is a novel NSCLP 
candidate gene and additional studies are [warranted] to determine 
the role that this gene has in orofacial clefting etiology.  
Understanding the role of CRISPLD2 will provide additional 
information needed to understand the complex development of lip 
and palate and will help further delineate the genetic factors 
contributing to NSCLP. 
203
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Supplemental Table 5.1:  Linkage disequlibrium data on dbSNPs genotyped.  D’ is above the 
diagonal, p-value is below the diagonal. 
  a) Caucasian population 
  b) Hispanic population 
c) Columbian population 
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(A) Caucasian population LD 
Caucasian rs4572384 rs1874014 rs8051428 rs1546124 rs1874015 rs12051468 rs8061351 rs2646129 rs2326398 rs721005 rs774206 rs767050 rs2646112 rs2641670 rs4783099 rs16974880 rs903194 rs2641674 
rs4572384  0.00182 0.29459 0.125 0.07151 0.40109 0.72008 0.87537 0.14341 0.81397 0.78685 0.71278 0.89542 0.46258 0.56729 0.35162 0.24071 0.74533 
rs1874014 0.320  0.00000 0.31186 0.21094 0.08330 0.01434 0.38586 0.48807 0.44843 0.97689 0.47329 0.10315 0.33295 0.85089 0.67191 0.18713 0.11605 
rs8051428 0.119 0.401  0.00031 0.72258 0.00001 0.02266 0.50033 0.03735 0.03778 0.00809 0.18745 0.07456 0.37305 0.65078 0.00656 0.13986 0.05724 
rs1546124 0.109 0.127 0.445  0.00000 0.00000 0.05967 0.58329 0.21975 0.50437 0.74948 0.98977 0.84637 0.65200 0.31983 0.16206 0.40598 0.47144 
rs1874015 0.115 0.147 0.043 0.686  0.00000 0.00003 0.00075 0.01884 0.26118 0.18582 0.32908 0.15462 0.57861 0.00271 0.02576 0.40594 0.04532 
rs12051468 0.075 0.145 0.452 0.790 0.693  0.00146 0.41171 0.00106 0.00178 0.00085 0.00158 0.59907 0.16403 0.00052 0.00058 0.70742 0.34859 
rs8061351 0.026 0.285 0.175 0.118 0.292 0.340  0.00000 0.00101 0.00003 0.00007 0.00000 0.18542 0.02845 0.00181 0.00005 0.78724 0.84022 
rs2646129 0.017 0.089 0.047 0.042 0.237 0.079 0.772  0.16666 0.10510 0.38397 0.00002 0.71925 0.67054 0.33849 0.20835 0.09488 0.03767 
rs2326398 0.101 0.064 0.248 0.090 0.305 0.252 0.405 0.168  0.00000 0.00000 0.00000 0.00000 0.05871 0.00000 0.00000 0.03423 0.94668 
rs721005 0.016 0.060 0.221 0.050 0.129 0.212 0.470 0.177 0.948  0.00000 0.00000 0.00000 0.00217 0.00000 0.00000 0.01609 0.55548 
rs774206 0.018 0.002 0.310 0.022 0.163 0.243 0.481 0.103 0.841 0.970  0.00000 0.00000 0.00288 0.00000 0.00000 0.00085 0.69520 
rs767050 0.038 0.069 0.113 0.001 0.085 0.242 0.493 0.366 0.813 0.861 0.862  0.00003 0.00000 0.00002 0.00049 0.01887 0.00001 
rs2646112 0.018 0.430 0.254 0.026 0.196 0.090 0.186 0.061 0.838 1.000 1.000 0.892  0.00226 0.02543 0.04139 0.28258 0.83028 
rs2641670 0.067 0.142 0.154 0.034 0.044 0.181 0.187 0.043 0.330 0.474 0.497 0.553 0.355  0.00001 0.00292 0.08706 0.00001 
rs4783099 0.075 0.020 0.063 0.139 0.374 0.278 0.435 0.129 0.405 0.483 0.502 0.444 0.333 0.851  0.00000 0.00000 0.00000 
rs16974880 0.081 0.046 0.420 0.230 0.323 0.336 0.643 0.189 0.410 0.462 0.480 0.437 0.607 0.622 0.869  0.00000 0.00000 
rs903194 0.083 0.119 0.151 0.064 0.061 0.030 0.031 0.165 0.222 0.227 0.333 0.206 0.283 0.257 0.723 0.879  0.00000 
rs2641674 0.023 0.140 0.153 0.057 0.149 0.083 0.027 0.239 0.004 0.036 0.025 0.404 0.034 0.625 0.654 0.662 0.458  
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(B) Hispanic population LD 
Hispanic rs4572384 rs1874014 rs8051428 rs1546124 rs1874015 rs12051468 rs8061351 rs2646129 rs2326398 rs721005 rs774206 rs767050 rs2646112 rs2641670 rs4783099 rs16974880 rs903194 rs2641674 
rs4572384  0.07314 0.24108 0.82051 0.15488 0.00085 0.13827 0.00231 0.06211 0.06974 0.06698 0.80926 0.45105 0.14652 0.77986 0.42520 0.00056 0.02542 
rs1874014 0.247  0.44465 0.11291 0.59856 0.02904 0.87973 0.91394 0.02424 0.01503 0.03546 0.50023 0.08935 0.62938 0.42433 0.84594 0.87252 0.32876 
rs8051428 0.247 0.181  0.00018 0.63155 0.58464 0.49559 0.48269 0.14213 0.04130 0.05408 0.41317 0.77715 0.95702 0.76440 0.11223 0.33800 0.35337 
rs1546124 0.075 0.534 0.659  0.00000 0.35842 0.75856 0.11036 0.45408 0.23908 0.57703 0.01727 0.95748 0.78614 0.33405 0.36395 0.00148 0.02404 
rs1874015 0.227 0.232 0.115 1.000  0.15532 0.28318 0.00004 0.94473 0.57125 0.23972 0.18893 0.31958 0.28290 0.99168 0.63995 0.00123 0.00212 
rs12051468 0.420 0.329 0.104 0.115 0.222  0.03785 0.00171 0.02047 0.04814 0.11230 0.43475 0.65843 0.05399 0.28338 0.35543 0.00556 0.00002 
rs8061351 0.230 0.046 0.110 0.041 0.408 0.467  0.48408 0.43031 0.20390 0.25477 0.39037 0.00223 0.49675 0.52616 0.87227 0.24865 0.89230 
rs2646129 0.427 0.042 0.152 0.310 0.455 0.486 0.126  0.88233 0.78220 0.49193 0.20893 0.17213 0.54881 0.80530 0.55697 0.00062 0.03617 
rs2326398 0.230 0.318 0.271 0.090 0.022 0.267 0.201 0.046  0.00000 0.00000 0.00001 0.06208 0.31207 0.60030 0.16343 0.05133 0.02054 
rs721005 0.250 0.383 0.374 0.148 0.097 0.238 0.329 0.093 0.962  0.00000 0.00000 0.01848 0.18329 0.33855 0.21375 0.11794 0.04008 
rs774206 0.240 0.360 0.405 0.083 0.193 0.184 0.299 0.115 0.869 0.956  0.00000 0.02538 0.34739 0.29749 0.22457 0.04806 0.08058 
rs767050 0.056 0.190 0.123 0.445 0.329 0.153 0.194 0.261 0.835 0.920 1.000  0.00086 0.00201 0.00064 0.00001 0.24452 0.06932 
rs2646112 0.160 0.256 0.097 0.024 0.857 0.081 0.611 0.997 0.353 0.499 0.447 1.000  0.33048 0.48766 0.05241 0.00038 0.00770 
rs2641670 0.398 0.139 0.008 0.056 0.282 0.359 0.143 0.171 0.219 0.300 0.243 0.434 0.263  0.00000 0.00014 0.69810 0.40246 
rs4783099 0.076 0.159 0.045 0.229 0.003 0.228 0.082 0.067 0.082 0.157 0.203 0.651 0.295 0.942  0.00000 0.01174 0.00707 
rs16974880 0.221 0.058 0.261 0.113 0.075 0.215 0.036 0.169 0.193 0.168 0.192 0.843 0.709 0.773 0.885  0.08215 0.04195 
rs903194 0.482 0.056 0.180 0.472 0.496 0.339 0.169 0.517 0.244 0.208 0.264 0.256 0.648 0.095 0.628 0.508  0.00000 
rs2641674 0.294 0.153 0.197 0.295 0.450 0.498 0.018 0.277 0.254 0.243 0.213 0.365 0.481 0.180 0.586 0.499 0.636  
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(C) Columbian population LD 
Colombian rs4572384 rs1874014 rs8051428 rs1546124 rs1874015 rs12051468 rs8061351 rs2646129 rs2326398 rs721005 rs774206 rs767050 rs2646112 rs2641670 rs4783099 rs16974880 rs903194 rs2641674 
rs4572384      0.83433 0.45756 0.82462 0.74959  0.02033 0.13929 0.46181 0.00419  0.89265 0.00060 0.00339   
rs1874014                      
rs8051428                      
rs1546124 0.022      0.00000 0.00000 0.02976  0.34113 0.43297 0.42755 0.34374  0.29150 0.16889 0.35768   
rs1874015 0.078     0.678  0.00000 0.24477  0.54369 0.89062 0.73042 0.73606  0.80120 0.01737 0.00614   
rs12051468 0.022     0.702 0.782  0.20808  0.00184 0.00078 0.03456 0.16341  0.02560 0.37741 0.05023   
rs8061351 0.032     0.177 0.107 0.208   0.00082 0.00042 0.01201 0.02534  0.49423 0.25406 0.71040   
rs2646129                      
rs2326398 0.263     0.149 0.107 0.247 0.472   0.00000 0.00000 0.00000  0.14360 0.01179 0.00027   
rs721005 0.160     0.114 0.021 0.267 0.466  0.922  0.00000 0.00000  0.09332 0.00335 0.00038   
rs774206 0.082     0.115 0.056 0.161 0.367  0.748 0.863  0.00000  0.23179 0.00857 0.00077   
rs767050 0.239     0.110 0.044 0.172 0.201  0.775 0.836 0.879   0.00000 0.00000 0.00000   
rs2646112                      
rs2641670 0.017     0.186 0.051 0.374 0.074  0.267 0.301 0.201 0.559   0.00000 0.00000   
rs4783099 0.313     0.171 0.327 0.082 0.149  0.237 0.259 0.240 0.612  1.000  0.00000   
rs16974880 0.367     0.150 0.469 0.150 0.039  0.290 0.282 0.275 0.677  0.941 0.877    
rs903194                      
rs2641674                      
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Supplemental Figure 5.1:  LD plot for CRISPLD2 SNPs in nonHispanic white population.† 
 
 
 
†Taken from 203.
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Supplemental Figure 5.2:  LD plot for CRISPLD2 SNPs in Hispanic population.† 
 
 
 
†Taken from 203
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Supplemental Figure 5.3:  LD plot for CRISPLD2 SNPs in Columbian population.† 
 
 
 
†Taken from 203
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Chapter Six: Using previous studies to identify new candidate genes: 
Identification of association between NSCLP and CRISPLD1 
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6.0. Introduction 
In chapter three, the WNT gene family, which plays an important role in craniofacial 
development, was interrogated and we identified association between five WNT genes and 
NSCLP 
118
.  In chapter five, after identifying significance with STR marker d16s3037 which 
lies near the IRF6 gene family member IRF8, we tested for association between IRF8 and 
NSCLP 
203
.  IRF8 was not associated with NSCLP; however, we did find that variation in 
the CRISPLD2 gene, located adjacent to this STR, was associated with NSCLP and is 
expressed in the developing murine craniofacies 
203
.  CRISPLD2 is a novel gene with no 
known function.  There is a second CRISPLD gene, CRISPLD1, that shares 70% homology 
at the nucleotide level and 58% at the peptide level with CRISPLD2 
160
.  Recent findings 
from a genome scan performed in our laboratory suggest that chromosome region 8q13.2-
21.13, which contains the CRISPLD1 gene, may be linked to NSCLP. 
 
6.1. Chromosome 8q13.2-21.13 
Results of our recent genome scan from nine multiplex nonHispanic white NSCLP 
families identified 11 chromosomal regions with LOD score ≥ 1.5 105 (see Chapter 3).  
Regions with LOD score between 1.0 and 1.5 were noted but not included in the original 
manuscript.  Of particular interest was the additional finding that the 8q13.2-21.13 
chromosomal region, with a LOD score of 1.23, contained the CRISPLD1 gene (Figure 6.1).  
This region has not been previously detected to be associated with NSCLP using genome 
scans.  CRISPLD1 is a member of the same family as CRISPLD2, which is a novel gene 
that we have recently shown to be associated with NSCLP and expressed in developing 
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Figure 6.1: LOD score plot shown by cMs for the NHW families on chromosome 8.  
 
Legend: The CRISPLD1 gene (basepairs 76059309-76108097) fall between dbSNPs 
rs2016354 (88.14cM), rs10701 (88.20cM) and rs1464092 (88.57), all with LOD=1.226. 
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murine craniofacies 
203
.  Additionally, CRISPLD1 has been shown to be expressed in the 
brain, spinal cord, nose, alimentary system, respiratory system, skeleton and limbs 
(EURExpress II; www.eurexpress.org/ee/).  These findings led us to assess whether there 
was an association between CRISPLD1 and NSCLP. 
 
6.2. CRISPLD gene family and folic acid 
Both CRISPLD1 and CRISPLD2 contain more cysteine residues (25 and 26, 
respectively) when compared to the average cysteine composition of comparable sized 
proteins (5% vs. <2%) 
273
.  Cysteine, a nonessential amino acid, is synthesized in the folate 
pathway (Figure 6.2) 
274
.  Genes in this pathway have been of interest in the study of birth 
defects because periconceptional folic acid usage decreases the birth prevalence of neural 
tube defects up to 70% 
59,60,275-278
.  Likewise, the recurrence rate of orofacial clefting has 
been reduced in mothers taking higher doses of periconceptional folate but the reduction of 
NSCLP on a population level has been modest 
29,63,96,279-283
.  The 5,10-
methylenetetrahydrofolate reductase (MTHFR) gene regulates homocysteine levels and two 
nonsynonymous coding polymorphisms C677T (alanine to valine) and A1298C (glutamate 
to alanine) affect the enzymatic activity 
88,284
.  Studies assessing these MTHFR variants find 
minimal if any association with NSCLP 
64,65,67,68,81,83,88,284-286
.  However, a new study finds 
evidence suggesting that the folate pathway genes have a role in NSCLP 
286
. 
Perturbation of the folate pathway could affect the production of cysteines with a 
resulting downstream effect on the synthesis and/or function of the CRISPLD genes, both of 
which require a large number of cysteine residues.  Here, we asked if CRISPLD1 was 
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Figure 6.2:  Folate gene pathway* 
 
 
*dUMP = deoxyuridine monophosphate; TYMS = Tymidylate synthetase; FOLR2 = Folate 
receptor 2; MTHFS = 5,10-methylenetetrahydrofolate synthase; MTHFR = 5,10-
methylenetetrahydrofolate reductase; MTRR = 5-methyletetrahydrofolate-homocysteine 
methyltransferase reductase; MTR = Methylenetetrahydrofolate dehydrogenase 
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associated with NSCLP and then tested whether CRISPLD1, CRISPLD2 and folate pathway 
genes interact to create a susceptibility to NSCLP.  
 
6.3. Materials and Methods 
Refer to chapter two for sample collection, DNA extraction, Linkage IVb Panel 
Genotyping, SNP criteria, genotyping, and analysis (parametric and nonparametric linkage 
parameters and analysis, FBAT, PDT, G-PDT, APL and GEE). 
When this study was undertaken, 91 and 258 nonHispanic white and 39 and 91 Hispanic 
families with positive (multiplex) and negative (trios) histories of NSCLP, respectively, 
were genotyped with nine SNPs (Table 6.1; Figure 6.3).  Additionally, 97 SNPs spanning 14 
folate pathway genes were interrogated and included: Betaine-homocysteine 
methyltransferase (BHMT, 6 SNPs), BHMT2 (6 SNPs), Cystathionine-beta-synthase (CBS, 
12 SNPs), Folate receptor 1 (FOLR1, 4 SNPs), FOLR2 (4 SNPs), Methylenetetrahydrofolate 
dehydrogenase 1 (MTHFD1, 12 SNPs), MTHFD2 (4 SNPs), 5,10-methylenetetrahydrofolate 
reductase (MTHFR, 8 SNPs), 5,10-methylenetetrahydrofolate synthase (MTHFS, 4 SNPs), 
Methylenetetrahydrofolate dehydrogenase (MTR, 9 SNPs), 5-methyletetrahydrofolate-
homocysteine methyltransferase reductase (MTRR, 3 SNP), ATG9 autophagy related 9 
homolog (NOS3, 6 SNPs), Solute carrier family 19, member 1 (SLC19A1, 10 SNPs) and 
Tymidylate synthetase (TYMS, 9 SNPs) 
286
 (Supplemental Table 6.1). 
 
6.4. Results 
Ten SNPs spanning chromosome 8q21.11-8q21.12 (Illumina Linkage IVb panel) in the 
nonHispanic white multiplex families gave parametric and nonparametric linkage LOD 
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Table 6.1:  CRISPLD1 SNPs genotyped in this study and allele frequencies 
Gene  dbSNP Chr:bp Location Alleles† 
NHW 
MAF
a
 
Hispanic 
MAF
b,*
 p-value 
CRISPLD1 rs2925155 8:76048852 upstream A/G 0.263 0.317 0.033 
CRISPLD1 rs960856 8:76057462 upstream T/A 0.329 0.248* 0.002* 
CRISPLD1 rs7841231 8:76065317 intron 2 A/G 0.321 0.232* 0.0005* 
CRISPLD1 rs17295835 8:76069196 intron 2 T/C 0.299 0.354 0.035 
CRISPLD1 rs1455809 8:76075622 intron 2 T/C 0.312 0.234* 0.002* 
CRISPLD1 rs1455796 8:76086362 intron 2 C/G 0.405 0.411 0.804 
CRISPLD1 rs10957748 8:76101956 intron 12 C/T 0.292 0.21* 0.001* 
CRISPLD1 rs13248650 8:76109250 downstream T/G 0.3 0.362 0.019 
CRISPLD1 rs11988595 8:76115241 downstream C/T 0.31 0.233* 0.003* 
 
†Major allele as identified in NHW listed first 
a
Minor allele frequency of nonHispanic white dataset 
b
Corresponding frequency in Hispanic dataset of nonHispanic white minor allele 
c
Corresponding frequency in Columbian dataset of nonHispanic white minor allele; p-values 
represent allele frequency differences between Columbian and Hisp datasets. 
*p<0.01 
 
 
Figure 6.3:  CRISPLD1 SNPS 
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scores of 1.23 and 1.07, respectively (Figure 6.1).  Although these LOD scores are not 
considered significant, the CRISPLD1 gene is in this region. 
Nine CRISPLD1 SNPs (5 intragenic, 4 intergenic; Figure 6.3, Table 6.1) were 
genotyped in our NHW and Hispanic families.  All SNPs had >95% call rate and were in 
HWE.  The data was stratified by ethnicity because the allele frequencies for five of the nine 
SNPs differed between the NHW and Hispanic groups (p≤0.006).  The data was also 
stratified by the presence or absence of family history (FH) 
214
. Significant linkage 
disequilibrium was found in both datasets (r
2
>0.95; Supplemental Table 6.1).  A maximum 
LOD score of 1.35 was found to CRISPLD1 SNPs in NHWs (data not shown). There was no 
evidence of linkage in the Hispanic dataset.  
Association analysis of the single SNPs identified altered transmission for only 
rs1455809 in the NHW simplex families (p=0.05) (Supplemental Table 6.2).  No single SNP 
associations were detected in the Hispanic group.  None of the CRISPLD1 2-SNP 
haplotypes demonstrated altered transmission in either ethnicity (data not shown). 
Three gene-gene interactions were detected between CRISPLD1 and CRISPLD2 SNPs 
(0.003≤p<0.01) (Table 6.2).  The same CRISPLD1 SNPs in NHW and Hispanics interacted 
with different CRISPLD2 SNPs in each ethnic group (Table 6.2).  The most significant 
interactions were rs13248650–rs12051468 (p=0.004) and rs13248650-rs8051428 (p=0.003) 
in the NHW and Hispanic groups, respectively. 
   GEE analysis identified numerous interactions between SNPs in CRISPLD1 and 
CRISPLD2 and the folate pathway genes, even after Bonferroni correction (p<0.0017).  In 
the NHW dataset, SNPs in five of the folate pathway genes interacted with SNPs in 
CRISPLD1.  The most significant interaction was between rs7166109 in MTHFS and 
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Table 6.2:  CRISPLD1-CRISPLD2 Gene Interactions   
    
Ethnicity CRISPLD1/SNP CRISPLD2/SNP 
p-
value* 
n
o
n
H
is
p
an
ic
 w
h
it
e 
rs13248650 rs12051468 0.004 
rs2925155 rs12051468 0.010 
rs960856 rs903194 0.012 
rs7841231 rs903194 0.015 
rs13248650 rs8051428 0.022 
rs17295835 rs12051468 0.023 
rs10957748 rs12051468 0.039 
rs10957748 rs903194 0.043 
H
is
p
an
ic
 
rs13248650 rs8051428 0.003 
rs17295835 rs8051428 0.018 
rs7841231 rs2646112 0.02 
rs17295835 rs2646112 0.022 
rs13248650 rs2646112 0.024 
rs960856 rs721005 0.024 
rs7841231 rs721005 0.03 
 
*p<0.05, p<0.01 bolded   
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rs10957748 (p=0.0005) (Table 6.3).   rs7166109/MTHFS interacted with four other 
CRISPLD1 SNPs  (p≤0.002).  Three different CBS SNPs interacted with four different 
CRISPLD1 SNPs; rs1455796/CRISPLD1 interacted with two different CBS SNPs (Table 
6.3).  In the Hispanic dataset, the most significant CRISPLD1 interactions involved SNPs in 
MTR (0.001≤p≤0.005) (Table 6.3).  Additionally, two different SNPs in TYMS interacted 
with different CRISPLD1 SNPS in each ethnic group.    
Numerous interactions between CRISPLD2 and folate pathway genes were detected in 
both datasets (Table 6.4).  In the NHWs, there were seventeen SNPs in eleven folate 
pathway genes interacting with CRISPLD2 SNPs; SNPs in two genes survive Bonferroni 
correction.  In addition, by chance alone, there should be only one (0.05 x 14) gene 
interaction with p<0.05; however, eleven genes interacted with CRISPLD2 SNPs with 
p<0.01.  The most significant interaction was with BHMT2 (0.0005≤p≤0.003).  Two MTR 
SNPs, rs1546124 and rs1874015, also interacted with CRISPLD2 (0.0009≤p≤0.007).  In the 
Hispanics, there were ten SNPs in six folate pathway genes interacting with CRISPLD2.  
The most significant interaction was with a SNP in TYMS.  Interestingly, in both groups, 
rs2236222/MTHFD1 interacted with rs12051468/CRISPLD2 (0.003≤p≤0.008).  Again, 
while only one gene would be expected to interact with CRISPLD2 SNPs with p<0.05, there 
are six genes with p<0.01. Furthermore, for both ethnic groups, SNPs in TYMS, MTHFR 
and FOLR1 interacted with CRISPLD2 SNPs.  
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Table 6.3:  Folate Pathway and CRISPLD1 gene interactions 
    
Ethnicity Gene/SNP 
CRISPLD1 
SNP 
p-
value* 
n
o
n
H
is
p
an
ic
 w
h
it
e 
CBS/rs234783 
rs1455796 0.004 
rs13248650 0.005 
rs17295835 0.006 
CBS/rs2851391 rs2925155 0.007 
CBS/rs12329790 rs1455796 0.008 
MTHFS/rs7166109 
rs10957748 0.0005 
rs960856 0.001 
rs7841231 0.001 
rs11988595 0.001 
rs1455809 0.002 
TYMS/rs502396 rs10957748 0.01 
H
is
p
an
ic
 MTR/rs1266164 rs1455796 0.001 
MTR/rs12354209 rs1455796 0.004 
MTR/rs1806505 rs10957748 0.005 
TYMS/rs11540152 rs1455796 0.004 
 
*p-value≤0.01    
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Table 6.4:  Folate Pathway and CRISPLD2 Gene Interactions 
    
Ethnicity Gene/SNP 
CRISPLD2 
SNP 
p-
value* 
n
o
n
H
is
p
an
ic
 w
h
it
e 
BHMT/rs645112 rs1874014 0.009 
BHMT/rs3733890 rs16974880 0.01 
BHMT2/rs2253262 rs1874014 0.0005 
BHMT2/rs682985 rs1874014 0.001 
BHMT2/rs1422086 rs1874014 0.003 
FOLR1/rs3016432 rs2646112 0.007 
FOLR2/rs2276048 rs2646112 0.005 
MTHFD1/rs2236222 rs12051468 0.008 
MTHFD2/rs7587117 rs2641670 0.003 
MTHFR/rs1476413 rs8051428 0.007 
MTHFS/rs2586179 
rs1874015 0.003 
rs767050 0.009 
MTR/rs12354209 
rs1546124 0.0009 
rs1874015 0.007 
MTR/rs1266164 rs1546124 0.004 
NOS3/rs1800779 rs16974880 0.005 
NOS3/rs2373929 rs16974880 0.005 
TYMS/rs11540152 rs2646129 0.008 
TYMS/rs2853532 rs12051468 0.010 
H
is
p
an
ic
 
CBS/rs2851391 rs2646112 0.009 
FOLR1/rs2071010 
rs774206 0.006 
rs721005 0.009 
MTHFD1/rs2236222 rs12051468 0.003 
MTHFD1/rs11849530 rs2641674 0.006 
MTHFR/rs1801131 rs2646112 0.003 
MTHFR/rs1476413 rs2646112 0.003 
MTHFR/rs535107 rs8061351 0.007 
SLC19A1/rs3788205 rs4783099 0.01 
TYMS/rs495139 rs8061351 0.002 
TYMS/rs1001761 rs8061351 0.003 
 
*p-value≤0.01    
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6.5. Discussion 
In previous studies, we reported the association of variation in CRISPLD2 with NSCLP 
and showed that CRISPLD2 was expressed in the craniofacies of developing mouse 
embryos at E13.5 
203
.  This association has been confirmed in an independent dataset 
287
.  In 
our on-going studies to define the genetic loci contributing to NSCLP, 11 chromosomal 
regions with LOD scores ≥ 1.5 were identified in a genome scan performed on nine 
multiplex NHW NSCLP families 
105
.  A LOD score of 1.23 was found for the 8q13.2-21.13 
chromosomal region which contains the CRISPLD1 gene; CRISPLD1 has significant 
homology to CRISPLD2 and both genes are composed of more cysteines than comparable-
sized proteins (5% protein composition vs. 2%) 
273
.  The cysteines provide secondary 
structure to the protein backbone and help protect cells against the harmful effects of 
oxidation 
288,289
.    These interesting results led to the interrogation of CRISPLD1 as a 
candidate NSCLP gene.  In complementary studies, we show that variation in different 
folate pathway genes individually and through interactions contribute to NSCLP 
290
.  
Interestingly, cysteines, which could potentially be utilized by the CRISPLD genes, are 
produced in the homocysteine biosynthesis pathway, which is part of the folate pathway 
291
.  
Based on these observations, we asked whether the CRISPLD genes interacted with genes in 
the folate pathway.   
We show that only one CRISPLD1 SNP, rs1455809, had marginally altered transmission 
(p=0.05) suggesting that variation in CRISPLD1 alone does not play a significant etiologic 
role in NSCLP.  Moreover, there were only three CRISPLD1-CRISPLD2 interactions (two 
in NHWs and one in Hispanics) suggesting that variants in these genes do not interact to 
create a significant susceptibility to NSCLP.  Indeed, their expression patterns in mice are 
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different.  At E14.5, CRISPLD1 is expressed in the mouse brain, spinal cord, nose, 
alimentary system, respiratory system, skeleton and limbs, while CRISPLD2 is expressed in 
the oral region, visceral organs, alimentary system and salivary gland 
(www.eurexpress.org/ee/) 
203
.  In zebrafish, CRISPLD2 is expressed in the craniofacial 
region and tail at all stages of development while CRISPLD1 localizes to the 
splanchocranium, pectoral fin, presumptive vertebrate and epiphysis  (Chiquet and Hecht, 
unpublished results) 
292
.   
Folic acid is important in embryogenesis and this is underscored by the 70% reduction of 
neural tube defects since folic acid supplementation of grain products in 1998 
277,281,293,294
.  
While a similar reduction has not been observed for NSCLP on a population-basis, 
decreased recurrence of NSCLP has been observed when high-risk mothers take high dose 
folic acid pre- and post conception 
29,60,282,283,295
.  This suggests that perturbation of folic 
acid levels or genes in the folate pathway could contribute to NSCLP.  To evaluate this 
question, we first assessed whether folate pathway genes were associated with NSCLP 
290
.  
Evidence for an association was found for SNPs in NOS3, TYMS, MTR, BHMT2, MTHFS 
and SLC19A1; many of the associated variants occurred in potential promoter or regulatory 
regions.  Complete description of the results is found in Blanton et al. 2010.  The 
endogenous folate pathway is responsible for synthesizing cysteine and cysteine is required 
for the CRISPLD1/2 protein structures.  This led us to postulate that CRISPLD genes 
interact with genes in the folate pathway.  Indeed, we found evidence for several 
interactions.  In the NHWs, rs502396 in TYMS interacted with CRISPLD1 and this SNP 
had altered transmission in the single SNP folate pathway gene analysis 
290
.  Similarly, for 
CRISPLD2, two different SNPs in TYMS, rs11540152 and rs2853532, interacted although 
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these SNPs did not have altered transmission in the folate study.  Additionally, rs2373929 in 
NOS3 interacted with CRISPLD2 and this SNP also exhibited altered transmission in the 
single SNP folate pathway gene analysis.  In the Hispanics, three MTR SNPs interacted with 
CRISPLD1 but they were different from the MTR SNPs identified in the single SNP folate 
analysis.  For CRISPLD2, rs3788203 in SLC19A1, which was associated in the single folate 
SNP analysis, also showed interaction.  These results are particularly interesting because 
MTR is necessary to metabolize homocysteine to methionine 
291
.  NOS3 directly regulates 
MTR and SLC19A1 affects 5mTHF, an intermediary that is also metabolized by MTR.  
Additionally, interactions with both CRISPLD genes were found for CBS, BHMT and 
BHMT2 in the NHW dataset.  These genes also participate in the methionine cycle.  Other 
interactions were found for both CRISPLD genes and TYMS and MTHFS, both of which 
participate in the DNA synthesis necessary for embryonic development.   
Altogether, these results suggest that CRISPLD genes play a role in NSCLP but not 
through a simple mechanism.  We have shown that variation in CRISPLD2 is associated 
with NSCLP but CRISPLD1 alone is not.  A more likely mechanism that is suggested by 
these results is that perturbation of multiple genes in a pathway affects protein function, 
which can have a profound effect on embryogenesis.  Indeed, we have found the same 
etiologic model for nonsyndromic clubfoot, which is another common complex birth defect 
296
.  These results would also fit what is known about recurrence in NSCLP wherein high 
dose folic acid reduces the recurrence in high-risk families.  These families may have more 
liability genes that could potentially respond to drug/vitamin therapy.  In contrast, on a 
population basis, genetic heterogeneity may play a role and folate deficiency may only be a 
small piece of the puzzle. Thus additional studies are necessary to define all the genetic 
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contributions.  Additionally, validation and functional studies will help determine the 
significance of these findings to NSCLP.  These results are intriguing because they help 
expand our understanding of the CRISPLD gene family and its role in clefting etiology.   
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Supplemental Table 6.1:  Folate SNPs genotyped in Blanton et al., 2010 that were used for 
GEE interactions in this study.  Modified from 
286
. 
 
 
 111 
 
 
 112 
 
 113 
 
Supplemental Table 6.2:  CRISPLD1 Linkage Disequilibrium 
 
 rs2925155 rs960856 rs7841231 rs17295835 rs1455809 rs1455796 rs10957748 rs13248650 rs11988595 
rs2925155   0.092 0.088 0.627 0.086 0.266 0.078 0.611 0.086 
rs960856 0.055   0.924 0.131 0.864 0.134 0.772 0.141 0.864 
rs7841231 0.062 0.964   0.175 0.974 0.149 0.861 0.176 0.974 
rs17295835 0.593 0.191 0.201   0.176 0.373 0.149 0.970 0.173 
rs1455809 0.055 0.876 0.886 0.179   0.178 0.864 0.180 1.000 
rs1455796 0.230 0.247 0.254 0.279 0.281   0.166 0.369 0.178 
rs10957748 0.047 0.821 0.838 0.170 0.904 0.266   0.154 0.864 
rs13248650 0.609 0.186 0.192 0.967 0.193 0.284 0.179   0.179 
rs11988595 0.052 0.887 0.893 0.186 0.972 0.287 0.903 0.193   
          
*Hispanic above diagonal, nonHispanic white below.  r2 values reported    
yellow= 0.7≤r2<0.8         
orange= 0.8≤r2<0.9         
red-orange: r
2≥0.9         
 114 
 
Supplemental Table 6.3:  CRISPLD1 association results in (A) NHW and (B) Hispanic datasets* 
(A) 
  All Positive Family History Negative Family History 
dbSNP PDT G-PDT APL FBAT-e PDT G-PDT APL FBAT-e PDT G-PDT APL FBAT-e 
rs2925155 0.7404 0.9496 0.1593 0.4170 0.9449 0.6764 0.1786 0.6174 0.5211 0.3040 0.4565 0.5211 
rs960856 0.4527 0.3119 0.2647 0.3440 0.7021 0.5830 0.3185 0.5446 0.4669 0.4009 0.4406 0.4669 
rs7841231 0.4225 0.0817 0.1201 0.3154 0.5186 0.3379 0.2494 0.3018 0.6331 0.1838 0.2427 0.6331 
rs17295835 0.7170 0.8964 0.1384 0.4214 0.7355 0.9047 0.6483 0.9452 0.3336 0.2588 0.1394 0.3336 
rs1455809 0.5741 0.0544 0.1702 0.4962 0.7400 0.5096 0.2320 0.6216 0.6310 0.0447 0.3453 0.6310 
rs1455796 0.1425 0.2988 0.5498 0.1942 0.3681 0.5477 0.7520 0.6029 0.2191 0.4790 0.6440 0.2191 
rs10957748 0.7595 0.0643 0.3004 0.6535 0.9484 0.3091 0.6522 0.9857 0.5610 0.0760 0.2746 0.5640 
rs13248650 1.0000 0.8348 0.2349 0.6331 0.5773 0.8800 0.9358 0.9302 0.5050 0.2904 0.1726 0.5050 
rs11988595 0.7206 0.0630 0.3696 0.6712 0.7928 0.4365 0.3222 0.7066 0.8071 0.0810 0.5822 0.8071 
(B) 
  All Postive Family History Negative Family History 
dbSNP PDT G-PDT APL FBAT-e PDT G-PDT APL FBAT-e PDT G-PDT APL FBAT-e 
rs2925155 0.7237 0.9488 0.4669 0.8539 0.3532 0.6146 0.7940 0.4489 0.7009 0.8381 0.5219 0.3532 
rs960856 0.8728 0.9255 0.3265 0.4855 0.4838 0.4987 0.2697 0.8348 0.6733 0.6748 0.5831 0.4838 
rs7841231 0.7456 0.9248 0.1243 0.4533 0.3545 0.3515 0.3497 1.0000 0.6547 0.6612 0.9022 0.3545 
rs17295835 0.8618 0.7953 0.4030 0.6732 0.3304 0.6381 0.6514 0.5896 0.5529 0.7393 0.9409 0.3304 
rs1455809 1.0000 0.5914 0.3373 0.3173 0.3763 0.1901 0.3053 0.6374 0.5023 0.1548 0.5954 0.3763 
rs1455796 0.8788 0.4925 0.8088 0.9104 0.5994 0.7456 0.8152 0.2752 0.7653 0.9063 0.7550 0.5994 
rs10957748 1.0000 0.8678 0.9729 0.1724 0.2278 0.0875 0.1434 0.5127 0.3650 0.1618 0.2152 0.2278 
rs13248650 0.5775 0.7266 0.2977 0.3683 0.0641 0.1457 0.6053 0.3452 0.2855 0.5985 0.8834 0.0641 
rs11988595 1.0000 0.5914 0.3108 0.3173 0.3763 0.1901 0.2639 0.6374 0.5023 0.1548 0.5640 0.3763 
 
*p<0.05 in bold. 
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Chapter Seven: The role of CRISPLD2 during zebrafish development 
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7.0. Introduction 
In chapters five and six, we showed an association of CRISPLD2 with NSCLP, which 
suggests that perturbation of CRISPLD2 expression plays a role in this birth defect.  
However, the function of this gene in craniofacial development is unknown.  As previously 
discussed in Section 1.5.2.d, animal studies have provided important insights about the 
function of NSCLP genes.  A number of different organisms, including mouse, zebrafish 
and chicken, have been utilized to study the role of the IRF6 gene in the etiology of 
orofacial clefting.  Two studies discussed in Section 1.5.2.d showed that mice lacking Irf6 
had, among other anomalies, a clefting phenotype.  This resulted from abnormal 
keratinocyte proliferation and differentiation 
147,149
.  The zebrafish model has also been used 
to determine the function of zirf6 and identify the role it plays in NSCLP.  Studies have 
shown that Irf6 is expressed in the developing zebrafish mouth and pharyngeal arches 
297
.  
Morpholino knockdown of Irf6 in zebrafish embryos failed to disrupt development; 
however, deletion of the maternal Irf6 transcripts from these embryos arrested development 
at the blastula stage 
298
.  Further investigation showed that these embryos had abnormal and 
weak superficial epithelium 
298
.  These findings and those in the mouse supports the role of 
IRF6 in normal epithelium development.  Expression studies of Irf6 in chick embryos have 
found it to also be expressed in the developing craniofacial processes, including the 
maxillary process, medial nasal process, nasal pit and medial epithelial edge of the lateral 
palatine shelves 
299,300
.  Altogether, these three animal studies indicate that IRF6 is an 
important regulator of epithelial growth and differentiation.  
In previous studies, we have shown that CRISPLD2 is expressed in the developing 
orofacial region and liver of mouse embryos (see Section 5.3.3 and Figure 5.2, page 79) 
203
.  
 117 
 
Table 7.1.  Expression of murine CRISPLD2 
 
Prostate    Testis 
Placenta    Uterus 
Adipocyte    Spinal Cord 
Ovary     CD 14+ Monocytes 
Fetal and Adult Lung   CD33+ Myeloid 
Whole Blood    Olfactory Bulb 
As shown in Table 7.1, Crispld2 is expressed in many tissues  (Genomics Institute of the 
Novartis Research Foundation GNF, http://symatlas.gnf.org and T1Dbase, http://t1dbase.org 
301
).  Interestingly, while neither database lists expression in the fetal face or head, the clone 
used for in situ analysis was derived from the head of an E17.5 mouse, indicating that 
CRISPLD2 is expressed in that region (Riken CRISPLD2 clone 3321402M02, GeneService, 
Cambridge, UK). 
As shown in Table 7.1, CRISPLD2 
is expressed in the fetal and adult lung.  
In 1999, Kaplan et al. reported their 
findings of a novel CRISP family 
gene, late-gestation lung I (Lgl1), that 
was differentially expressed in rat lung tissue 
302
.  Lgl1 was later classified as a CAP 
(cysteine-rich secretory proteins, antigen 5 and pathogenesis-related 1) superfamily gene and 
named CRISPLD2 
303
.  Although the HUGO Gene Nomenclature Committee at the 
European Bioinformatics Institute still lists the gene name as CRISPLD2 
(http://www.genenames.org), the Lgl1 nomenclature remains in use in pulmonary research.  
Lgl1 is a glycoprotein that participates in fetal lung and ureteric branching 
304-306
.  
Crispld2/Lgl1 null mice are embryonic lethals while Crispld2/Lgl1 heterozygous mice are 
grossly normal 
307
.  Closer inspection of the lungs from Crispld2/Lgl1 heterozygous mice 
found delayed maturation; Crispld2 appears to play an important role in epithelial to 
mesenchymal transition (EMT) in lung tissue 
307
.  EMT has previously been shown to play 
an important role in the transition of neuroepithelial cells to neural crest cells (NCCs) prior 
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to migration and formation of craniofacies, suggesting a potential role of CRISPLD2 in 
craniofacial development 
308,309
. 
Here, zebrafish was used to define the expression and function of zCrispld2.  The 
zebrafish model was chosen because it has been used to study many genes that regulate 
craniofacial development, including the Runx, Dlx and Sox gene families (see Section 
1.5.2.d) 
168-170,297
. 
 
7.1. Materials and Methods 
The details of the expression, morpholino (MO) and in situ hybridization studies are 
completely described in Chapter 2.  Wildtype zebrafish (Danio rerio) were raised and 
housed following standard protocols 
310
. 
 
7.4. Results 
7.4.1. Zebrafish and human CRISPLD2 sequences are homologous   
Amino acid alignment of CRISPLD2 in seven vertebrate species identified homology 
between all species (Figure 7.1).  The zcrispld2 is 55% homologous to human CRISPLD2 at 
the peptide level.  The zebrafish CRISPLD2 protein is 407 amino acids in length compared 
461-507 of other species.  This difference is reflected in the 108 amino acid residue gap in 
the alignment field that maps to human amino acid residue numbers 337-444.  This 
difference is species-specific for the zebrafish. 
7.4.2. CRISPLD2 is expressed during zebrafish development.   
As shown in Figure 7.2A, CRISPLD2 was detected early in development at 3, 4, 27 and 
72 hpf.   Whole mount in situ hybridization was performed to define expression at: 5-7 
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Figure 7.1: CRISPLD2 amino acid alignment across vertebrate species.  Black boxes indicate >50% of sequences have the identical 
amino acid; Grey boxes indicate >50% of sequences have a conserved substitution. 
 
 
 
 120 
 
Figure 7.2.  CRISPLD2 is expressed in zebrafish during development.  (A) Detection of 
zCRISPLD2 mRNA by RTPCR during development (NTC = no template control, UWT = 
unfertilized wild type embryo, hpf = hrs post fertilization).  (B-H) zCRISPLD2 expression is 
shown by in situ hybridization in purple at (B) 5-7 somite, (C) 13-15 somite, (D) 1 dpf, (E) 2 
dpf, (F) 3 dpf, (G) 4 dpf, and (H) 5 dpf. 
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somite, 13-15 somite, 1dpf, 2dpf, 3dpf, 4dpf and 5dpf using two antisense probes.  As 
shown in Figs. 1B and C, CRISPLD2 is ubiquitously expressed during early development.  
CRISPLD2 localizes to the anterior half of the embryo including the head region between 
1dpf to 5dpf (Figure 7.2D-H).  These results were confirmed using multiple probes (data not 
shown). 
7.4.3. Knockdown of CRISPLD2 adversely affects survival rate and causes abnormal 
phenotypes.   
We first tested the efficacy of two zcrispld2 MOs; one directed at exon 1 (designated 
controlMO) and the other at exon 2 (Figure 7.3A).  The controlMO failed to block gene 
translation (Figure 7.3B, lanes 1-4).  crispld2MO knocked down gene translation at 
concentrations greater or equal to 1ng at 1 dpf (Figure 7.3B, lanes 5-6); gene expression was 
detected at 5 dpf and at concentrations less than 1ng per injection (Figure 7.3B, lanes 7-11). 
Crispld2MO knockdown embryos had lower survival rates, at 1 and 5 dpf, when 
compared to control embryos (p<0.05 and p<0.005, respectively) (Figure 7.4A). A higher 
percentage of abnormal phenotypes were also found in these embryos (p<0.05) (Figure 
7.4B).  At 1 dpf, these abnormal phenotypes included failure to develop (Figure 7.4D), 
delayed development (Figure 7.4E-F) and grossly normal embryos when compared to wild 
type (Figure 7.4C).  At 5 dpf, of those embryos that survived, a range of phenotypes was 
observed including severely truncated body (Figure 7.4H), shortened and curved tail with 
cardiac edema (Figure 7.4I) and grossly normal when compared to wild type (Figure 7.4G). 
7.4.4. Knockdown of CRISPLD2 disrupts NCC formation.  
NCCs originate in the hindbrain and migrate into the craniofacial region to form the 
maxillary and mandibular jaw structures 
311
.  Dlx2 is expressed in these migrating NCCs 
 122 
 
 
 
 
 
 
 
 
Figure 7.3:  Morpholino knockdown of CRISPLD2.  (A) Gene showing controlMO (*) and 
crispld2MO (†) targets (boxes = exons). (B) RTPCR results following MO injection at 
various timepoints.  CRISPLD2 expression is knocked down at crispld2MO concentrations 
greater or equal to 1 ng.  -Actin was used as a control. 
 
 (A) 
 
 
 
(B) 
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Figure 7.4:  CRISPLD2 knockdown causes decreased survival and abnormal phenotypes.  
Quantification of survival and abnormal phenotypes after MO knockdown.  (A) Embryos 
with CRISPLD2 knockdown have significantly lower survival rates compared to control 
embryos  (T-test: * p<0.05; ** p<0.005).  (B) Embryos with CRISPLD2 knockdown have 
significantly more abnormal phenotypes compared to control embryos.  Examples of 
phenotypes are shown in C-F at 1dpf and G-I at 5 dpf.  (C) Uninjected embryo at 1 dpf.  (D-
F) Various MO phenotypes at 1 dpf.  (G) Uninjected embryo at 5 dpf.  (H-I) MO phenotypes 
at 5 dpf. 
 
(A)  (B)  
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and is useful as a marker to visualize normal NCC formation and migration 
312,313
.  
Knockdown of CRISPLD2 altered the pattern of Dlx2 clustering compared to control 
embryos at 1 dpf (Figure 7.5).  Four distinct clusters of NCCs were seen in the crispld2MO 
injected embryos compared to controls.  Additionally, the anterior NCCs clustering appeared 
less dense and clusters 3 and 4 were indistinct from each other.  ControlMO injected (data 
not shown) and uninjected embryos had identical Dlx2 expression patterns (Figure 7. 5). 
7.4.5. Knockdown of CRISPLD2 disrupts normal craniofacial cartilage.   
Alcian blue staining was use to visualize the cartilage structures of the craniofacies.   
Numerous anomalies were found in the crispld2MO injected embryos including fewer 
ceratobranchial cartilages forming the lower jaw ( three pairs compared to five) and 
broader Meckel’s and palatoquadrate cartilages that are more “U” shaped than “V” shaped 
(Figure 7.6). 
7.5. Discussion 
Previously, we showed that CRISPLD2 is associated with NSCLP in humans and 
expressed during specific stages of mouse craniofacial development 
203,314
.  In these studies, 
zebrafish were used to further define expression and function of CRISPLD2 during 
craniofacial development.  We found that zCrispld2 is expressed throughout development 
from 3hpf to 5dpf (Figure 7.2).  zCrispld2 was diffusely expressed throughout all tissues 
during early development (5-15 somite stages) and later localized to the craniofacial tissues 
(1-5 dpf).  This expression pattern suggests that zcrispld2 might play an important role in 
overall early development as well as craniofacial development.  This is supported by the 
observation that the Crispld2/Lgl1 null mouse resulted in embryonic lethality by E9.5, and  
 125 
 
 
 
 
 
 
 
Figure 7.5:  Dlx2 expression is altered by knockdown of CRISPLD2. Dlx2 expression is 
visualized by whole mount in situ staining at 1 dpf. (A, B)  Dlx2 expression in wild type 
embryos and (C, D) Dlx2 expression in zCRISPLD2 knock down embryos (125X).  Arrows 
denote Dlx2 clustering. 
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Figure 7.6:  Knockdown of CRISPLD2 causes craniofacial abnormalities.  Alcian blue 
staining at 5 dpf shows structural craniofacial anomalies in crispld2MO knockdown 
zebrafish (100X).  (A and B) Lateral and ventral view of wild type embryos. (C and D) 
control MO injected embryos. (E, F and G)  crispld2MO injected embryos had fewer pairs 
of ceratobranchial cartilages (CB) and broader Meckel’s (MC) and palatoquadrate (PQ) 
cartilages.  (E = eye, CH = ceratohyal) 
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by our finding that loss of zcrispld2 at 1dpf resulted in lower survival rates and an array of 
abnormal phenotypes in surviving embryos (Figure 7.4).   
In the Crispld2/Lgl1 mouse model, heterozygous mice were grossly normal.  However, 
close examination revealed abnormal lung development with delayed alveolar maturation 
and disorganization of lung elastin fibers that were trapped in the interstitium, both of these 
findings resolved with age 
307
.  Lan et al. concluded that Crispld2/Lgl1 functions to regulate 
epithelial-mesenchymal interactions, similar to lung alveolarization 
307
.  Interestingly, 
epithelial-mesenchymal interactions play an important role in gastrulation, craniofacial and 
cardiac development and cancer progression and metastasis 
309,315-317
.  In craniofacial 
development, neuroepithelial cells programmed to become NCCs undergo EMT before they 
can migrate into the craniofacies 
308,309
.   This suggests that Crispld2/Lgl1 plays a role in 
regulating NCC development and migration.  This is supported by our observations in 
zebrafish, where loss of zcrispld2 resulted in altered NCC clustering at 1dpf, including less 
dense first and second NCC clusters (Figure 7.5).  These clusters will form the structures of 
the first and second pharyngeal arches, including the Meckel’s and palatoquadrate cartilages, 
which were abnormal in zebrafish lacking zcripsld2 (Figure 7.6). The ceratobranchial 
cartilages forming the lower jaw are derived from the third, fourth, fifth, sixth and seventh 
pharyngeal arches 
318
.  Interestingly, the first three pairs of ceratobranchial cartilages, which 
were missing in crispld2MO embryos, are derived from NCC clusters and pharyngeal arches 
three and four, which were indistinct from each other at 1 dpf (Figures 7.5 and 7.6).  
Although the oral facial malformations found in crispld2MO zebrafish are different from 
human NSCLP, this may reflect species-specific differences 
318
.  Our findings in both 
zebrafish and mouse show that CRISPLD2 plays an important role in craniofacial 
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development, and specifically in NCC regulation 
203
 (Hecht 2010, unpublished data).  While 
we found that loss of zcrispld2 caused perturbation of NCC migration, we did not identify 
whether zCrispld2 inhibits normal EMT in the craniofacies, as it does in the lung 
307
.  To test 
whether zCrispld2 specifically affects craniofacial EMT, future studies should compare the 
expression of neuroepithelial cell markers, such as crestin or snail1b, in crispld2MO and 
wild-type embryos 
319-321
. 
The Crispld2/Lgl1 heterozygote mouse has provided some insights about the potential 
factors that regulate Crispld2/Lgl1.  In mouse mesenchymal tissue, Crispld2/Lgl1 has two 
distinct functions. First, during early lung and kidney organogenesis, Crispld2/Lgl1 aids in 
branching morphogenesis, a process that is stimulated by retinoic acid.  Then, during later 
gestation events, Crispld2/Lgl1 appears to participate in mesenchymal maturation, which is 
regulated by glucocorticoids 
305,306
.  Retinoic acid appears to play a dichotomous role in 
Crispld2/Lgl1 regulation; while it stimulates branching during early gestation, retinoic acid 
downregulates Crispld2/Lgl1 expression that is induced by glucocorticoids during late 
gestation 
322
.  In mouse studies, retinoic acid disrupts normal pharyngeal arch development 
by altering NCC differentiation and patterning.  As such, it is a strong teratogen, inducing 
cleft palate when administered at critical times in development 
150,323-328
.  Retinoic acid 
regulates gene expression of Dlx2 and Hoxb2, two genes that play critical roles in 
proximodistal and dorsoventral NCC patterning, respectively 
328-331
.  In zebrafish, retinoic 
treatment results in the loss of Dlx2 and specific craniofacial dysmorphogenesis 
328
.  Loss of 
Dlx2 in mouse caused multiple defects in first and second pharyngeal arch derived tissues, 
including cleft palate, while loss of Hoxb2 does not result in orofacial clefting 
330,332
.  Our 
findings in zebrafish also show that zcripld2 alters Dlx2 expression (Figure 7.5).  This data, 
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combined with those of Nadeau et al. in the Crispld2/Lgl1 mouse, suggests that CRISPLD2 
mediates Dlx2 regulation by retinoic acid 
322
.   Future studies should focus on treating wild-
type zebrafish embryos with retinoic acid to determine whether Crispld2 levels are altered.  
Crispld2 levels should decrease with retinoic acid treatment, while treatment of zebrafish 
embryos with a retinoic acid receptor antagonist should cause Crispld2 levels to increase.  
The Dlx2 expression pattern of retinoic acid treated embryos and crispld2MO embryos 
should be compared, and, if similar, wild-type zcrispld2 mRNA can be injected into 
embryos that are treated with retinoic acid to determine if normal Dlx2 patterning can be 
rescued.  These studies will define the relationship between retinoic acid, Crispld2 and Dlx2. 
In vivo mouse studies have shown that retinoic acid receptor null embryos had midline 
craniofacial anomalies in tissues of NCC origin 
325
.  Similar phenotypes were also seen in 
retinoic acid receptor null chick embryos 
333
.  Studies in the chick embryo have shown that 
the conversion of retinal to retinoic acid is inhibited by homocysteine and that chick 
embryos treated with homocysteine have similar defects to those embryos lacking the 
retinoic acid receptor 
333
.  Homocysteine and cysteine are endogenously produced in the 
methionine arm of the folate gene pathway 
94,274,334
.  Elevated homocysteine levels, which 
can be caused by low levels of folic acid, has been shown to decrease both NCC numbers 
and distance migrated 
335,336
.  Moreover, hyperhomocysteinemia, caused by reduced folate 
intake, has been implicated as a cause of orofacial clefting 
337-341
.  High doses of folic acid, 
six to ten times greater than what is found in most prenatal supplements, result in decreased 
homocysteine levels which have been shown to reduce the recurrence of orofacial clefting.  
Recently, we have shown that variants in genes in the folate gene pathway are associated 
with NSCLP, with our most significant associations found in genes in the methionine arm 
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286
.  Variants in five of the genes in the methionine arm interacted with variants in 
CRISPLD2, suggesting that homocysteine and genes that regulate homocysteine could also 
regulate CRISPLD2 and that CRISPLD2 could mediate the effects of homocysteine on 
NCCs 
342
.   This can be tested by treating wild-type zebrafish embryos ewith homocysteine 
to determine whether Crispld2 expression changes.  If the change is identical to retinoic acid 
treated embryos, a relationship between homocysteine, retinoic acid and Crispld2would be 
established.  Alternatively, Crispld2 could be regulated by additional mechanisms. 
Craniofacial morphogenesis is a finely tuned process consisting of cell growth, growth 
factors and receptors, apoptosis and adequate nutrient supply 
14
.  Perturbation of any of these 
processes can result in craniofacial dysmorphology.  The number of genes that contribute to 
NSCLP is growing and studies are now focusing on determining the function of these genes 
in craniofacial morphogenesis.  Results from our studies suggest that perturbations in 
CRISPLD2 expression contribute to NSCLP.  However, as shown in the model depicted in 
Figure 7.7, the process is likely to be complex; CRISPLD2, under the influence of retinoic 
acid, folic acid and homocysteine, directs EMT of neuroepithelial cells to become NCCs and 
form the craniofacies.  Additionally, CRISPLD2 may also regulate NCCs by other 
mechanisms.  Although loss of zcrispld2 did not result in a cleft, our findings have 
important implications that suggest CRISPLD2 function should be further evaluated.  For 
example, the CRISPLD2-homocysteine-retinoic acid connection needs to be further defined.  
Our findings are important because they demonstrate a role of CRISPLD2 
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Figure 7.7: Proposed model for CRISPLD2 regulation of NCCs during craniofacial 
development. CRISPLD2 is required for EMT of neuroepithelial cells to NCCs.  When there 
are insufficient levels of folic acid, homocysteine prevents the conversion of retinal to 
retinoic acid.  Retinoic acid is an upstream regulator of CRISPLD2.  CRISPLD2 may also 
regulate NCCs by other mechanisms (dotted line). 
 
 
 132 
 
in the formation of NCC and early craniofacial development in zebrafish e Moreover, we 
suggest that perturbations in genes that regulate NCCs, such as CRISPLD2, can have a 
detrimental effect on NCC-derived tissues and alter normal craniofacial development and 
thereby contribute to NSCLP. 
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Chapter 8: Summary and Future Studies 
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8.1. Summary 
Cleft lip and palate, a common, complex birth disorder, affects one out of every 700 live 
births in Texas and approximately 4000 newborns each year in the United States.  Patients 
with cleft lip and palate face significant healthcare challenges related to surgical, dental and 
speech therapies.  The exact cause of this disorder is unknown, but multiple genetic and 
environmental influences are known to be involved.  The purpose of this study was to 
identify genetic causes of NSCLP and to understand how these genes contribute to normal 
craniofacial development.  The ultimate goal of these studies is to gain a better 
understanding of the causes of NSCLP in order to better diagnose and counsel NSCLP 
families and to develop potential therapeutic interventions. 
As discussed in Section 1.5 (page 9), there are two methods of gene identification for 
genetic diseases: genome scan and candidate gene approach.  In chapter three, we 
demonstrated the effectiveness of a genome scan to identify genomic regions that were 
linked to NSCLP in our dataset.  Eleven regions in our NHW dataset were associated with 
NSCLP.  Interestingly, five of these regions, including our most significant findings in the 
nonHispanic dataset, from chromosome 22q12.2-12.3, were novel regions not previously 
identified in NSCLP genome scans (see Table 3.2, page 41).  Candidate gene interrogation 
of myosin heavy chain 9 (MYH9) gene identified an association and confirmed the 
association reported in an Italian NSCLP dataset 
55,105
.  These results demonstrate the 
effectiveness of genome scans in identifying chromosome regions that may harbor genes 
contributing to disease etiology. 
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In chapter four, we interrogated the WNT gene family.  WNT genes are expressed in the 
craniofacies throughout development and knockout WNT animal models have orofacial 
clefts 
20,21,112,114-117,233-235
.  Interestingly, the WNT genes that were most significantly 
associated with our NSCLP dataset, Wnt3A and Wnt11, were those that function in NCC 
differentiation and migration 
118
.  NCCs play a critical role during craniofacial development 
and form the tissues that populate the maxillary and mandibular jaw structures 
311
.  These 
results demonstrated the effectiveness of a candidate gene approach in identifying genes that 
have a known role in normal development, that when perturbed, may contribute to disease 
etiology. 
In chapters five through seven, we describe studies that identified an association of 
CRISPLD2 with NSCLP, CRISPLD2 had not previously been associated with NSCLP or 
any craniofacial anomalies.  CRISPLD2 had previously been identified in mice and rats and 
is called Lgl1 (late gestational lung 1) 
302
.   Studies in mice suggest that CRISPLD2 (Lgl1) 
aids in branching morphogenesis during kidney and lung organogenesis (Quinlan, Nadeau).  
The chromosomal 16q21-24 region has previously been identified as potentially harboring a 
NSCLP candidate gene in four genome scans and 2 meta-analyses of genome scan data 
97,99,100,103,104,262
.  CRISPLD2 was identified after we confirmed that polymorphic variants in 
that chromosome region were associated with NSCLP.  While we did not find any coding 
mutations in our probands with CRISPLD2 susceptible haplotypes, we did find that 
CRISPLD2 is expressed during mouse craniofacial morphogenesis. 
As demonstrated in chapter four, a candidate gene approach can be used to assess genes 
in the same family.  Therefore, we interrogated the CRISPLD1 gene for association with 
NSCLP.   No significant association was identified for SNPs in the CRISPLD1 gene and 
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NSCLP.  However, we did find that variants in CRISPLD1 and CRISPLD2 interacted 
together and that variants in both genes interacted with variants in genes in the folate 
pathway.  We next used zebrafish to define expression and timing of CRISPLD2 in 
craniofacial morphogenesis.  Zebrafish ubiquitously express CRISPLD2 throughout 
development from 5-7 somite stage to 5dpf; gene expression localizes to the craniofacial 
region by 1dpf.  Knockdown of CRISPLD2 resulted in lower survival rates and a higher 
number of phenotypic abnormalities.  At 1dpf, embryos showed altered NCC clustering 
which translated into abnormal cartilage in the jaw by 5dpf.  While we did not see a cleft, 
these results suggest that CRISPLD2 is still required for normal craniofacial development in 
zebrafish. 
 
8.2. Future Studies 
8.2.1. Genome scan  
While association was found to the MYH9 gene in chromosome 22q12.2-12.3, the 
results do not exclude the possibility that other genes in 22q12.2-12.3 chromosomal region 
play a role in NSCLP.  This genome scan was only conducted on only nine of our more than 
100 NHW multiplex families.  While these nine families were some of the larger multiplex 
families, the results do not necessarily represent clefting etiology in the entire sample since 
NSCLP is genetically heterogeneous.  Additionally, of the 11 regions identified in this 
study, only one region was interrogated in any depth.  Additional studies are needed to 
follow up these initial results.  First, the significant SNPs in each of the eleven regions 
identified in the NHW population should be tested in the entire dataset.  This may narrow 
the regions into more defined peaks and reduce the number of genes requiring interrogation.  
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Additionally, candidate genes can be interrogated or all regions can be resequenced to 
determine which genes/variants contribute to NSCLP.  
Besides nine NHW families, the genome scan was also performed on a large African 
American family, where we identified three other regions (2p22, 3p26, and 8q21.3-24.12), 
none of which showed linkage in the NHW family dataset.  These results and subsequent 
follow-up of the chromosome 8 region, which had the highest LOD score, were not part of 
my studies 
105
.  Briefly, two candidate genes were interrogated, syndecan 2 (SDC2) and 
growth differentiation factor 6 (GDF6), but no association was identified 
105
.  However, this 
was not unexpected because the candidate gene analysis was performed using our NHW and 
Hispanic populations, as clefting is rare in the African American population.  To best 
interrogate these three regions, additional African American families must be collected and a 
similar approach to the NHW studies should be performed. 
8.2.2. WNT 
NCCs play a critical role in normal craniofacial development; therefore, it is not 
surprising that variation in genes that regulate NCCs contribute to NSCLP etiology 
118
.  
Future NSCLP genetic studies should focus on other genes that regulate NCC function, 
especially in light of our findings that knockdown of CRISPLD2 in zebrafish alters NCC 
clustering. 
8.2.3. CRISPLD  
As mentioned in Section 1.4 (page 7), NSCLP is a genetically heterogeneous birth defect 
with individual genes being shown to play a role in clefting etiology in different populations 
41,42
.  Interestingly, the association between CRISPLD2 and NSCLP have recently been 
replicated in  NHW and Brazilian datasets, supporting our finding that variation in 
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CRISPLD2 contributes to NSCLP 
314
.  The gene interaction results are interesting but are 
based on statistical testing 
202
.  It is important to test whether these variants interact on a 
biochemical level as well.  If an interaction between the folic acid pathway and CRISPLD 
genes is detected at the biochemical level, it would be interesting to test if decreased 
maternal folate levels during fetal development correlated with NSCLP-susceptible 
CRISPLD2 genotypes, and if so, whether these pregnant women had an increased risk of 
having a child with NSCLP.  These studies will further help assess the role of the CRISPLD 
gene family in clefting etiology. 
The zebrafish studies provided insight on the role of CRISPLD2 during early 
development.  We show that CRISPLD2 plays a role in normal NCC clustering, and further 
research is warranted to delineate the CRISPLD2-homocysteine-RA connection and 
determine how these genes contribute to clefting etiology.  The zebrafish model could be 
used to for these experiments.  Zebrafish embryos can be treated with RA and/or 
homocysteine to determine if Dlx2 or CRISPLD2 expression is decreased or altered, as 
suggested by previous homocysteine-RA and CRISPLD2-RA studies in other zebrafish 
tissues 
326-328,333
.  
Additional animal studies are necessary to further delineate the role of CRISPLD2 in 
craniofacial development because the zebrafish model is only useful as a simple vertebrate 
model.  To do this, a transgenic mouse is an appropriate model.  To accomplish this goal, a 
CRISPLD2 ES cell line has been purchased from the Knock Out Mouse Project (KOMP) 
and the conditional CRISPLD2 knockout mice will be generated.  The conditional approach 
is being used because the CRISPLD2 traditional knockout mouse is embryonic lethal (ref).  
Additionally, our lab has recently performed whole mount in situ hybridizations on mouse 
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embryos that show that CRISPLD2 is expressed in the NCC clusters during early mouse 
craniofacial development (Yuan and Hecht, 2010 unpublished data), further supporting our 
findings that CRISPLD2 plays a role in normal NCC development and migration.  
Additional studies are warranted to determine how CRISPLD2 variation can lead to 
detrimental effects of NCC-derived tissues. 
 140 
 
References 
 
1. Kang P, Svoboda KK: Epithelial-mesenchymal transformation during craniofacial 
development. J Dent Res 2005; 84: 678-690. 
 
2. Kulesa PM, Schnell S, Rudloff S, Baker RE, Maini PK: From segment to somite: 
segmentation to epithelialization analyzed within quantitative frameworks. 
Developmental dynamics : an official publication of the American Association of 
Anatomists 2007; 236: 1392-1402. 
 
3. Gorlin RJ, M.M. Cohen, and R.C.M. Hennekam: Syndromes of the Head and Neck, 
Fourth Edition edn. New York: Oxford University Press, 2001. 
 
4. Johnston MC, Hassell JR, Brown KS: The embryology of cleft lip and cleft palate. 
Clin Plast Surg 1975; 2: 195-203. 
 
5. Trasler DG, Fraser FC: Handbook of Teratology. New York: Plenum Press, 1977. 
 
6. Fraser FC: The genetics of cleft lip and palate. Am J Hum Genet 1970; 22: 336-352. 
 
7. Johnston MC, Bronsky PT: Prenatal craniofacial development: new insights on 
normal and abnormal mechanisms. Crit Rev Oral Biol Med 1995; 6: 368-422. 
 
 141 
 
8. Koo SH, Cunningham MC, Arabshahi B, Gruss JS, Grant JH, 3rd: The transforming 
growth factor-beta 3 knock-out mouse: an animal model for cleft palate. Plast 
Reconstr Surg 2001; 108: 938-948; discussion 949-951. 
 
9. Lan Y, Ryan RC, Zhang Z, Bullard SA, Bush JO, Maltby KM, Lidral AC, Jiang R: 
Expression of Wnt9b and activation of canonical Wnt signaling during midfacial 
morphogenesis in mice. Dev Dyn 2006; 235: 1448-1454. 
 
10. Lidral AC, Moreno LM: Progress toward discerning the genetics of cleft lip. Curr 
Opin Pediatr 2005; 17: 731-739. 
 
11. Miyazaki Y, Oshima K, Fogo A, Hogan BL, Ichikawa I: Bone morphogenetic 
protein 4 regulates the budding site and elongation of the mouse ureter. J Clin Invest 
2000; 105: 863-873. 
 
12. Murray JC: Face facts: genes, environment, and clefts. Am J Hum Genet 1995; 57: 
227-232. 
 
13. Murray JC: Gene/environment causes of cleft lip and/or palate. Clin Genet 2002; 61: 
248-256. 
 
14. Nanci A: Ten Cate's Oral Histology - Development, Structure, and Function, 6th 
edn. Los Angelos: Mosby, 2003. 
 142 
 
 
15. Nusse R: Wnt signaling in disease and in development. Cell Res 2005; 15: 28-32. 
 
16. Robertson CP, Braun MM, Roelink H: Sonic hedgehog patterning in chick neural 
plate is antagonized by a Wnt3-like signal. Dev Dyn 2004; 229: 510-519. 
 
17. Schutte BC, Murray JC: The many faces and factors of orofacial clefts. Hum Mol 
Genet 1999; 8: 1853-1859. 
 
18. Senders CW, Peterson EC, Hendrickx AG, Cukierski MA: Development of the upper 
lip. Arch Facial Plast Surg 2003; 5: 16-25. 
 
19. Wyszynski D (ed): Cleft Lip and Palate: From Origin to Treatment. Oxford: Oxford 
University Press, 2002. 
 
20. Yamaguchi TP, Bradley A, McMahon AP, Jones S: A Wnt5a pathway underlies 
outgrowth of multiple structures in the vertebrate embryo. Development 1999; 126: 
1211-1223. 
 
21. Yamaguchi TP, Takada S, Yoshikawa Y, Wu N, McMahon AP: T (Brachyury) is a 
direct target of Wnt3a during paraxial mesoderm specification. Genes Dev 1999; 13: 
3185-3190. 
 
 143 
 
22. Brewer C, Holloway S, Zawalnyski P, Schinzel A, FitzPatrick D: A chromosomal 
deletion map of human malformations. Am J Hum Genet 1998; 63: 1153-1159. 
 
23. Shi M, Mostowska A, Jugessur A, Johnson MK, Mansilla MA, Christensen K, Lie 
RT, Wilcox AJ, Murray JC: Identification of microdeletions in candidate genes for 
cleft lip and/or palate. Birth defects research Part A, Clinical and molecular 
teratology 2009; 85: 42-51. 
 
24. Jiang R, Bush JO, Lidral AC: Development of the upper lip: Morphogenetic and 
molecular mechanisms. Dev Dyn 2006; 235: spc1. 
 
25. Hinrichsen K: The early development of morphology and patterns of the face in the 
human embryo. Adv Anat Embryol Cell Biol 1985; 98: 1-79. 
 
26. Brewer C, Holloway S, Zawalnyski P, Schinzel A, FitzPatrick D: A chromosomal 
duplication map of malformations: regions of suspected haplo- and triplolethality--
and tolerance of segmental aneuploidy--in humans. Am J Hum Genet 1999; 64: 
1702-1708. 
 
27. Kobayashi J, Kimijima Y, Yamada S, Amagasa T, Saito-Ohara F: 4p- syndrome and 
9p tetrasomy mosaicism with cleft lip and palate. Journal of cranio-maxillo-facial 
surgery : official publication of the European Association for Cranio-Maxillo-Facial 
Surgery 2000; 28: 165-170. 
 144 
 
 
28. Gandelman KY, Gibson L, Meyn MS, Yang-Feng TL: Molecular definition of the 
smallest region of deletion overlap in the Wolf-Hirschhorn syndrome. Am J Hum 
Genet 1992; 51: 571-578. 
 
29. Hashmi SS, Waller DK, Langlois P, Canfield M, Hecht JT: Prevalence of 
nonsyndromic oral clefts in Texas: 1995-1999. Am J Med Genet A 2005; 134: 368-
372. 
 
30. Altemus LA: The incidence of cleft lip and palate among North American negroes. 
Cleft Palate J 1966; 3: 357-361. 
 
31. Bonaiti C, Briard ML, Feingold J, Pavy B, Psaume J, Migne-Tufferand G, Kaplan J: 
An epidemiological and genetic study of facial clefting in France. I. Epidemiology 
and frequency in relatives. J Med Genet 1982; 19: 8-15. 
 
32. Plotner PL, Smith JL, Northrup H: Trisomy 20q caused by der(4) t(4;20) 
(q35;q13.1): report of a new patient and review of the literature. Am J Med Genet 
2002; 111: 71-75. 
 
33. Chung CS, Mi MP, Beechert AM: Genetic epidemiology of cleft lip with or without 
cleft palate in the population of Hawaii. Genet Epidemiol 1987; 4: 415-423. 
 
 145 
 
34. Murray JC: Face facts: genes, environment, and clefts.[comment]. Am J Hum Genet 
1995; 57: 227-232. 
 
35. Wyszynski DF, Beaty TH, Maestri NE: Genetics of nonsyndromic oral clefts 
revisited. Cleft Palate Craniofac J 1996; 33: 406-417. 
 
36. Lidral AC, Murray JC: Genetic approaches to identify disease genes for birth defects 
with cleft lip/palate as a model. Birth Defects Res A Clin Mol Teratol 2004; 70: 893-
901. 
 
37. Letra A, Menezes R, Granjeiro JM, Vieira AR: Defining subphenotypes for oral 
clefts based on dental development. J Dent Res 2007; 86: 986-991. 
 
38. Marazita ML: Subclinical features in non-syndromic cleft lip with or without cleft 
palate (CL/P): review of the evidence that subepithelial orbicularis oris muscle 
defects are part of an expanded phenotype for CL/P. Orthodontics & craniofacial 
research 2007; 10: 82-87. 
 
39. Menezes R, Vieira AR: Dental anomalies as part of the cleft spectrum. The Cleft 
palate-craniofacial journal : official publication of the American Cleft Palate-
Craniofacial Association 2008; 45: 414-419. 
 
 146 
 
40. Harville EW, Wilcox AJ, Lie RT, Vindenes H, Abyholm F: Cleft lip and palate 
versus cleft lip only: are they distinct defects? Am J Epidemiol 2005; 162: 448-453. 
 
41. Maestri NE, Beaty TH, Hetmanski J, Smith EA, McIntosh I, Wyszynski DF, Liang 
KY, Duffy DL, VanderKolk C: Application of transmission disequilibrium tests to 
nonsyndromic oral clefts: including candidate genes and environmental exposures in 
the models. Am J Med Genet 1997; 73: 337-344. 
 
42. Schliekelman P, Slatkin M: Multiplex relative risk and estimation of the number of 
loci underlying an inherited disease. Am J Hum Genet 2002; 71: 1369-1385. 
 
43. Wyszynski DF, Duffy DL, Beaty TH: Maternal cigarette smoking and oral clefts: a 
meta-analysis. Cleft Palate Craniofac J 1997; 34: 206-210. 
 
44. Shi M, Wehby GL, Murray JC: Review on genetic variants and maternal smoking in 
the etiology of oral clefts and other birth defects. Birth defects research Part C, 
Embryo today : reviews 2008; 84: 16-29. 
 
45. Mitchell LE, Risch N: Mode of inheritance of nonsyndromic cleft lip with or without 
cleft palate:  a reanalysis. Am J Hum Genet 1992; 51: 323-332. 
 
 147 
 
46. Blanton SH, Cortez A, Stal S, Mulliken JB, Finnell RH, Hecht JT: Variation in IRF6 
contributes to nonsyndromic cleft lip and palate. Am J Med Genet A 2005; 137: 259-
262. 
 
47. Scapoli L, Palmieri A, Martinelli M, Pezzetti F, Carinci P, Tognon M, Carinci F: 
Strong evidence of linkage disequilibrium between polymorphisms at the IRF6 locus 
and nonsyndromic cleft lip with or without cleft palate, in an Italian population. Am J 
Hum Genet 2005; 76: 180-183. 
 
48. Zucchero TM, Cooper ME, Maher BS, Daack-Hirsch S, B. N, Ribeiro L, Caprau D, 
Christensen K, Suzuki Y, Machida J, Natsume N, Yoshiura K, Vieira AR, Orioli IM, 
Castilla EE, Moreno L, Arcos-Burgos M, Lidral AC, Field LL, Liu Y, Ray A, 
Goldstein TH, Schultz RE, Shi M, Kondo S, Schutte BC, Marazita M, Murray J: 
Interferon Regulatory Factor 6 (IRF6) is a Modifier for Isolated Cleft Lip and Palate. 
Am J Human Genet 2003; 73: 162. 
 
49. Zucchero TM, Cooper ME, Maher BS, Daack-Hirsch S, Nepomuceno B, Ribeiro L, 
Caprau D, Christensen K, Suzuki Y, Machida J, Natsume N, Yoshiura K, Vieira AR, 
Orioli IM, Castilla EE, Moreno L, Arcos-Burgos M, Lidral AC, Field LL, Liu YE, 
Ray A, Goldstein TH, Schultz RE, Shi M, Johnson MK, Kondo S, Schutte BC, 
Marazita ML, Murray JC: Interferon regulatory factor 6 (IRF6) gene variants and the 
risk of isolated cleft lip or palate. N Engl J Med 2004; 351: 769-780. 
 
 148 
 
50. Shaw D, Ray AK, Marazita ML, Field L: Further evidence of a relationship between 
the retinoic acid receptor alpha locus and nonsyndromic cleft lip with or without cleft 
palate (CL+ P). Am J Hum Genet 1993; 53: 1156-1157. 
 
51. Suzuki Y, Jezewski PA, Machida J, Watanabe Y, Shi M, Cooper ME, Viet le T, 
Nguyen TD, Hai H, Natsume N, Shimozato K, Marazita ML, Murray JC: In a 
Vietnamese population, MSX1 variants contribute to cleft lip and palate. Genet Med 
2004; 6: 117-125. 
 
52. Amos C, Gasser D, Hecht JT: Nonsyndromic cleft lip with or without cleft palate: 
new BCL3 information. Am J Hum Genet 1996; 59: 743-744. 
 
53. Stein J, Mulliken JB, Stal S, Gasser DL, Malcolm S, Winter R, Blanton SH, Amos C, 
Seemanova E, Hecht JT: Nonsyndromic cleft lip with or without cleft palate: 
evidence of linkage to BCL3 in 17 multigenerational families. Am J Hum Genet 
1995; 57: 257-272. 
 
54. Marazita ML, Mooney MP: Current concepts in the embryology and genetics of cleft 
lip and cleft palate. Clin Plast Surg 2004; 31: 125-140. 
 
55. Martinelli M, Di Stazio M, Scapoli L, Marchesini J, Di Bari F, Pezzetti F, Carinci F, 
Palmieri A, Carinci P, Savoia A: Cleft lip with or without cleft palate: implication of 
the heavy chain of non-muscle myosin IIA. J Med Genet 2007. 
 149 
 
 
56. Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J: Antiepileptic drug use 
of women with epilepsy and congenital malformations in offspring. Neurology 2005; 
64: 1874-1878. 
 
57. Azarbayjani F, Danielsson BR: Phenytoin-induced cleft palate: evidence for 
embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ 
channels resulting in hypoxia-reoxygenation damage. Teratology 2001; 63: 152-160. 
 
58. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA: Folic acid antagonists 
during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608-1614. 
 
59. Prevention of neural tube defects: results of the Medical Research Council Vitamin 
Study. MRC Vitamin Study Research Group. Lancet 1991; 338: 131-137. 
 
60. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong 
LY, Gindler J, Hong SX, Correa A: Prevention of neural-tube defects with folic acid 
in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N 
Engl J Med 1999; 341: 1485-1490. 
 
61. Ray JG, Meier C, Vermeulen MJ, Wyatt PR, Cole DE: Association between folic 
acid food fortification and congenital orofacial clefts. J Pediatr 2003; 143: 805-807. 
 
 150 
 
62. Czeizel AE, Tâimâar L, Sâarkèozi A: Dose-dependent effect of folic acid on the 
prevention of orofacial clefts. Pediatrics 1999; 104: e66. 
 
63. Tolarova M, Harris J: Reduced recurrence of orofacial clefts after periconceptual 
supplementation with high dose folic acid and multivitamins. Teratology 1995; 51: 
71-78. 
 
64. Blanton SH, Kolle BS, Hecht JT, Mulliken JB, Martin ER: No evidence supporting 
MTHFR as a risk factor in the development of familial NSCLP. Am J Med Genet 
2000; 92: 370-371. 
 
65. Hecht JT, Patel S, Mulliken JB, Blanton SH: MTHFR is not a risk factor for the 
development of isolated NSCLP. Am  J Med Genet 2002; 110: 404-405. 
 
66. Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH: Maternal 
periconceptional vitamin use, genetic variation of infant reduced folate carrier 
(A80G), and risk of spina bifida. Am J Med Genet 2002; 108: 1-6. 
 
67. Shaw GM, Rozen R, Finnell RH, Todoroff K, Lammer EJ: Infant C677T mutation in 
MTHFR, maternal periconceptional vitamin use, and cleft lip. Am J Med Genet 
1998; 80: 196-198. 
 
 151 
 
68. Shaw GM, Todoroff K, Finnell RH, Rozen R, Lammer EJ: Maternal vitamin use, 
infant C677T mutation in MTHFR, and isolated cleft palate risk. Am J Med Genet 
1999; 85: 84-85. 
 
69. Shaw GM, Wasserman CR, Lammer EJ, O'Malley CD, Murray JC, Basart AM, 
Tolarova MM: Orofacial clefts, parental cigarette smoking, and transforming growth 
factor-alpha gene variants. Am J Hum Genet 1996; 58: 551-561. 
 
70. Hartsfield JK, Jr., Hickman TA, Everett ET, Shaw GM, Lammer EJ, Finnell RA: 
Analysis of the EPHX1 113 polymorphism and GSTM1 homozygous null 
polymorphism and oral clefting associated with maternal smoking. Am J Med Genet 
2001; 102: 21-24. 
 
71. van Rooij IA, Wegerif MJ, Roelofs HM, Peters WH, Kuijpers-Jagtman AM, Zielhuis 
GA, Merkus HM, Steegers-Theunissen RP: Smoking, genetic polymorphisms in 
biotransformation enzymes, and nonsyndromic oral clefting: a gene-environment 
interaction. Epidemiology 2001; 12: 502-507. 
 
72. Dejmek J, Solansk y I, Podrazilovâa K, Srâam RJ: The exposure of nonsmoking and 
smoking mothers to environmental tobacco smoke during different gestational 
phases and fetal growth. Environ Health Perspect 2002; 110: 601-606. 
 
 152 
 
73. Beaty TH, Hetmanski JB, Zeiger JS, Fan YT, Liang KY, VanderKolk CA, McIntosh 
I: Testing candidate genes for non-syndromic oral clefts using a case-parent trio 
design. Genet Epidemiol 2002; 22: 1-11. 
 
74. Christensen K, Olsen J, Norgaard-Pedersen B, Basso O, Stovring H, Milhollin-
Johnson L, Murray JC: Oral clefts, transforming growth factor alpha gene variants, 
and maternal smoking: a population-based case-control study in Denmark, 1991-
1994. Am J Epidemiol 1999; 149: 248-255. 
 
75. Mitchell LE, Murray JC, O'Brien S, Christensen K: Evaluation of two putative 
susceptibility loci for oral clefts in the Danish population. Am J Epidemiol 2001; 
153: 1007-1015. 
 
76. Romitti PA, Lidral AC, Munger RG, Daack-Hirsch S, Burns TL, Murray JC: 
Candidate genes for nonsyndromic cleft lip and palate and maternal cigarette 
smoking and alcohol consumption: evaluation of genotype-environment interactions 
from a population-based case-control study of orofacial clefts. Teratology 1999; 59: 
39-50. 
 
77. Shi M, Christensen K, Weinberg CR, Romitti P, Bathum L, Lozada A, Morris RW, 
Lovett M, Murray JC: Orofacial cleft risk is increased with maternal smoking and 
specific detoxification-gene variants. Am J Hum Genet 2007; 80: 76-90. 
 
 153 
 
78. Ramirez D, Lammer EJ, Iovannisci DM, Laurent C, Finnell RH, Shaw GM: 
Maternal smoking during early pregnancy, GSTP1 and EPHX1 variants, and risk of 
isolated orofacial clefts. The Cleft palate-craniofacial journal : official publication of 
the American Cleft Palate-Craniofacial Association 2007; 44: 366-373. 
 
79. Lammer EJ, Shaw GM, Iovannisci DM, Finnell RH: Maternal smoking, genetic 
variation of glutathione s-transferases, and risk for orofacial clefts. Epidemiology 
2005; 16: 698-701. 
 
80. Beaty TH, Maestri NE, Hetmanski JB, Wyszynski DF, Vanderkolk CA, Simpson JC, 
McIntosh I, Smith EA, Zeiger JS, Raymond GV, Panny SR, Tifft CJ, Lewanda AF, 
Cristion CA, Wulfsberg EA: Testing for interaction between maternal smoking and 
TGFA genotype among oral cleft cases born in Maryland 1992-1996. Cleft Palate 
Craniofac J 1997; 34: 447-454. 
 
81. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den 
Heijer M, Kluijtmans LA, van den Heuvel LP: A candidate genetic risk factor for 
vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat 
Genet 1995; 10: 111-113. 
 
82. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, Conley 
MR, Weir DG, Scott JM: Thermolabile variant of 5,10-methylenetetrahydrofolate 
 154 
 
reductase associated with low red-cell folates: implications for folate intake 
recommendations. Lancet 1997; 349: 1591-1593. 
 
83. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van 
den Heuvel LP, Blom HJ: A second common mutation in the 
methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube 
defects? Am J Hum Genet 1998; 62: 1044-1051. 
 
84. van Rooij IA, Vermeij-Keers C, Kluijtmans LA, Ocke MC, Zielhuis GA, Goorhuis-
Brouwer SM, van der Biezen JJ, Kuijpers-Jagtman AM, Steegers-Theunissen RP: 
Does the interaction between maternal folate intake and the 
methylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with 
or without cleft palate? Am J Epidemiol 2003; 157: 583-591. 
 
85. Martinelli M, Scapoli L, Pezzetti F, Carinci F, Carinci P, Stabellini G, Bisceglia L, 
Gombos F, Tognon M: C677T variant form at the MTHFR gene and CL/P: a risk 
factor for mothers? Am J Med Genet 2001; 98: 357-360. 
 
86. Wyszynski DF, Diehl SR: Infant C677T mutation in MTHFR, maternal 
periconceptional vitamin use, and risk of nonsyndromic cleft lip. Am J Med Genet 
2000; 92: 79-80. 
 
 155 
 
87. Gaspar DA, Pavanello RC, Zatz M, Passos-Bueno MR, Andre M, Steman S, 
Wyszynski DF, Matiolli SR: Role of the C677T polymorphism at the MTHFR gene 
on risk to nonsyndromic cleft lip with/without cleft palate: results from a case-
control study in Brazil. Am J Med Genet 1999; 87: 197-199. 
 
88. Jugessur A, Wilcox AJ, Lie RT, Murray JC, Taylor JA, Ulvik A, Drevon CA, 
Vindenes HA, Abyholm FE: Exploring the effects of methylenetetrahydrofolate 
reductase gene variants C677T and A1298C on the risk of orofacial clefts in 261 
Norwegian case-parent triads. Am J Epidemiol 2003; 157: 1083-1091. 
 
89. Prescott NJ, Winter RM, Malcolm S: Maternal MTHFR genotype contributes to the 
risk of non-syndromic cleft lip and palate. J Med Genet 2002; 39: 368-369. 
 
90. Shotelersuk V, Ittiwut C, Siriwan P, Angspatt A: Maternal 677CT/1298AC genotype 
of the MTHFR gene as a risk factor for cleft lip. J Med Genet 2003; 40: e64. 
 
91. Gaspar DA, Pavanello RC, Zatz M, Passos-Bueno MR, Andre M, Steman S, 
Wyszynski DF, Matiolli SR: Role of the C677T polymorphism at the MTHFR gene 
on risk to nonsyndromic cleft lip with/without cleft palate: results from a case-
control study in Brazil. Am J Med Genet 1999; 87: 197-199. 
 
92. Pezzetti F, Martinelli M, Scapoli L, Carinci F, Palmieri A, Marchesini J, Carinci P, 
Caramelli E, Rullo R, Gombos F, Tognon M: Maternal MTHFR variant forms 
 156 
 
increase the risk in offspring of isolated nonsyndromic cleft lip with or without cleft 
palate. Hum Mutat 2004; 24: 104-105. 
 
93. Zhu J, Ren A, Hao L, Pei L, Liu J, Zhu H, Li S, Finnell RH, Li Z: Variable 
contribution of the MTHFR C677T polymorphism to non-syndromic cleft lip and 
palate risk in China. American Journal of Medical Genetics Part A 2006; 140: 551-
557. 
 
94. Boyles AL, Wilcox AJ, Taylor JA, Meyer K, Fredriksen A, Ueland PM, Drevon CA, 
Vollset SE, Lie RT: Folate and one-carbon metabolism gene polymorphisms and 
their associations with oral facial clefts. Am J Med Genet A 2008; 146A: 440-449. 
 
95. Blanton SH, Patel S, Hecht JT, Mulliken JB: MTHFR is not a risk factor in the 
development of isolated nonsyndromic cleft lip and palate. Am J Med Genet 2002; 
110: 404-405. 
 
96. van Rooij IA, Vermeij-Keers C, Kluijtmans LA, Ocke MC, Zielhuis GA, Goorhuis-
Brouwer SM, van der Biezen JJ, Kuijpers-Jagtman AM, Steegers-Theunissen RP: 
Does the interaction between maternal folate intake and the 
methylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with 
or without cleft palate? Am J Epidemiol 2003; 157: 583-591. 
 
 157 
 
97. Field LL, Ray AK, Cooper ME, Goldstein T, Shaw DF, Marazita ML: Genome scan 
for loci involved in nonsyndromic cleft lip with or without cleft palate in families 
from West Bengal, India. Am J Med Genet A 2004; 130: 265-271. 
 
98. Marazita ML, Field LL, Cooper ME, Tobias R, Maher BS, Peanchitlertkajorn S, Liu 
YE: Genome scan for loci involved in cleft lip with or without cleft palate in Chinese 
multiplex families. Am J Hum Genet 2002; 71: 349-364. 
 
99. Marazita ML, Field LL, Tuncbilek G, Cooper ME, Goldstein T, Gursu KG: Genome-
scan for loci involved in cleft lip with or without cleft palate in consanguineous 
families from Turkey. Am J Med Genet A 2004; 126: 111-122. 
 
100. Marazita ML, Murray JC, Lidral AC, Arcos-Burgos M, Cooper ME, Goldstein T, 
Maher BS, Daack-Hirsch S, Schultz R, Mansilla MA, Field LL, Liu YE, Prescott N, 
Malcolm S, Winter R, Ray A, Moreno L, Valencia C, Neiswanger K, Wyszynski DF, 
Bailey-Wilson JE, Albacha-Hejazi H, Beaty TH, McIntosh I, Hetmanski JB, 
Tuncbilek G, Edwards M, Harkin L, Scott R, Roddick LG: Meta-analysis of 13 
genome scans reveals multiple cleft lip/palate genes with novel loci on 9q21 and 
2q32-35. Am J Hum Genet 2004; 75: 161-173. 
 
101. Prescott NJ, Lees MM, Winter RM, Malcolm S: Identification of susceptibility loci 
for nonsyndromic cleft lip with or without cleft palate in a two stage genome scan of 
affected sib-pairs. Hum Genet 2000; 106: 345-350. 
 158 
 
 
102. Radhakrishna U, Ratnamala U, Gaines M, Beiraghi S, Hutchings D, Golla J, Husain 
SA, Gambhir PS, Sheth JJ, Sheth FJ, Chetan GK, Naveed M, Solanki JV, Patel UC, 
Master DC, Memon R, Antonarakis GS, Antonarakis SE, Nath SK: Genomewide 
scan for nonsyndromic cleft lip and palate in multigenerational Indian families 
reveals significant evidence of linkage at 13q33.1-34. Am J Hum Genet 2006; 79: 
580-585. 
 
103. Wyszynski DF, Albacha-Hejazi H, Aldirani M, Hammod M, Shkair H, Karam A, 
Alashkar J, Holmes TN, Pugh EW, Doheny KF, McIntosh I, Beaty TH, Bailey-
Wilson JE: A genome-wide scan for loci predisposing to non-syndromic cleft lip 
with or without cleft palate in two large Syrian families. Am J Med Genet 2003; 
123A: 140-147. 
 
104. Schulz RE, Cooper ME, Daack-Hirsch S, Nepomucena B, Graf KA, O'Brien EK, 
Narazita ML, Murray JC: A targeted scan for loci linked to nonsyndromic cleft lip 
and palate in Filipino families. Am J Med Genet 2003; 10: 1-5. 
 
105. Chiquet BT, Hashmi SS, Henry R, Burt A, Mulliken JB, Stal S, Bray M, Blanton SH, 
Hecht JT: Genomic screening identifies novel linkages and provides further evidence 
for a role of MYH9 in nonsyndromic cleft lip and palate. Eur J Hum Genet 2009; 17: 
195-204. 
 
 159 
 
106. Blanton SH, Bertin T, Patel S, Stal S, Mulliken JB, Hecht JT: Nonsyndromic cleft lip 
and palate: four chromosomal regions of interest. Am J Med Genet A 2004; 125: 28-
37. 
 
107. Riley BM, Schultz RE, Cooper ME, Goldstein-McHenry T, Daack-Hirsch S, Lee 
KT, Dragan E, Vieira AR, Lidral AC, Marazita ML, Murray JC: A genome-wide 
linkage scan for cleft lip and cleft palate identifies a novel locus on 8p11-23. Am J 
Med Genet A 2007; 143: 846-852. 
 
108. Riley BM, Mansilla MA, Ma J, Daack-Hirsch S, Maher BS, Raffensperger LM, 
Russo ET, Vieira AR, Dode C, Mohammadi M, Marazita ML, Murray JC: Impaired 
FGF signaling contributes to cleft lip and palate. Proc Natl Acad Sci U S A 2007; 
104: 4512-4517. 
 
109. Riley BM, Murray JC: Sequence evaluation of FGF and FGFR gene conserved non-
coding elements in non-syndromic cleft lip and palate cases. Am J Med Genet A 
2007. 
 
110. Rice R, Spencer-Dene B, Connor EC, Gritli-Linde A, McMahon AP, Dickson C, 
Thesleff I, Rice DP: Disruption of Fgf10/Fgfr2b-coordinated epithelial-mesenchymal 
interactions causes cleft palate. J Clin Invest 2004; 113: 1692-1700. 
 
 160 
 
111. Nie X, Luukko K, Kettunen P: FGF signalling in craniofacial development and 
developmental disorders. Oral Dis 2006; 12: 102-111. 
 
112. Cadigan KM, Nusse R: Wnt signaling: a common theme in animal development. 
Genes Dev 1997; 11: 3286-3305. 
 
113. Logan CY, Nusse R: The Wnt signaling pathway in development and disease. Annu 
Rev Cell Dev Biol 2004; 20: 781-810. 
 
114. De Calisto J, Araya C, Marchant L, Riaz CF, Mayor R: Essential role of non-
canonical Wnt signalling in neural crest migration. Development 2005; 132: 2587-
2597. 
 
115. Lewis JL, Bonner J, Modrell M, Ragland JW, Moon RT, Dorsky RI, Raible DW: 
Reiterated Wnt signaling during zebrafish neural crest development. Development 
2004; 131: 1299-1308. 
 
116. Juriloff DM, Harris MJ, McMahon AP, Carroll TJ, Lidral AC: Wnt9b is the mutated 
gene involved in multifactorial nonsyndromic cleft lip with or without cleft palate in 
A/WySn mice, as confirmed by a genetic complementation test. Birth Defects Res A 
Clin Mol Teratol 2006; 76: 574-579. 
 
 161 
 
117. Brugmann SA, Goodnough LH, Gregorieff A, Leucht P, ten Berge D, Fuerer C, 
Clevers H, Nusse R, Helms JA: Wnt signaling mediates regional specification in the 
vertebrate face. Development 2007; 134: 3283-3295. 
 
118. Chiquet BT, Blanton SH, Burt A, Ma D, Stal S, Mulliken JB, Hecht JT: Variation in 
WNT genes is associated with non-syndromic cleft lip with or without cleft palate. 
Hum Mol Genet 2008; 17: 2212-2218. 
 
119. Vijayaragavan K, Szabo E, Bossâe M, Ramos-Mejia V, Moon RT, Bhatia M: 
Noncanonical Wnt signaling orchestrates early developmental events toward 
hematopoietic cell fate from human embryonic stem cells. Cell stem cell 2009; 4: 
248-262. 
 
120. Geetha-Loganathan P, Nimmagadda S, Antoni L, Fu K, Whiting CJ, Francis-West P, 
Richman JM: Expression of WNT signalling pathway genes during chicken 
craniofacial development. Dev Dyn 2009; 238: 1150-1165. 
 
121. Lidral AC, Murray JC, Buetow KH, Basart AM, Schearer H, Shiang R, Naval A, 
Layda E, Magee K, Magee W: Studies of the candidate genes TGFB2, MSX1, 
TGFA, and TGFB3 in the etiology of cleft lip and palate in the Philippines. Cleft 
Palate Craniofac J 1997; 34: 1-6. 
 
 162 
 
122. Shiang R, Lidral AC, Ardinger HH, Buetow KH, Romitti PA, Munger RG, Murray 
JC: Association of transforming growth-factor alpha gene polymorphisms with 
nonsyndromic cleft palate only (CPO). Am J Hum Genet 1993; 53: 836-843. 
 
123. Vieira AR, Meira R, Modesto A, Murray JC: MSX1, PAX9, and TGFA contribute to 
tooth agenesis in humans. J Dent Res 2004; 83: 723-727. 
 
124. Lidral AC, Romitti PA, Basart AM, Doetschman T, Leysens NJ, Daack-Hirsch S, 
Semina EV, Johnson LR, Machida J, Burds A, Parnell TJ, Rubenstein JL, Murray 
JC: Association of MSX1 and TGFB3 with nonsyndromic clefting in humans. Am J 
Hum Genet 1998; 63: 557-568. 
 
125. Jezewski P, Vierira A, Schultz R, Machida J, Suzuki K, Liudwig B, Daack-Hirsch S: 
Mutations in MSX1 are associated with non-syndromic orofacial clefting. Am J Hum 
Genet 2001; 69: 558. 
 
126. Vieira AR, Avila JR, Daack-Hirsch S, Dragan E, Felix TM, Rahimov F, Harrington 
J, Schultz RR, Watanabe Y, Johnson M, Fang J, O'Brien SE, Orioli IM, Castilla EE, 
Fitzpatrick DR, Jiang R, Marazita ML, Murray JC: Medical sequencing of candidate 
genes for nonsyndromic cleft lip and palate. PLoS Genet 2005; 1: e64. 
 
127. Tongkobpetch S, Siriwan P, Shotelersuk V: MSX1 mutations contribute to 
nonsyndromic cleft lip in a Thai population. J Hum Genet 2006; 51: 671-676. 
 163 
 
 
128. Park J, Park BY, Kim HS, Lee JE, Suh I, Nam CM, Kang DR, Kim S, Yun JE, Go 
EN, Jee SH, Beaty TH: MSX1 polymorphism associated with risk of oral cleft in 
Korea: evidence from case-parent trio and case-control studies. Yonsei Med J 2007; 
48: 101-108. 
 
129. Cox TC: Taking it to the max: the genetic and developmental mechanisms 
coordinating midfacial morphogenesis and dysmorphology. Clin Genet 2004; 65: 
163-176. 
 
130. Tissier-Seta JP, Mucchielli ML, Mark M, Mattei MG, Goridis C, Brunet JF: Barx1, a 
new mouse homeodomain transcription factor expressed in cranio-facial 
ectomesenchyme and the stomach. Mech Dev 1995; 51: 3-15. 
 
131. Hu D, Helms JA: The role of sonic hedgehog in normal and abnormal craniofacial 
morphogenesis. Development 1999; 126: 4873-4884. 
 
132. Orioli IM, Vieira AR, Castilla EE, Ming JE, Muenke M: Mutational analysis of the 
Sonic Hedgehog gene in 220 newborns with oral clefts in a South American 
(ECLAMC) population. Am J Med Genet 2002; 108: 12-15. 
 
 164 
 
133. Online Mendelian Inheritance in Man OT: The Human Genome Data Base Project, 
Johns Hopkins University, Baltimore, MD World Wide 
Web<URL:http//gdbwww.gdb.org/omim/docs/omimtop.html>,. 1995. 
 
134. Item T, Thurnher, Yerit, Sinko, Wittwer, Adeyemo, Frei, Erginel-Unaltuna, 
Watzinger: Van Der Woude syndrome: variable penetrance of a novel mutation 
(p.Arg84Gly) of the IRF6 gene in a Turkish family. Int J Mol Med 2005; 15: 247-
251. 
 
135. Kayano S, Kure S, Suzuki Y, Kanno K, Aoki Y, Kondo S, Schutte BC, Murray JC, 
Yamada A, Matsubara Y: Novel IRF6 mutations in Japanese patients with Van der 
Woude syndrome: two missense mutations (R45Q and P396S) and a 17-kb deletion. 
J Hum Genet 2003; 48: 622-628. 
 
136. Kim Y, Park JY, Lee TJ, Yoo HW: Identification of two novel mutations of IRF6 in 
Korean families affected with Van der Woude syndrome. Int J Mol Med 2003; 12: 
465-458. 
 
137. Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, Watanabe Y, Howard 
E, de Lima RL, Daack-Hirsch S, Sander A, McDonald-McGinn DM, Zackai EH, 
Lammer EJ, Aylsworth AS, Ardinger HH, Lidral AC, Pober BR, Moreno L, Arcos-
Burgos M, Valencia C, Houdayer C, Bahuau M, Moretti-Ferreira D, Richieri-Costa 
 165 
 
A, Dixon MJ, Murray JC: Mutations in IRF6 cause Van der Woude and popliteal 
pterygium syndromes. Nat Genet 2002; 32: 285-289. 
 
138. Peyrard-Janvid P, Koillinen, Larsson, Frannson, Rautio, Hukki, Larson, Karsten, 
Kere: Novel and de novo mutations of the IRF6 gene detected in patients with Van 
der Woude or popliteal pterygium syndrome. Eur J Hum Genet 2005; 13: 1261-
1267. 
 
139. Schutte BC, Basart AM, Watanabe Y, Laffin JJ, Coppage K, Bjork BC, Daack-
Hirsch S, Patil S, Dixon MJ, Murray JC: Microdeletions at chromosome bands 1q32-
q41 as a cause of Van der Woude syndrome. Am J Med Genet 1999; 84: 145-150. 
 
140. Shotelersuk V, Srichomthong C, Yoshiura K, Niikawa N: A novel mutation, 
1234del(C), of the IRF6 in a Thai family with Van der Woude syndrome. Int J Mol 
Med 2003; 11: 505-507. 
 
141. Wang  LJ, Zhang H, Xiao M, Li J, Yang C, Lin X, Wu Z, Hu L, Kong X: Novel 
mutations in the IRF6 gene for Van der Woude syndrome. Hum Genet 2003; 113: 
382-386. 
 
142. Ye J, Shi, Fan, Song, Fan, Bian: Identification of novel mutations of IRF6 gene in 
Chinese families with Van der Woude syndrome. Int J Mol Med 2005; 16: 851-856. 
 
 166 
 
143. Burdick AB, Bixler D, Puckett CL: Genetic analysis in families with van der Woude 
syndrome. J Craniofac Genet Dev Biol 1985; 5: 181-208. 
 
144. Woolf CM: Congenital cleft lip:  A genetic study of 496 propositi. J Med Genet 
1971; 8: :65-72. 
 
145. Ghassibe M, Bayet B, Revencu N, Verellen-Dumoulin C, Gillerot Y, Vanwijck R, 
Vikkula M: Interferon regulatory factor-6: a gene predisposing to isolated cleft lip 
with or without cleft palate in the Belgian population. Eur J Hum Genet 2005; 13: 
1239-1242. 
 
146. Srichomthong C, Siriwan P, Shotelersuk V: Significant association between IRF6 
820G->A and non-syndromic cleft lip with or without cleft palate in the Thai 
population. J Med Genet 2005; 42: e46. 
 
147. Ingraham CR, Kinoshita A, Kondo S, Yang B, Sajan S, Trout KJ, Malik MI, 
Dunnwald M, Goudy SL, Lovett M, Murray JC, Schutte BC: Abnormal skin, limb 
and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 
(Irf6). Nat Genet 2006; 38: 1335-1340. 
 
148. Rahimov F, Marazita ML, Visel A, Cooper ME, Hitchler MJ, Rubini M, Domann 
FE, Govil M, Christensen K, Bille C, Melbye M, Jugessur A, Lie RT, Wilcox AJ, 
Fitzpatrick DR, Green ED, Mossey PA, Little J, Steegers-Theunissen RP, 
 167 
 
Pennacchio LA, Schutte BC, Murray JC: Disruption of an AP-2alpha binding site in 
an IRF6 enhancer is associated with cleft lip. Nat Genet 2008; 40: 1341-1347. 
 
149. Richardson RJ, Dixon J, Malhotra S, Hardman MJ, Knowles L, Boot-Handford RP, 
Shore P, Whitmarsh A, Dixon MJ: Irf6 is a key determinant of the keratinocyte 
proliferation-differentiation switch. Nat Genet 2006; 38: 1329-1334. 
 
150. Johnston MC, Bronsky PT: Animal models for human craniofacial malformations. J 
Craniofac Genet Dev Biol 1991; 11: 277-291. 
 
151. Juriloff DM, Harris MJ: Mouse genetic models of cleft lip with or without cleft 
palate. Birth defects research Part A, Clinical and molecular teratology 2008; 82: 
63-77. 
 
152. Brown SD: Mouse models of genetic disease: new approaches, new paradigms. J 
Inherit Metab Dis 1998; 21: 532-539. 
 
153. Nagao T, Fujikawa K: Male-mediated teratogenesis: spectrum of congenital 
malformations in the offspring of A/J male mice treated with ethylnitrosourea. 
Teratog Carcinog Mutagen 1996; 16: 301-305. 
 
 168 
 
154. Yamada T, Fujiwara K, Mishima K, Sugahara T: Effect of ENU (ethylnitrosourea) 
mutagenesis in cleft lip and/or palate pathogenesis in mice. Int J Oral Maxillofac 
Surg 2005; 34: 74-77. 
 
155. Juriloff DM: Differences in frequency of cleft lip among the A strains of mice. 
Teratology 1982; 25: 361-368. 
 
156. Kalter H: The history of the A family of inbred mice and the biology of its 
congenital malformations. Teratology 1979; 20: 213-232. 
 
157. Gong SG: Phenotypic and molecular analyses of A/WySn mice. The Cleft palate-
craniofacial journal : official publication of the American Cleft Palate-Craniofacial 
Association 2001; 38: 486-491. 
 
158. Juriloff DM, Harris MJ, Dewell SL: A digenic cause of cleft lip in A-strain mice and 
definition of candidate genes for the two loci. Birth Defects Res A Clin Mol Teratol 
2004; 70: 509-518. 
 
159. Juriloff DM, Harris MJ, Dewell SL, Brown CJ, Mager DL, Gagnier L, Mah DG: 
Investigations of the genomic region that contains the clf1 mutation, a causal gene in 
multifactorial cleft lip and palate in mice. Birth Defects Res A Clin Mol Teratol 
2005; 73: 103-113. 
 
 169 
 
160. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D: 
The human genome browser at UCSC. Genome Res 2002; 12: 996-1006. 
 
161. Fleck MW, Hirotsune S, Gambello MJ, Phillips-Tansey E, Suares G, Mervis RF, 
Wynshaw-Boris A, McBain CJ: Hippocampal abnormalities and enhanced 
excitability in a murine model of human lissencephaly. J Neurosci 2000; 20: 2439-
2450. 
 
162. Zhu H, Wlodarczyk BJ, Scott M, Yu W, Merriweather M, Gelineau-van Waes J, 
Schwartz RJ, Finnell RH: Cardiovascular abnormalities in Folr1 knockout mice and 
folate rescue. Birth Defects Research 2007; 79: 257-268. 
 
163. Matsuzawa N, Yoshiura K, Machida J, Nakamura T, Niimi T, Furukawa H, Toyoda 
T, Natsume N, Shimozato K, Niikawa N: Two missense mutations in the IRF6 gene 
in two Japanese families with Van der Woude syndrome. Oral Surgery Oral 
Medicine Oral Pathology Oral Radiology & Endodontics 2004; 98: 414-417. 
 
164. Koillinen H, Wong FK, Rautio J, Ollikainen V, Karsten A, Larson O, Teh BT, 
Huggare J, Lahermo P, Larsson C, Kere J: Mapping of the second locus for the Van 
der Woude syndrome to chromosome 1p34. Eur J Hum Genet 2001; 9: 747-752. 
 
 170 
 
165. Hamachi T, Sasaki Y, Hidaka K, Nakata M: Association between palatal 
morphogenesis and Pax9 expression pattern in CL/Fr embryos with clefting during 
palatal development. Arch Oral Biol 2003; 48: 581-587. 
 
166. Peters H, Neubuser A, Kratochwil K, Balling R: Pax9-deficient mice lack 
pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb 
abnormalities. Genes Dev 1998; 12: 2735-2747. 
 
167. Jugessur A, Murray JC: Orofacial clefting: recent insights into a complex trait. Curr 
Opin Genet Dev 2005; 15: 270-278. 
 
168. Flores MV, Lam EY, Crosier P, Crosier K: A hierarchy of Runx transcription factors 
modulate the onset of chondrogenesis in craniofacial endochondral bones in 
zebrafish. Dev Dyn 2006; 235: 3166-3176. 
 
169. Kaji T, Artinger KB: dlx3b and dlx4b function in the development of Rohon-Beard 
sensory neurons and trigeminal placode in the zebrafish neurula. Dev Biol 2004; 276: 
523-540. 
 
170. Yan YL, Willoughby J, Liu D, Crump JG, Wilson C, Miller CT, Singer A, Kimmel 
C, Westerfield M, Postlethwait JH: A pair of Sox: distinct and overlapping functions 
of zebrafish sox9 co-orthologs in craniofacial and pectoral fin development. 
Development 2005; 132: 1069-1083. 
 171 
 
 
171. Gato A, Martinez ML, Tudela C, Alonso I, Moro JA, Formoso MA, Ferguson MW, 
Martâinez-Alvarez C: TGF-beta(3)-induced chondroitin sulphate proteoglycan 
mediates palatal shelf adhesion. Dev Biol 2002; 250: 393-405. 
 
172. Ashique AM, Fu K, Richman JM: Endogenous bone morphogenetic proteins 
regulate outgrowth and epithelial survival during avian lip fusion. Development 
2002; 129: 4647-4660. 
 
173. Freimer N, Sabatti C: The use of pedigree, sib-pair and association studies of 
common diseases for genetic mapping and epidemiology. Nat Genet 2004; 36: 1045-
1051. 
 
174. Burton PR, Tobin MD, Hopper JL: Key concepts in genetic epidemiology. Lancet 
2005; 366: 941-951. 
 
175. Lehninger AL: Biochemistry : the molecular basis of cell structure and function, 2d 
edn. New York: Worth Publishers, 1975. 
 
176. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, 
Gottesman MM: A "silent" polymorphism in the MDR1 gene changes substrate 
specificity. Science 2007; 315: 525-528. 
 
 172 
 
177. Vidyarani M, Selvaraj P, Prabhu Anand S, Jawahar MS, Adhilakshmi AR, 
Narayanan PR: Interferon gamma (IFNgamma) & interleukin-4 (IL-4) gene variants 
& cytokine levels in pulmonary tuberculosis.[see comment]. Indian J Med Res 2006; 
124: 403-410. 
 
178. Ben Nasr H, Chahed K, Bouaouina N, Chouchane L: PTGS2 (COX-2) -765 G > C 
functional promoter polymorphism and its association with risk and lymph node 
metastasis in nasopharyngeal carcinoma. Mol Biol Rep 2007. 
 
179. Milunsky JM, Maher TA, Zhao G, Roberts AE, Stalker HJ, Zori RT, Burch MN, 
Clemens M, Mulliken JB, Smith R, Lin AE: TFAP2A mutations result in branchio-
oculo-facial syndrome. Am J Hum Genet 2008; 82: 1171-1177. 
 
180. Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick JS, Haussler D: 
Ultraconserved elements in the human genome. Science 2004; 304: 1321-1325. 
 
181. Woolfe A, Goodson M, Goode DK, Snell P, McEwen GK, Vavouri T, Smith SF, 
North P, Callaway H, Kelly K, Walter K, Abnizova I, Gilks W, Edwards YJ, Cooke 
JE, Elgar G: Highly conserved non-coding sequences are associated with vertebrate 
development. PLoS Biol 2005; 3: e7. 
 
182. Daly AK, Day CP: Candidate gene case-control association studies: advantages and 
potential pitfalls. Br J Clin Pharmacol 2001; 52: 489-499. 
 173 
 
 
183. Li M, Atmaca-Sonmez P, Othman M, Branham KE, Khanna R, Wade MS, Li Y, 
Liang L, Zareparsi S, Swaroop A, Abecasis GR: CFH haplotypes without the Y402H 
coding variant show strong association with susceptibility to age-related macular 
degeneration. Nat Genet 2006; 38: 1049-1054. 
 
184. Maller J, George S, Purcell S, Fagerness J, Altshuler D, Daly MJ, Seddon JM: 
Common variation in three genes, including a noncoding variant in CFH, strongly 
influences risk of age-related macular degeneration. Nat Genet 2006; 38: 1055-1059. 
 
185. McWhinney SR, Boru G, Binkley PK, Peczkowska M, Januszewicz AA, Neumann 
HP, Eng C: Intronic single nucleotide polymorphisms in the RET protooncogene are 
associated with a subset of apparently sporadic pheochromocytoma and may 
modulate age of onset. J Clin Endocrinol Metab 2003; 88: 4911-4916. 
 
186. CDC: Economic Costs of Birth Defects and Cerebral Palsy -- United States. MMWR 
CDC Surveill Summ 1992; 44: 694-699. 
 
187. Kasten EF, Schmidt SP, Zickler CF, Berner E, Damian LA, Christian GM, Workman 
H, Freeman M, Farley MD, Hicks TL: Team care of the patient with cleft lip and 
palate. Current problems in pediatric and adolescent health care 2008; 38: 138-158. 
 
 174 
 
188. Rivkin CJ, Keith O, Crawford PJ, Hathorn IS: Dental care for the patient with a cleft 
lip and palate. Part 1: From birth to the mixed dentition stage. Br Dent J 2000; 188: 
78-83. 
 
189. Cheng LL, Moor SL, Ho CT: Predisposing factors to dental caries in children with 
cleft lip and palate: a review and strategies for early prevention. The Cleft palate-
craniofacial journal : official publication of the American Cleft Palate-Craniofacial 
Association 2007; 44: 67-72. 
 
190. Sambrook J, Fritsch  EF, Maniatis T: Molecular cloning.  A laboratory manual, 2nd 
ed. NY: Cold Spring Harbor Laboratory Press, 1989. 
 
191. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD 
and haplotype maps. Bioinformatics 2005; 21: 263-265. 
 
192. Shaw GM, Lu W, Zhu H, Yang W, Briggs FB, Carmichael SL, Barcellos LF, 
Lammer EJ, Finnell RH: 118 SNPs of folate-related genes and risks of spina bifida 
and conotruncal heart defects. BMC medical genetics 2009; 10: 49. 
 
193. Blanton SH, Bertin T, Serna ME, Stal S, Mulliken JB, Hecht JT: Association of 
chromosomal regions 3p21.2, 10p13, and 16p13.3 with nonsyndromic cleft lip and 
palate. Am J Med Genet A 2004; 125: 23-27. 
 
 175 
 
194. O'Connell JR, Weeks DE: PedCheck: a program for identification of genotype 
incompatibilities in linkage analysis. Am J Hum Genet 1998; 63: 259-266. 
 
195. Abecasis GR, Cookson WO: GOLD--graphical overview of linkage disequilibrium. 
Bioinformatics 2000; 16: 182-183. 
 
196. Abecasis GR, Cherny SS, Cookson WO, Cardon LR: Merlin--rapid analysis of dense 
genetic maps using sparse gene flow trees.[see comment]. Nat Genet 2002; 30: 97-
101. 
 
197. Sobel E, Lange K: Descent graphs in pedigree analysis: Applications to haplotyping 
location scores and marker sharing statistics. Am J Hum Genet 1996; 58: 1323-1337. 
 
198. Van Steen K, McQueen MB, Herbert A, Raby B, Lyon H, Demeo DL, Murphy A, 
Su J, Datta S, Rosenow C, Christman M, Silverman EK, Laird NM, Weiss ST, Lange 
C: Genomic screening and replication using the same data set in family-based 
association testing. Nat Genet 2005; 37: 683-691. 
 
199. Martin ER, Monks SA, Warren LL, Kaplan NL: A test for linkage and association in 
general pedigrees: the pedigree disequilibrium test. Am J Hum Genet 2000; 67: 146-
154. 
 
 176 
 
200. Martin ER, Bass MP, Gilbert JR, Pericak-Vance MA, Hauser ER: Genotype-based 
association test for general pedigrees: the genotype-PDT. Genet Epidemiol 2003; 25: 
203-213. 
 
201. Chung RH, Hauser ER, Martin ER: The APL test: extension to general nuclear 
families and haplotypes and examination of its robustness. Hum Hered 2006; 61: 
189-199. 
 
202. Hancock DB, Martin ER, Li YJ, Scott WK: Methods for interaction analyses using 
family-based case-control data: conditional logistic regression versus generalized 
estimating equations. Genet Epidemiol 2007; 8: 883-893. 
 
203. Chiquet BT, Lidral AC, Stal S, Mulliken JB, Moreno LM, Arco-Burgos M, 
Valencia-Ramirez C, Blanton SH, Hecht JT: CRISPLD2: A Novel NSCLP 
Candidate Gene. Hum Mol Genet 2007; 16: 2241-2248. 
 
204. Hecht JT, Hogue D, Strong LC, Hansen MF, Blanton SH, Wagner M: Hereditary 
multiple exostosis and chondrosarcoma: linkage to chromosome II and loss of 
heterozygosity for EXT-linked markers on chromosomes II and 8. Am J Hum Genet 
1995; 56: 1125-1131. 
 
205. Shen J, Deininger PL, Zhao H: Applications of computational algorithm tools to 
identify functional SNPs in cytokine genes. Cytokine 2006; 35: 62-66. 
 177 
 
 
206. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR: ESEfinder: A web resource to 
identify exonic splicing enhancers. Nucleic Acids Res 2003; 31: 3568-3571. 
 
207. Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR: An increased 
specificity score matrix for the prediction of SF2/ASF-specific exonic splicing 
enhancers. Hum Mol Genet 2006; 15: 2490-2508. 
 
208. Grabe N: AliBaba2: context specific identification of transcription factor binding 
sites. In Silico Biol 2002; 2: S1-15. 
 
209. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, 
Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-Potapov B, 
Saxel H, Kel AE, Wingender E: TRANSFAC and its module TRANSCompel: 
transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006; 34: D108-
110. 
 
210. Mooney S: Bioinformatics approaches and resources for single nucleotide 
polymorphism functional analysis. Briefings in Bioinformatics 2005; 6: 44-56. 
 
211. Shen MM: Identification of differentially expressed genes in mouse development 
using differential display and in situ hybridization. Methods 2001; 24: 15-27. 
 
 178 
 
212. Sprague J, Bayraktaroglu L, Clements D, Conlin T, Fashena D, Frazer K, Haendel 
M, Howe DG, Mani P, Ramachandran S, Schaper K, Segerdell E, Song P, Sprunger 
B, Taylor S, Van Slyke CE, Westerfield M: The Zebrafish Information Network: the 
zebrafish model organism database. Nucleic Acids Res 2006; 34: D581-585. 
 
213. Rosner B: Fundamentals of Biostatistics, 5th edn.: Duxbury, 2000. 
 
214. Lewis SW, Reveley AM, Reveley MA, Chitkara B, Murray RM: The 
familial/sporadic distinction as a strategy in schizophrenia research. Br J Psychiatry 
1987; 151: 306-313. 
 
215. Marigo V, Nigro A, Pecci A, Montanaro D, Di Stazio M, Balduini CL, Savoia A: 
Correlation between the clinical phenotype of MYH9-related disease and tissue 
distribution of class II nonmuscle myosin heavy chains. Genomics 2004; 83: 1125-
1133. 
 
216. Pecci A, Panza E, Pujol-Moix N, Klersy C, Di Bari F, Bozzi V, Gresele P, Lethagen 
S, Fabris F, Dufour C, Granata A, Doubek M, Pecoraro C, Koivisto PA, Heller PG, 
Iolascon A, Alvisi P, Schwabe D, De Candia E, Rocca B, Russo U, Ramenghi U, 
Noris P, Seri M, Balduini CL, Savoia A: Position of nonmuscle myosin heavy chain 
IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. 
Hum Mutat 2007. 
 
 179 
 
217. Matsushita T, Hayashi H, Kunishima S, Hayashi M, Ikejiri M, Takeshita K, Yuzawa 
Y, Adachi T, Hirashima K, Sone M, Yamamoto K, Takagi A, Katsumi A, Kawai K, 
Nezu T, Takahashi M, Nakashima T, Naoe T, Kojima T, Saito H: Targeted 
disruption of mouse ortholog of the human MYH9 responsible for 
macrothrombocytopenia with different organ involvement: hematological, 
nephrological, and otological studies of heterozygous KO mice. Biochem Biophys 
Res Commun 2004; 325: 1163-1171. 
 
218. Mhatre AN, Li Y, Bhatia N, Wang KH, Atkin G, Lalwani AK: Generation and 
characterization of mice with Myh9 deficiency. Neuromolecular Med 2007; 9: 205-
215. 
 
219. Gavin BJ, McMahon JA, McMahon AP: Expression of multiple novel Wnt-1/int-1-
related genes during fetal and adult mouse development. Genes Dev 1990; 4: 2319-
2332. 
 
220. Alappat S, Zhang ZY, Chen YP: Msx homeobox gene family and craniofacial 
development. Cell Res 2003; 13: 429-442. 
 
221. Suda N, Kitahara Y, Ohyama K: A case of amelogenesis imperfecta, cleft lip and 
palate and polycystic kidney disease. Orthod Craniofac Res 2006; 9: 52-56. 
 
 180 
 
222. Edwards YH, Putt W, Lekoape KM, Stott D, Fox M, Hopkinson DA, Sowden J: The 
human homolog T of the mouse T(Brachyury) gene; gene structure, cDNA sequence, 
and assignment to chromosome 6q27. Genome Res 1996; 6: 226-233. 
 
223. Trembath D, Sherbondy AL, Vandyke DC, Shaw GM, Todoroff K, Lammer EJ, 
Finnell RH, Marker S, Lerner G, Murray JC: Analysis of select folate pathway 
genes, PAX3, and human T in a Midwestern neural tube defect population. 
Teratology 1999; 59: 331-341. 
 
224. Morrison K, Papapetrou C, Attwood J, Hol F, Lynch SA, Sampath A, Hamel B, Burn 
J, Sowden J, Stott D, Mariman E, Edwards YH: Genetic mapping of the human 
homologue (T) of mouse T(Brachyury) and a search for allele association between 
human T and spina bifida. Hum Mol Genet 1996; 5: 669-674. 
 
225. Verlinsky Y, Rechitsky S, Verlinsky O, Ozen S, Sharapova T, Masciangelo C, 
Morris R, Kuliev A: Preimplantation diagnosis for sonic hedgehog mutation causing 
familial holoprosencephaly. N Engl J Med 2003; 348: 1449-1454. 
 
226. Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G, Kamdar S, Bruse SE, 
Tischfield S, Smith BJ, Zimmerman RA, Dicicco-Bloom E, Brzustowicz LM, 
Millonig JH: Support for the homeobox transcription factor gene ENGRAILED 2 as 
an autism spectrum disorder susceptibility locus. Am J Hum Genet 2005; 77: 851-
868. 
 181 
 
 
227. Chenevix-Trench G, Jones K, Green AC, Duffy DL, Martin NG: Cleft lip with or 
without cleft palate: associations with transforming growth factor alpha and retinoic 
acid receptor loci. Am J Hum Genet 1992; 51: 1377-1385. 
 
228. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, 
Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, 
Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R, Chenevix-Trench G, 
Wainwright B, Bale AE: Mutations of the human homolog of Drosophila patched in 
the nevoid basal cell carcinoma syndrome. Cell 1996; 85: 841-851. 
 
229. Trueba SS, Auge J, Mattei G, Etchevers H, Martinovic J, Czernichow P, Vekemans 
M, Polak M, Attie-Bitach T: PAX8, TITF1, and FOXE1 gene expression patterns 
during human development: new insights into human thyroid development and 
thyroid dysgenesis-associated malformations. J Clin Endocrinol Metab 2005; 90: 
455-462. 
 
230. J. Machida LMM, M.A. Mansilla, S.B. Bullard, T.D. Busch, M.K. Johnson, T. 
McHenry, M.E. Cooper, C. Valencia-Ramirez, M. Arcos-Burgos, A. Hing, E.J. 
Lammer, M. Jones, K. Christensen, J.C. Murray, M.L. Marazita, and A.C. Lidral: 
The Role of FOXE1 in the Etiology of Cleft Lip: 57th Annual Meeting of the 
American Society of Human Genetics. San Diego, California, 2007, p 470. 
 
 182 
 
231. Bejsovec A: Wnt pathway activation: new relations and locations. Cell 2005; 120: 
11-14. 
 
232. Dale RM, Sisson BE, Topczewski J: The Emerging Role of Wnt/PCP Signaling in 
Organ Formation. Zebrafish 2009; 6: 9-14. 
 
233. Girotti M, Zingg HH: Gene expression profiling of rat uterus at different stages of 
parturition. Endocrinology 2003; 144: 2254-2265. 
 
234. Kemp C, Willems E, Abdo S, Lambiv L, Leyns L: Expression of all Wnt genes and 
their secreted antagonists during mouse blastocyst and postimplantation 
development. Dev Dyn 2005; 233: 1064-1075. 
 
235. Heisenberg CP, Tada M, Rauch GJ, Saude L, Concha ML, Geisler R, Stemple DL, 
Smith JC, Wilson SW: Silberblick/Wnt11 mediates convergent extension movements 
during zebrafish gastrulation. Nature 2000; 405: 76-81. 
 
236. Liu Y, Wang X, Lu CC, Kerman R, Steward O, Xu XM, Zou Y: Repulsive Wnt 
signaling inhibits axon regeneration after CNS injury. The Journal of neuroscience : 
the official journal of the Society for Neuroscience 2008; 28: 8376-8382. 
 
237. Louis I, Heinonen KM, Chagraoui J, Vainio S, Sauvageau G, Perreault C: The 
signaling protein Wnt4 enhances thymopoiesis and expands multipotent 
 183 
 
hematopoietic progenitors through beta-catenin-independent signaling. Immunity 
2008; 29: 57-67. 
 
238. Andersson ER, Prakash N, Cajanek L, Minina E, Bryja V, Bryjova L, Yamaguchi 
TP, Hall AC, Wurst W, Arenas E: Wnt5a regulates ventral midbrain morphogenesis 
and the development of A9-A10 dopaminergic cells in vivo. PLoS ONE 2008; 3: 
e3517. 
 
239. Niemann S, Zhao C, Pascu F, Stahl U, Aulepp U, Niswander L, Weber JL, Muller U: 
Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. 
Am J Hum Genet 2004; 74: 558-563. 
 
240. Liu P, Wakamiya M, Shea MJ, Albrecht U, Behringer RR, Bradley A: Requirement 
for Wnt3 in vertebrate axis formation. Nat Genet 1999; 22: 361-365. 
 
241. Nordstrèom U, Jessell TM, Edlund T: Progressive induction of caudal neural 
character by graded Wnt signaling. Nat Neurosci 2002; 5: 525-532. 
 
242. Riccomagno MM, Takada S, Epstein DJ: Wnt-dependent regulation of inner ear 
morphogenesis is balanced by the opposing and supporting roles of Shh. Genes Dev 
2005; 19: 1612-1623. 
 
 184 
 
243. Yang DH, Yoon JY, Lee SH, Bryja V, Andersson ER, Arenas E, Kwon YG, Choi 
KY: Wnt5a is required for endothelial differentiation of embryonic stem cells and 
vascularization via pathways involving both Wnt/beta-catenin and protein kinase 
Calpha. Circ Res 2009; 104: 372-379. 
 
244. Lange C, Mix E, Rateitschak K, Rolfs A: Wnt signal pathways and neural stem cell 
differentiation. Neurodegener Dis 2006; 3: 76-86. 
 
245. Stenman JM, Rajagopal J, Carroll TJ, Ishibashi M, McMahon J, McMahon AP: 
Canonical Wnt signaling regulates organ-specific assembly and differentiation of 
CNS vasculature. Science 2008; 322: 1247-1250. 
 
246. Parr BA, McMahon AP: Sexually dimorphic development of the mammalian 
reproductive tract requires Wnt-7a. Nature 1998; 395: 707-710. 
 
247. Woods CG, Stricker S, Seemann P, Stern R, Cox J, Sherridan E, Roberts E, Springell 
K, Scott S, Karbani G, Sharif SM, Toomes C, Bond J, Kumar D, Al-Gazali L, 
Mundlos S: Mutations in WNT7A cause a range of limb malformations, including 
Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia 
syndrome. Am J Hum Genet 2006; 79: 402-408. 
 
248. Kumar D, Duggan MB, Mueller RF, Karbani G: Familial aplasia/hypoplasia of 
pelvis, femur, fibula, and ulna with abnormal digits in an inbred Pakistani Muslim 
 185 
 
family: a possible new autosomal recessive disorder with overlapping manifestations 
of the syndromes of Fuhrmann, Al-Awadi, and Raas-Rothschild. Am J Med Genet 
1997; 70: 107-113. 
 
249. Woods CG, Stricker S, Seemann P, Stern R, Cox J, Sherridan E, Roberts E, Springell 
K, Scott S, Karbani G, Sharif SM, Toomes C, Bond J, Kumar D, Al-Gazali L, 
Mundlos S: Mutations in WNT7A cause a range of limb malformations, including 
Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia 
syndrome. Am J Hum Genet 2006; 79: 402-408. 
 
250. LaBonne C, Bronner-Fraser M: Neural crest induction in Xenopus: evidence for a 
two-signal model. Development 1998; 125: 2403-2414. 
 
251. Ciruna B, Rossant J: FGF signaling regulates mesoderm cell fate specification and 
morphogenetic movement at the primitive streak. Dev Cell 2001; 1: 37-49. 
 
252. Liu W, Sun X, Braut A, Mishina Y, Behringer RR, Mina M, Martin JF: Distinct 
functions for Bmp signaling in lip and palate fusion in mice. Development 2005; 
132: 1453-1461. 
 
253. Chai Y, Maxson RE, Jr.: Recent advances in craniofacial morphogenesis. Dev Dyn 
2006; 235: 2353-2375. 
 
 186 
 
254. Brewer S, Feng W, Huang J, Sullivan S, Williams T: Wnt1-Cre-mediated deletion of 
AP-2alpha causes multiple neural crest-related defects. Dev Biol 2004; 267: 135-
152. 
 
255. Dixon J, Jones NC, Sandell LL, Jayasinghe SM, Crane J, Rey JP, Dixon MJ, Trainor 
PA: Tcof1/Treacle is required for neural crest cell formation and proliferation 
deficiencies that cause craniofacial abnormalities. Proc Natl Acad Sci U S A 2006; 
103: 13403-13408. 
 
256. Ito Y, Yeo JY, Chytil A, Han J, Bringas P, Jr., Nakajima A, Shuler CF, Moses HL, 
Chai Y: Conditional inactivation of Tgfbr2 in cranial neural crest causes cleft palate 
and calvaria defects. Development 2003; 130: 5269-5280. 
 
257. Pfeiffer RA, Stoss H, Voight HJ, Wundisch GF: Absence of fibula and ulna with 
oligodactyly, contractures, right-angle bowing of femora, abnormal facial 
morphology, cleft lip/palate and brain malformation in two sibs: a possibly new 
lethal syndrome. Am J Med Genet 1988; 29: 901-908. 
 
258. Camera G, Ferraiolo G, Leo D, Spaziale A, Pozzolo S: Limb/pelvis-
hypoplasia/aplasia syndrome (Al-Awadi/Raas-Rothschild syndrome): report of two 
Italian sibs and further confirmation of autosomal recessive inheritance. J Med Genet 
1993; 30: 65-69. 
 
 187 
 
259. Inoue K, Ohyama T, Sakuragi Y, Yamamoto R, Inoue NA, Yu LH, Goto Y, Wegner 
M, Lupski JR: Translation of SOX10 3' untranslated region causes a complex severe 
neurocristopathy by generation of a deleterious functional domain. Hum Mol Genet 
2007; 16: 3037-3046. 
 
260. Moore SW, Sidler D, Zaahl MG: The ITGB2 immunomodulatory gene (CD18), 
enterocolitis, and Hirschsprung's disease. J Pediatr Surg 2008; 43: 1439-1444. 
 
261. Reamon-Buettner SM, Cho SH, Borlak J: Mutations in the 3'-untranslated region of 
GATA4 as molecular hotspots for congenital heart disease (CHD). BMC medical 
genetics 2007; 8: 38. 
 
262. Marazita ML, A.C. Lidral, J.C. Murray, L.L. Field, B.S. Maher, T.G. McHenry, 
M.E. Cooper, M. Govil, S. Daack-Hirsch, B. Riley, A. Jugessur, T. Felix, L. Morene, 
M.A. Mansilla, A.R. Vieira, K. Doheny, E. Pugh, C. Valencia-Ramirez, and M. 
Arcos-Burgos: Genome Scan, Fine-Mapping, and Candidate Gene Analysis of Non-
Syndromic Cleft Lip with or without Cleft Palate Reveals Phenotype-Specific 
Differences in Linkage and Association Results. Hum Hered 2009; 68: 151-170. 
 
263. Ahsan M, Ohta K, Kuriyama S, Tanaka H: Novel soluble molecule, Akhirin, is 
expressed in the embryonic chick eyes and exhibits heterophilic cell-adhesion 
activity. Dev Dyn 2005; 233: 95-104. 
 
 188 
 
264. Liepinsh E, Trexler M, Kaikkonen A, Weigelt J, Banyai L, Patthy L, Otting G: NMR 
structure of the LCCL domain and implications for DFNA9 deafness disorder. 
EMBO J 2001; 20: 5347-5353. 
 
265. Nagai H, Sugito N, Matsubara H, Tatematsu Y, Hida T, Sekido Y, Nagino M, 
Nimura Y, Takahashi T, Osada H: CLCP1 interacts with semaphorin 4B and 
regulates motility of lung cancer cells. Oncogene 2007. 
 
266. Trexler M, Banyai L, Patthy L: The LCCL module. Eur J Biochem 2000; 267: 5751-
5757. 
 
267. Robertson NG, Resendes BL, Lin JS, Lee C, Aster JC, Adams JC, Morton CC: Inner 
ear localization of mRNA and protein products of COCH, mutated in the 
sensorineural deafness and vestibular disorder, DFNA9. Hum Mol Genet 2001; 10: 
2493-2500. 
 
268. Alkuraya FS, Saadi I, Lund JJ, Turbe-Doan A, Morton CC, Maas RL: SUMO1 
haploinsufficiency leads to cleft lip and palate. Science 2006; 313: 1751. 
 
269. Faniello MC, Fregola A, Nistico A, Quaresima B, Crugliano T, Faraonio R, 
Puzzonia P, Baudi F, Parlato G, Cuda G, Morrone G, Venuta S, Costanzo F: 
Detection and functional analysis of an SNP in the promoter of the human ferritin H 
gene that modulates the gene expression. Gene 2006; 377: 1-5. 
 189 
 
 
270. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, 
Kleinman JE, Weinberger DR: Neuregulin 1 transcripts are differentially expressed 
in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl 
Acad Sci U S A 2006; 103: 6747-6752. 
 
271. Nielsen KB, Sorensen S, Cartegni L, Corydon TJ, Doktor TK, Schroeder LD, 
Reinert LS, Elpeleg O, Krainer AR, Gregersen N, Kjems J, Andresen BS: Seemingly 
neutral polymorphic variants may confer immunity to splicing-inactivating 
mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious 
mutations in a flanking exonic splicing enhancer. Am J Hum Genet 2007; 80: 416-
432. 
 
272. Arcos-Burgos M, Muenke M: Genetics of population isolates. Clin Genet 2002; 61: 
233-247. 
 
273. White SH: Amino acid preferences of small proteins. Implications for protein 
stability and evolution. J Mol Biol 1992; 227: 991-995. 
 
274. Aguilar B, Rojas JC, Collados MT: Metabolism of homocysteine and its relationship 
with cardiovascular disease. J Thromb Thrombolysis 2004; 18: 75-87. 
 
 190 
 
275. Lumley J, Watson L, Watson M, Bower C: Periconceptional supplementation with 
folate and/or multivitamins for preventing neural tube defects. Cochrane Database 
Syst Rev 2001: CD001056. 
 
276. Czeizel AE, Dudas I: Prevention of the first occurrence of neural-tube defects by 
periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832-1835. 
 
277. Sayed AR, Bourne D, Pattinson R, Nixon J, Henderson B: Decline in the prevalence 
of neural tube defects following folic acid fortification and its cost-benefit in South 
Africa. Birth Defects Res A Clin Mol Teratol 2008; 82: 211-216. 
 
278. Bower C, D'Antoine H, Stanley FJ: Neural tube defects in Australia: Trends in 
encephaloceles and other neural tube defects before and after promotion of folic acid 
supplementation and voluntary food fortification. Birth Defects Res A Clin Mol 
Teratol 2009. 
 
279. Badovinac RL, Werler MM, Williams PL, Kelsey KT, Hayes C: Folic acid-
containing supplement consumption during pregnancy and risk for oral clefts: a 
meta-analysis. Birth Defects Res A Clin Mol Teratol 2007; 79: 8-15. 
 
280. Bille C, Olsen J, Vach W, Knudsen VK, Olsen SF, Rasmussen K, Murray JC, 
Andersen AM, Christensen K: Oral clefts and life style factors--a case-cohort study 
based on prospective Danish data. Eur J Epidemiol 2007; 22: 173-181. 
 191 
 
 
281. Canfield MA, Collins JS, Botto LD, Williams LJ, Mai CT, Kirby RS, Pearson K, 
Devine O, Mulinare J: Changes in the birth prevalence of selected birth defects after 
grain fortification with folic acid in the United States: findings from a multi-state 
population-based study. Birth Defects Res A Clin Mol Teratol 2005; 73: 679-689. 
 
282. Czeizel AE, Toth M, Rockenbauer M: Population-based case control study of folic 
acid supplementation during pregnancy. Teratology 1996; 53: 345-351. 
 
283. Shaw GM, Lammer EJ, Wasserman CR, O'Malley CD, Tolarova MM: Risks of 
orofacial clefts in children born to women using multivitamins containing folic acid 
periconceptionally. Lancet 1995; 346: 393-396. 
 
284. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R: A second genetic 
polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with 
decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172. 
 
285. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen 
R: Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and 
mutation identification. Nat Genet 1994; 7: 195-200. 
 
 192 
 
286. Blanton SH, R. R. Henry, J. B. Mulliken, S. Stal, R. H. Finnell and J. T. Hecht: The 
Folate Pathway and Nonsyndromic Cleft Lip and Palate. Birth Defects Research Part 
A: Clinical and Molecular Teratology (revisions submitted) 2010. 
 
287. Letra A, Menezes R, Cooper ME, Fonseca RF, Tropp S, Govil M, Granjeiro JM, 
Mansilla MA, Murray JC, Castilla EE, I.M. O, Czeizel AE, Ma L, Chiquet BT, 
Hecht JT, Vieira AR, Marazita ML: CRISPLD2 variants including a  C471T silent 
mutation may contribute tononsyndromic cleft lip  with or without palate. Cleft 
Palate J 2010 in press. 
 
288. Saitão N: Principles of protein architecture. Adv Biophys 1989; 25: 95-132. 
 
289. Benard O, Balasubramanian KA: Effect of oxidant exposure on thiol status in the 
intestinal mucosa. Biochem Pharmacol 1993; 45: 2011-2015. 
 
290. Blanton SH, Henry RR, Mulliken JB, Stal S, Burt A, Finnell RH, Hecht JT: The 
Folate Pathway and Nonsyndromic Cleft Lip and Palate. Birth Defects Res Part A: 
Clin and Mol Terat (submitted) 2010. 
 
291. Ramakrishnan S, Sulochana KN, Lakshmi S, Selvi R, Angayarkanni N: 
Biochemistry of homocysteine in health and diseases. Indian J Biochem Biophys 
2006; 43: 275-283. 
 
 193 
 
292. Thisse B, Thisse, C.: Fast Release Clones: A High Throughput Expression Analysis. 
ZFIN Direct Data Submission (http://zfinorg) 2004. 
 
293. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY: Impact of folic acid 
fortification of the US food supply on the occurrence of neural tube defects. JAMA 
2001; 285: 2981-2986. 
 
294. MMWR: Spina bifida and anencephaly before and after folic acid mandate--United 
States, 1995-1996 and 1999-2000. MMWR Morb Mortal Wkly Rep 2004; 53: 362-
365. 
 
295. Tolorova M, Harris J: Reduced recurrence of orofacial clefts after periconceptual 
supplementation with high dose folic acid and multivitamins. Teratology 1995; 51: 
71-78. 
 
296. Ester AR, Weymouth KS, Burt A, Wise CA, Scott A, Gurnett CA, Dobbs MB, 
Blanton SH, Hecht JT: Altered transmission of HOX and apoptotic SNPs identify a 
potential common pathway for clubfoot. Am J Med Genet A 2009; 149A: 2745-2752. 
 
297. Ben J, Jabs EW, Chong SS: Genomic, cDNA and embryonic expression analysis of 
zebrafish IRF6, the gene mutated in the human oral clefting disorders Van der 
Woude and popliteal pterygium syndromes. Gene Expr Patterns 2005; 5: 629-638. 
 
 194 
 
298. Sabel JL, d'Alenðcon C, O'Brien EK, Van Otterloo E, Lutz K, Cuykendall TN, 
Schutte BC, Houston DW, Cornell RA: Maternal Interferon Regulatory Factor 6 is 
required for the differentiation of primary superficial epithelia in Danio and Xenopus 
embryos. Dev Biol 2009; 325: 249-262. 
 
299. Knight AS, Schutte BC, Jiang R, Dixon MJ: Developmental expression analysis of 
the mouse and chick orthologues of IRF6: the gene mutated in Van der Woude 
syndrome. Developmental dynamics : an official publication of the American 
Association of Anatomists 2006; 235: 1441-1447. 
 
300. Washbourne BJ, Cox TC: Expression profiles of cIRF6, cLHX6 and cLHX7 in the 
facial primordia suggest specific roles during primary palatogenesis. BMC 
developmental biology 2006; 6: 18. 
 
301. Hulbert EM, Smink LJ, Adlem EC, Allen JE, Burdick DB, Burren OS, Cavnor CC, 
Dolman GE, Flamez D, Friery KF, Healy BC, Killcoyne SA, Kutlu B, Schuilenburg 
H, Walker NM, Mychaleckyj J, Eizirik DL, Wicker LS, Todd JA, Goodman N: 
T1DBase: integration and presentation of complex data for type 1 diabetes research. 
Nucleic Acids Res 2007; 35: D742-746. 
 
302. Kaplan F, Ledoux P, Kassamali FQ, Gagnon S, Post M, Koehler D, Deimling J, 
Sweezey NB: A novel developmentally regulated gene in lung mesenchyme: 
 195 
 
homology to a tumor-derived trypsin inhibitor. Am J Physiol 1999; 276: L1027-
1036. 
 
303. Gibbs GM, Roelants K, O'Bryan MK: The CAP superfamily: cysteine-rich secretory 
proteins, antigen 5, and pathogenesis-related 1 proteins--roles in reproduction, 
cancer, and immune defense. Endocr Rev 2008; 29: 865-897. 
 
304. Oyewumi L, Kaplan F, Gagnon S, Sweezey NB: Antisense oligodeoxynucleotides 
decrease LGL1 mRNA and protein levels and inhibit branching morphogenesis in 
fetal rat lung. Am J Respir Cell Mol Biol 2003; 28: 232-240. 
 
305. Oyewumi L, Kaplan F, Sweezey NB: Lgl1, a mesenchymal modulator of early lung 
branching morphogenesis, is a secreted glycoprotein imported by late gestation lung 
epithelial cells. Biochem J 2003; 376: 61-69. 
 
306. Quinlan J, Kaplan F, Sweezey N, Goodyer P: LGL1, a novel branching morphogen 
in developing kidney, is induced by retinoic acid. Am J Physiol Renal Physiol 2007; 
293: F987-993. 
 
307. Lan J, Ribeiro L, Mandeville I, Nadeau K, Bao T, Cornejo S, Sweezey NB, Kaplan 
F: Inflammatory cytokines, goblet cell hyperplasia and altered lung mechanics in 
Lgl1+/- mice. Respir Res 2009; 10: 83. 
 
 196 
 
308. Berndt JD, Clay MR, Langenberg T, Halloran MC: Rho-kinase and myosin II affect 
dynamic neural crest cell behaviors during epithelial to mesenchymal transition in 
vivo. Dev Biol 2008; 324: 236-244. 
 
309. Kang P, Svoboda KK: Epithelial-mesenchymal transformation during craniofacial 
development. J Dent Res 2005; 84: 678-690. 
 
310. Westerfield M: The zebrafish book : a guide for the laboratory use of zebrafish 
(Danio rerio), Ed. 3. edn. Eugene, OR: M. Westerfield, 1995. 
 
311. Graham A: Jaw development: chinless wonders. Curr Biol 2002; 12: R810-812. 
 
312. Akimenko MA, Ekker M, Wegner J, Lin W, Westerfield M: Combinatorial 
expression of three zebrafish genes related to distal-less: part of a homeobox gene 
code for the head. J Neurosci 1994; 14: 3475-3486. 
 
313. Ellies DL, Stock DW, Hatch G, Giroux G, Weiss KM, Ekker M: Relationship 
between the genomic organization and the overlapping embryonic expression 
patterns of the zebrafish dlx genes. Genomics 1997; 45: 580-590. 
 
314. Letra A, Menezes R, Cooper ME, Fonseca RF, Tropp S, Govil M, Granjeiro JM, 
Imoehl SR, Mansill MA, Murray JC, Castilla EE, Orioli IM, Czeizel AE, Ma L, 
Chiquet BT, Hecht JT, Vieira AR, Marazita ML: CRISPLD2 variants including a 
 197 
 
C471T silent mutation may contribute to nonsyndromic cleft lip with or without cleft 
palate. Cleft Palate Craniofacial Journal (In Press) 2010. 
 
315. Feng Q, Di R, Tao F, Chang Z, Lu S, Fan W, Shan C, Li X, Yang Z: PDK1 regulates 
vascular remodeling and promotes epithelial-mesenchymal transition in cardiac 
development. Mol Cell Biol 2010. 
 
316. Micalizzi DS, Farabaugh SM, Ford HL: Epithelial-Mesenchymal Transition in 
Cancer: Parallels Between Normal Development and Tumor Progression. J 
Mammary Gland Biol Neoplasia 2010. 
 
317. Sanders EJ, Prasad S: Invasion of a basement membrane matrix by chick embryo 
primitive streak cells in vitro. J Cell Sci 1989; 92 ( Pt 3): 497-504. 
 
318. Schilling TF, Le Pabic P: Fishing for the signals that pattern the face. J Biol 2009; 8: 
101. 
 
319. Luo R, An M, Arduini BL, Henion PD: Specific pan-neural crest expression of 
zebrafish Crestin throughout embryonic development. Dev Dyn 2001; 220: 169-174. 
 
320. Rubinstein AL, Lee D, Luo R, Henion PD, Halpern ME: Genes dependent on 
zebrafish cyclops function identified by AFLP differential gene expression screen. 
Genesis 2000; 26: 86-97. 
 198 
 
 
321. Thisse C, Thisse B, Postlethwait JH: Expression of snail2, a second member of the 
zebrafish snail family, in cephalic mesendoderm and presumptive neural crest of 
wild-type and spadetail mutant embryos. Dev Biol 1995; 172: 86-99. 
 
322. Nadeau K, Montermini L, Mandeville I, Xu M, Weiss ST, Sweezey NB, Kaplan F: 
Modulation of lgl1 by steroid, retinoic Acid, and vitamin d models complex 
transcriptional regulation during alveolarization. Pediatr Res 2010; 67: 375-381. 
 
323. Campbell JL, Jr., Smith MA, Fisher JW, Warren DA: Dose-response for retinoic 
acid-induced forelimb malformations and cleft palate: a comparison of computerized 
image analysis and visual inspection. Birth Defects Res B Dev Reprod Toxicol 2004; 
71: 289-295. 
 
324. Padmanabhan R, Ahmed I: Retinoic acid-induced asymmetric craniofacial growth 
and cleft palate in the TO mouse fetus. Reprod Toxicol 1997; 11: 843-860. 
 
325. Lohnes D, Mark M, Mendelsohn C, Dolle P, Dierich A, Gorry P, Gansmuller A, 
Chambon P: Function of the retinoic acid receptors (RARs) during development (I). 
Craniofacial and skeletal abnormalities in RAR double mutants. Development 1994; 
120: 2723-2748. 
 
 199 
 
326. Li N, Kelsh RN, Croucher P, Roehl HH: Regulation of neural crest cell fate by the 
retinoic acid and Pparg signalling pathways. Development 2010; 137: 389-394. 
 
327. Reijntjes S, Rodaway A, Maden M: The retinoic acid metabolising gene, CYP26B1, 
patterns the cartilaginous cranial neural crest in zebrafish. Int J Dev Biol 2007; 51: 
351-360. 
 
328. Ellies DL, Langille RM, Martin CC, Akimenko MA, Ekker M: Specific craniofacial 
cartilage dysmorphogenesis coincides with a loss of dlx gene expression in retinoic 
acid-treated zebrafish embryos. Mech Dev 1997; 61: 23-36. 
 
329. Yan YL, Jowett T, Postlethwait JH: Ectopic expression of hoxb2 after retinoic acid 
treatment or mRNA injection: disruption of hindbrain and craniofacial 
morphogenesis in zebrafish embryos. Dev Dyn 1998; 213: 370-385. 
 
330. Davenne M, Maconochie MK, Neun R, Pattyn A, Chambon P, Krumlauf R, Rijli 
FM: Hoxa2 and Hoxb2 control dorsoventral patterns of neuronal development in the 
rostral hindbrain. Neuron 1999; 22: 677-691. 
 
331. Depew MJ, Simpson CA, Morasso M, Rubenstein JL: Reassessing the Dlx code: the 
genetic regulation of branchial arch skeletal pattern and development. J Anat 2005; 
207: 501-561. 
 
 200 
 
332. Qiu M, Bulfone A, Martinez S, Meneses JJ, Shimamura K, Pedersen RA, Rubenstein 
JL: Null mutation of Dlx-2 results in abnormal morphogenesis of proximal first and 
second branchial arch derivatives and abnormal differentiation in the forebrain. 
Genes Dev 1995; 9: 2523-2538. 
 
333. Limpach A, Dalton M, Miles R, Gadson P: Homocysteine inhibits retinoic acid 
synthesis: a mechanism for homocysteine-induced congenital defects. Exp Cell Res 
2000; 260: 166-174. 
 
334. Dalton ML, Gadson PF, Jr., Wrenn RW, Rosenquist TH: Homocysteine signal 
cascade: production of phospholipids, activation of protein kinase C, and the 
induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703-711. 
 
335. Rosenquist TH, Bennett GD, Brauer PR, Stewart ML, Chaudoin TR, Finnell RH: 
Microarray analysis of homocysteine-responsive genes in cardiac neural crest cells in 
vitro. Dev Dyn 2007; 236: 1044-1054. 
 
336. Tierney BJ, Ho T, Reedy MV, Brauer PR: Homocysteine inhibits cardiac neural crest 
cell formation and morphogenesis in vivo. Dev Dyn 2004; 229: 63-73. 
 
337. Knott L, Hartridge T, Brown NL, Mansell JP, Sandy JR: Homocysteine oxidation 
and apoptosis: a potential cause of cleft palate. In Vitro Cell Dev Biol Anim 2003; 
39: 98-105. 
 201 
 
 
338. Wong WY, Eskes TK, Kuijpers-Jagtman AM, Spauwen PH, Steegers EA, Thomas 
CM, Hamel BC, Blom HJ, Steegers-Theunissen RP: Nonsyndromic orofacial clefts: 
association with maternal hyperhomocysteinemia. Teratology 1999; 60: 253-257. 
 
339. Rubini M, Brusati R, Garattini G, Magnani C, Liviero F, Bianchi F, Tarantino E, 
Massei A, Pollastri S, Carturan S, Amadori A, Bertagnin E, Cavallaro A, Fabiano A, 
Franchella A, Calzolari E: Cystathionine beta-synthase c.844ins68 gene variant and 
non-syndromic cleft lip and palate. Am J Med Genet A 2005; 136A: 368-372. 
 
340. Verkleij-Hagoort A, Bliek J, Sayed-Tabatabaei F, Ursem N, Steegers E, Steegers-
Theunissen R: Hyperhomocysteinemia and MTHFR polymorphisms in association 
with orofacial clefts and congenital heart defects: a meta-analysis. Am J Med Genet 
A 2007; 143A: 952-960. 
 
341. Ozerol E, Ozerol I, Gokdeniz R, Temel I, Akyol O: Effect of smoking on serum 
concentrations of total homocysteine, folate, vitamin B12, and nitric oxide in 
pregnancy: a preliminary study. Fetal Diagn Ther 2004; 19: 145-148. 
 
342. Chiquet BT, R. R. Henry, A. Burt, J. B. Mulliken, S. Stal, S. H. Blanton and J. T. 
Hecht: Nonsyndromic cleft lip and palate: CRISPLD Genes and the Folate Gene 
Pathway Connection. Birth Defects Research Part A: Clinical and Molecular 
Teratology (revisions submitted) 2010. 
 202 
 
VITA 
Brett Thomas Chiquet was born in Thibodeaux, Lousiana to Carol LaBorde and 
Bryan Chiquet on October 5, 1981.  Brett grew up in Donaldsonville, Louisiana, attended 
and graduated as valedictorian from Ascension Catholic High School in May 1999.  Brett 
graduated Magna Cum Laude from the Louisiana Scholars’ College at Northwestern State 
University in Natchitoches, Louisiana, with a BA in Liberal Arts with a Concentration in 
Scientific Inquiry.  After graduation he worked as a research technician at UT Southwestern 
Medical Center in Dallas, Texas.  In May 2004 he entered the University of Texas Health 
Science Center at Houston Graduate School of Biomedical Sciences and in August 2004 he 
entered the Dental Branch.  Both DDS and PhD were completed in May 2011.  In July 2011, 
Brett will start a residency program in Pediatric Dentistry at the University of Texas Health 
Science Center in Houston, Texas, where he wishes to pursue a career in pediatric dentistry 
research. 
 
